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Chapter 1
1.1. HUMAN PAPILLOMAVIRUS (HPV) AND HEAD 
AND NECK SQUAMOUS CELL CARCINOMAS 
(HNSCCS)
Head and neck squamous cell carcinomas (HNSCCs) affect approximately 600000 
patients per year and are associated with a mortality of 40-50%.1 Abuse of tobacco and 
alcohol are well-established risk factors for the development of HNSCCs. The incidence 
of head and neck cancer as a consequence of tobacco and alcohol has decreased during 
the past decades.2 However, the incidence of oropharyngeal squamous cell carcinomas 
(OPSCCs) has not decreased implying the role of another agent in its carcinogenesis, id 
est human papillomavirus (HPV). In fact, epidemiological evidence has revealed a rapid 
increase in the prevalence rates of HPV-associated OPSCCs. 3, 4 In the USA and Northern 
Europe more than 70% of OPSCCs are estimated to be HPV-associated, as compared 
with only 17% in Southern Europe.3-6
Regarding the role of HPV in human lesions, mucocutaneous warts already were 
described in the classic Greek era. The viral etiology of HPV causing warts in humans 
was demonstrated more than a century ago in 1907 by Cuffio et al.7 In 1983, the first 
evidence was published for HPV involvement in benign and malignant squamous cell 
tumors of the oral mucosa by Syrjänen et al., and it was demonstrated that HPV may 
be the etiological agent of a subgroup of oral squamous cell carcinomas.8 It was not 
until 1989 that the first report on the presence of HPV16 DNA in tonsillar squamous 
cell carcinomas was published (TSCCs).9
Nowadays, HPV - and HPV16 as the predominant type - has been well established as 
additional risk factor for OPSCCs, as has been demonstrated in several meta-analyses.10 
The oropharyngeal subsites of the palatine tonsils and base of the tongue (BOT) are 
particularly involved.11
1.2. ANATOMY OF THE OROPHARYNX
The oropharynx is situated posterior of the oral cavity and cranially and caudally 
connected to the nasopharynx and the larynx/hypopharynx, respectively.
The oropharynx contains: 1) BOT, 2) the palatine tonsils and tonsillar pillars, 3) the soft 
palate, and 4) the pharyngeal wall (Figure 1).
Anteriorly, the border of the oropharynx is demarcated by the circumvallate papillae 
indicating the beginning of the BOT. The BOT is mainly composed of lymphoid tissue and 
extends laterally to the glossopalatine sulcus. The BOT ends inferiorly in the vallecula. 
The inferior border of the oropharynx is situated at this point, at the top of the hyoid 
bone.
Jos_Binnenwerk_v3.indd   8 24/09/2020   17:04:07
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Figure 1. Anatomy of the oropharynx
(For the National Cancer Institute © (2016) Terese Winslow LLC, U.S. Govt. has certain rights)
The palatine tonsils are located on the lateral wall of the oropharynx and are -just as 
the BOT- mainly composed of lymphoid tissue in a fibrous capsule. They are situated 
posterior to the retromolar trigone and are surrounded by the anterior and posterior 
tonsillar pillars. The anterior tonsillar pillar is formed by the palatoglossal muscle, 
whereas the posterior pillar is formed by the palatopharyngeal muscle.
Together with the adenoid located in the nasopharynx, the lymphoid tissue of the tonsils 
and the BOT form the ring of Waldeyer.
The soft palate forms the cranial border of the oropharynx and caudal border of the 
nasopharynx. It connects anteriorly with the hard palate demarcating the border with 
the oral cavity.
Posterior to the tonsillar pillars, the oropharynx is surrounded by pharyngeal wall, which 
is composed of the pharyngeal constrictor muscles, and forms as such the posterior 
wall and lateral walls of the oropharynx.
1
Jos_Binnenwerk_v3.indd   9 24/09/2020   17:04:08
10
Chapter 1
1.3. HPV: CARCINOGENESIS AND 
DEREGULATION OF THE CELL CYCLE
The tonsillar crypts may serve as the probable site for HPV to enter the tonsillar mucosa 
as it is considered to function as a storage location for HPV during and/or after an HPV-
infection. The crypt also lacks the highly structured barrier function of the squamous 
epithelium and has a high number of epithelial reserve cells/stem cells.12, 13 The possible 
occurrence of microlesions in the tonsillar squamous epithelium subsequently allows 
the virus to penetrate the mucosa and infect the basal cell layer of stratified epithelium. 
It has to be noted that primary premalignant lesions that can be attributed to the 
presence of high-risk HPV (HR-HPV) are only rarely observed.14 Therefore, studies on 
uterine cervical carcinogenesis provide most current knowledge on the initiation of 
HPV-associated mucosal disease and the dysregulation of the cell cycle by HR-HPV.6, 15 
After infection by HR-HPV, early HPV genes E1 and E2 are expressed and the viral DNA 
replicates from episomal DNA. The infected cells replicate and move into the parabasal 
layers. Then E6 and E7 are expressed, which result in suppression of differentiation and 
re-entering of the cell cycle. Infected cells move forward to the superficial layers in the 
epithelium, where the viral genome is replicated and late genes L1 and L2 and E4 are 
expressed. L1 and L2 proteins enable encapsulation of the viral genomes in the nucleus 
to form progeny virions (infectious virus particles), which are shed from the squamous 
epithelium to initiate new infections. Known uterine cervical lesions in which these 
non-neoplastic productive HPV infections occur are cervical intraepithelial neoplasia 
1 (CIN1) or low-grade intra-epithelial lesions (LSIL). Regression of these lesions by an 
adequate immune response is still possible. 6, 15
Approximately 5% of HPV infections are persistent, leading to local immune suppression, 
accumulation of chromosomal changes in the infected host cells, deregulated expression 
of HPV early genes, and reduced viral production. Approximately 0.3-1.2% of initial 
infections progress to invasive cancer. 12 In this transition, viral DNA often integrates 
into the host genome, leading to disruption or loss of E2 and upregulation of E6 and 
E7 oncogene expression. However, expression of viral oncoproteins E6 and E7 can also 
occur independently of HPV DNA integration in the host genome.12, 16 Although much 
research have been carried out to unravel the physical status and copy number of HPV 
in HNSCCs, the involvement of these parameters in deregulating human gene expression 
and their value in predicting prognosis has not been sufficiently clarified yet12,17
The ubiquitous expression of viral oncoproteins E6 and E7 is essential for tumor 
development and results in inactivation of p53 and the retinoblastoma protein (pRb), 
respectively. This leads amongst others to cell cycle deregulation and increased cellular 
proliferation, and inhibition of apoptosis. As a consequence, cyclin-dependent kinase 
(CDK) inhibitors, including p16Ink4a and p21Cip1/Waf1, and the Mdm2 inhibitor p14Arf, 
are upregulated, which subsequently leads to CDK4/6 inhibition and downregulation of 
Cyclin D1.18-21 Zhang et al. recently identified two possible HPV-positive OPSCC subgroups 
based on molecular expression profiles: HPV-KRT (HPV-keratinocyte differentiation and 
Jos_Binnenwerk_v3.indd   10 24/09/2020   17:04:08
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oxidative reduction process) or HPV-IMU (HPV-immune response and mesenchymal 
cell differentiation) tumors (Figure 2).22 Further study is required to confirm these 
findings.23
In contrast, HPV-negative carcinomas, induced by smoking and alcohol consumption, 
are generally characterized by near universal loss of function TP53 mutations and 
CDKN2A inactivation (p16Ink4a loss of function) or CCND1 amplification (overexpression 
Cyclin D1), also resulting in deregulation of the cell cycle and apoptosis.14, 23 Within 
HPV-negative HNSCCs, two distinct subgroups have been identified based on the 
presence of numerous or absent copy number alterations (CNA), resp. CNA-high and 
CNA-silent.23, 24
Figure 2. Genomic carcinogenesis models of head and neck squamous cell carcinoma.
A schematic overview of squamous cell carcinogenesis in the head and neck is shown. The main 
distinction among head and neck squamous cell carcinomas (HNSCCs) is the presence of three 
genetic subgroups: tumors that contain transcriptionally active human papillomavirus (HPV+ve), 
tumors that are HPV-negative (HPV–ve) and have numerous copy number alterations (CNA-high), 
and tumors that are HPV–ve but CNA-silent.
HPV infection in oral squamous epithelium mostly leads to productive infections, while infection 
particularly in specific oropharyngeal crypt cells (light blue) might lead to an oncogenic event 
resulting in either HPV-KRT (HPV-keratinocyte differentiation and oxidative reduction process) 
or HPV-IMU (HPV-immune response and mesenchymal cell differentiation)22 tumors. These 
subgroups have been identified by expression profiling but have not been definitively verified 
and are still under investigation.
1
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The P53 and RB pathways that play a key role in cell cycle control are frequently abrogated in 
HPV−ve tumors, except they seem to remain active in CNA-silent tumors. In addition, the etiology 
of this latter subgroup remains unclear, and ageing is hypothesized to be the risk factor. Many 
cancer genes and pathways seem to be involved in the progression of the HPV–ve, CNA-high 
tumors, but FAT1 and NOTCH1, which might act in the WNT–β-catenin pathway, are worth 
mentioning, and smoking is a known risk factor. At least three subgroups of tumors can be 
identified based on expression profiling, indicated as classical, basal and mesenchymal, but more 
may exist. The classical HPV–ve, CNA-high subgroup is characterized by nuclear factor erythroid 
2-related factor 2 (NFE2L2) pathway mutations. HPV–ve tumors typically develop from mucosal 
precursor changes that can present as leukoplakias. Cells in these ‘fields’ progress to cancer by an 
accumulation of mutations. The current lack of data on precursor changes hampers the precise 
timing of events, but it is likely that the accumulation of events is the most important factor. 
Specific details and references are indicated in the main text. CASP8, caspase 8; CDKN2A, cyclin-
dependent kinase inhibitor 2A; CUL3, cullin 3; KEAP1, kelch-like ECH-associated protein 1.
(source: Leemans CR, et al. The molecular landscape of head and neck cancer. Nat Rev Cancer. 
2018;18:269‐282. Approval for reproduction of the figure was obtained by Nature Cancer 
Reviews)23
1.4. PREVALENCE OF HPV: INFLUENCE OF 
DETECTION METHOD
In contrast to HNSCCs caused by tobacco and alcohol, the incidence of HPV in TSCCs 
has increased over the past decades and ranges from 20% to 90% in different studies.4 
Incidence numbers of HPV involvement in HNSCCs depend on the detection approach 
used and also a wide geographical variation in HPV distribution has been described.5, 
18, 25-27 Furthermore, the presence and detection of HPV-DNA in the tumor as only 
criterion for HPV-positivity might overestimate the true role of HPV in head and neck 
carcinogenesis, as it may reflect, for example, a transient infection unrelated to the 
carcinogenic process occurring for example after oral sexual intercourse, or DNA 
contamination during tissue processing.28, 29 Currently there is no single test that is 
considered the ‘gold standard’ for HPV-positivity in formalin fixed, paraffin-embedded 
(FFPE) HNSCC tissue. In order to detect a true biological HPV infection, it therefore 
has been proposed to combine HPV DNA detection by PCR with a second test that 
demonstrates viral activity. One option is reverse transcriptase PCR for HPV E6/E7 
transcripts, which is easy to carry out on fresh frozen tissue, but may be cumbersome on 
FFPE tissue.29 As an alternative, p16Ink4a overexpression has been reported as the most 
reliable surrogate marker for the presence of HR-HPV in OPSCC.18, 30-32 Many studies 
have shown, that the combination of p16Ink4aA immunohistochemistry (p16Ink4a-IHC) 
followed by detection of HR-HPV DNA by PCR is a reliable, and accurate algorithm to 
distinguish HPV-positive from -negative HNSCCs.18, 19, 33-36 Nevertheless, false-positive 
rates for p16Ink4a-IHC has been reported (up to 7%).32 Results on HPV-prevalence and 
consequently all results of clinical data associated with HPV in OPSCCs, thus, should be 
taken with care and with special regard to the detection methods used.
Jos_Binnenwerk_v3.indd   12 24/09/2020   17:04:09
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1.5. FEATURES DISTINGUISHING HPV-
POSITIVE FROM -NEGATIVE HNSCCS: ARE THEY 
STRAIGHTFORWARD?
There is increasing evidence that the pathogenesis of HPV-positive tumors is different 
from their HPV-negative counterparts, which is confirmed by molecular and clinical 
differences between the two subgroups.11 But is it really that simple?
Weinberger et al. (2006) proposed a model for the development of HNSCCs, in which 
three classes are differentiated, divided into two arms. In the first arm, tumorigenesis 
is induced by alcohol consumption and/or smoking tobacco (Class I). However, in this 
group HPV-superinfection of the tumor site may occur, with biological features that do 
not differ from alcohol/tobacco-related tumors (Class II). In contrast, in the second arm, 
the inducer of tumorigenesis is HPV (Class III), which is proposed to be independent of 
smoking tobacco and alcohol consumption.37 In general, patients with HPV-associated 
HNSCCs tend to be younger, smoke less tobacco and consume less alcohol, and have a 
more favorable prognosis when compared to patients with HPV-negative carcinomas. 
The true etiological role of HPV in HNSCCs, however, is challenged by factors such as 
concomitant tobacco and alcohol use together with the mentioned limitations caused 
by detection approaches used. This leads to questions like: Is the presence of HPV 16 
DNA in the oropharyngeal tumor of a tobacco-smoking patient indicative of a HPV- 
or smoking-driven carcinogenesis? And why is the prevalence of OPSCCs increased in 
smoking patients, independent of the presence of HPV in their tumors?38
From a molecular point of view, literature has provided evidence that there are also 
molecular differences within HPV-positive and HPV-negative HNSCCs (Zhang et al (2016), 
Leemans et al (2018), (TGCA: 2015), indicating the presence of different subgroups even 
within the three “Weinberger”-classes: CNA-high and -silent HPV-negative HNSCCs, and 
the subgroups HPV-KRT and HPV-IMU within the HPV-positive carcinomas. Verification 
of these subgroups and their association with clinical characteristics remains to be 
studied.22-24 On top of this, Wichmann et al. highlighted the possible importance of 
variants within the HPV 16-virusses worldwide, and their possible associated differences 
in clinical behavior and outcome in head and neck cancer, as is observed in uterine 
cervical cancer.39, 40
Clinical characteristics and demographics associated with HPV-positive tumors are 
also not always unequivocal. The numerous studies published are more than once 
contradictory and are once again often biased by definition and detection of HPV.28, 
41-44 Identifying the risk profile prone to HPV-induced HNSCC development seems to 
be complicated by the interaction of the different clinical variables as tobacco and 
alcohol use, age, gender, and sexual behavior. Moreover these variables are also 
affected by culture differences worldwide and even within continents (e.g. southern 
versus northern Europe).41
1
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Therefore, the identification of the ‘typical’ HPV-positive HNSCC patient may be less 
straightforward than expected. Therefore, research should be directed to improve the 
identification of the HPV-positive “persona”, because it may help in the selection of 
true-HPV-positive tumors as well as in identifying subgroups of HPV-positive tumors 
associated with different risk levels regarding disease progression and survival.
1.6. PROGNOSIS OF HPV-POSITIVE OPSCC: 
THE INFLUENCE OF ADEQUATE STAGING AND 
THERAPEUTIC MANAGEMENT
1.6.1. Lymphatic drainage of the oropharynx
To describe the role of TNM classification in OPSCCs and how classification is affected 
by HPV, the first part of this section is dedicated to the description of the lymphatic 
drainage of the oropharynx. This is important for the understanding of possible 
differences in drainage dependent on the oropharyngeal subsites.
Lymph node drainage from the BOT and the palatine tonsils is typically to levels II 
to IV and the lateral retropharyngeal nodes.45 The most common site of lymph node 
metastasis is to the jugulodigastric nodes in region II. Occasionally, levels Ib and V 
become involved. Level Ib is at increased risk of involvement in case of significant 
invasion of the oral tongue. Midline tumors, such as BOT tumors, are at higher risk for 
bilateral lymph node metastasis. Small lateralized TSCCs without midline extension 
have less risk of contralateral lymphadenopathy. Sood et al. confirmed the differences 
in lymphatic drainage between TSCCs and carcinomas of the BOT.46 The first group is 
found to have more ipsilateral node involvement, whereas bilateral node involvement 
occurs almost only when the BOT is involved.
1.6.2. Influence of HPV on the UICC staging system: consequences for 
therapeutic decision-making and prognosis
At the start of our research on HPV in OPSCCs, the most important prognostic marker 
for all head and neck carcinomas including carcinomas originating from the oropharynx 
was lymph node involvement (N-status). 47-49 Smoking and alcohol consumption were 
associated with a worse survival. HPV-presence in OPSCCs was reported to be associated 
with a better survival when compared to HPV-negative tumors. TNM-classification (7th 
edition UICC staging system) was leading in therapeutic decision making.30
The standard treatment of OPSCCs in the Netherlands has been dependent on tumor 
location and TNM stage (UICC), independent of HPV-status. Smaller primary tumors can 
be treated surgically or with radiotherapy, although currently tumors are predominantly 
treated with radiotherapy. Larger tumors (T3 and T4) are preferably treated with 
radiochemotherapy or dependent on the overall condition and age of the patient with 
radiotherapy alone. In residual/recurrent cases, salvage surgery may be performed.50
Jos_Binnenwerk_v3.indd   14 24/09/2020   17:04:09
15
General introduction
Literature on the prognostic importance of tumor spread to the cervical lymph nodes 
in TSCCs was not consistent when our research started. A higher N status was not 
always reported to result in a worse prognosis. It was reported that HPV-associated 
tumors show another clinical behavior than HPV-negative tumors. They often present 
with advanced lymph nodes in early primary tumor stages, resulting in advanced 
staged OPSCCs despite small (T1-T2) primary tumors.30, 51, 52 Moreover, HPV-positive 
OPSCCs respond significantly better to therapy than HPV-negative tumors.53 Therefore, 
the presence of HPV in OPSCCs alters the consequences of staging for determining 
patients’ prognosis and choice of treatment.37, 54-57 As a consequence in the course of 
the present PhD research the TNM classification for OPSCC has been adapted. In the 
newly introduced 8th edition UICC staging system, HPV-classification based on P16Ink4a-
IHC testing alters the staging of lymph node involvement of OPSCCs which is comparable 
to the staging of nasopharyngeal carcinomas as demonstrated in the ICON-S-study.58
1.6.3. Role of HPV in cervical metastases of unknown primary tumors
Knowledge on HPV-positive OPSCCs and its related pattern of lymph node metastases 
suggests a role for HPV detection in the diagnostic work-up of cervical metastases of 
unknown primary tumors (CUP). The additional value of HPV-testing in the diagnostic 
work-up in CUP patients was advocated in order to find the primary tumor, help improve 
outcomes and investigate de-intensification of treatment protocols in this group of 
patients because patients are often treated extensively with neck dissection, bilaterally 
applied radiotherapy and radiotherapy of the pharyngeal axis.59, 60 However, studies 
on the prevalence of HPV in lymph node metastases of which the primary tumor 
could not be detected after diagnostic workup, so-called “true” CUPs, are scarce and 
contradictory, and HPV prevalence rates range from 0% to 100% and were tested in 
relatively small sample numbers (range 1-25).60-65
1.6.4. De-escalation of therapy in HPV-positive TSCCs: primum non nocere
HPV-related OPSCC has emerged as a separate entity in terms of etiology, biology and 
clinical behavior; importantly, it has a more favorable prognosis and may require less 
intensive therapy. The ultimate goal in the treatment of patients with OPSCCs is to 
improve the efficacy and minimize the toxic effects of treatment. There are increasing 
indications that de-escalation could be possible. Different de-escalation trials have been 
recently published and/or are going on, however, with no clear evidence for adjusting 
current treatment protocols.66-68 Furthermore, it has to be kept in mind, that despite 
advances and innovations in multimodality treatment and a better understanding of 
head and neck carcinogenesis, the survival rates of a subgroup of locally advanced 
OPSCCs have not improved substantially and that the prognosis for patients with 
recurrent disease and/or distant metastases remains very poor even when tumors are 
HPV-positive.69
1
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Current de-escalation trials therefore focus on low-risk HPV-positive OPSCC subgroups. 
To better identify which patient groups are favorable for less intense therapy, adequate 
understanding of risk-profiles within HPV-positive OPSCCs is necessary.
1.7. AIMS OF THIS THESIS
Within the above mentioned context a couple of questions arose, which are given 
below. This thesis aims to provide the necessary answers to these questions and to 
attribute to a better understanding of the role of HPV in the clinical presentation of 
OPSCCs and CUPs, and its implications for tumor staging and therapeutic strategies.
1.7.1. To what extent are lymph nodes affected in HPV-positive carcinomas 
and what is the value of N-status in HPV-positive carcinomas?
For this purpose, the prognostic value of N status in TSCCs was examined in a population 
of 81 patients, while also taking into consideration the HPV status, clinicopathological 
features (age, gender, TNM classification, tumor differentiation grade, smoking tobacco, 
and alcohol consumption), and treatment of the tumor.
1.7.2. Is p16Ink4a immunohistochemistry (p16Ink4a-IHC) a reliable surrogate 
marker for the presence of high-risk- and low-risk-HPV in benign and 
malignant head and neck lesions?
To address this question, p16Ink4A-IHC immunohistochemistry was performed on a 
series of benign and dysplastic head and neck lesions and more specifically on paraffin-
embedded tissue sections of 162 oropharyngeal squamous cell carcinomas (OPSCC), 
14 tonsillar and 23 laryngeal dysplasias, and 20 tonsillar and 27 laryngeal papillomas. 
PCR, enzyme-immunoassay and FISH analysis were used to assess HPV-presence and 
type.
1.7.3.  Is there an additional value for HPV-testing in the diagnostic work-
up of CUP to identify a possible missed primary tumor?
29 true-CUP patients were analyzed for the presence of p16Ink4a and HPV 16 DNA in the 
histologic specimens of the resected cervical lymph node metastases. Patients with 
CUP underwent a comprehensive diagnostic-work-up and were considered as true-CUP 
patients if a primary tumor was not detected through staging examination.
Jos_Binnenwerk_v3.indd   16 24/09/2020   17:04:09
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1.7.4. If HPV-positive tumors present more often with metastases to the 
regional lymph nodes, what is the frequency of HPV in cervical metastases 
of carcinomas with unknown primary tumor (CUP) in the head and neck 
area? And independent of HPV-status, is de-escalation of therapy an 
option?
For this purpose, data of patients with ‘true’-CUP were evaluated for the presence 
of HPV by detection of p16Ink4a and HPV DNA, and how this affects outcome. First, 
the presence of HPV in neck metastases of CUP was analyzed. The data of a Dutch 
and a German academic cancer center (Maastricht and Cologne) were merged and a 
retrospective analysis was carried out. Second, the different therapeutic strategies and 
survival rates of both centers were analyzed. This gave us the possibility to study the 
additional value of irradiating the pharyngeal axis, as well as that of bilateral versus 
ipsilateral postsurgical radiation, with or without concomitant chemotherapy.
1.7.5. Does de-escalation of therapy in CUP results in different outcome 
and is it safe?
To critically evaluate the results of the above mentioned bi-national study, the outcome 
of patients with cervical CUP (n=124) in relation to the applied treatment in two Dutch 
academic head and neck clinics was examined. Both centers had a congruent history of 
de-escalation of therapy over time. Results of unilateral versus bilateral post-operative 
irradiation and radiotherapy of the pharyngeal axis were compared in terms of disease-
free survival (DFS), regional recurrence rate (RCR) and overall survival (OS). In the same 
series the relation of HPV-positivity (assessed by detection of p16Ink4a and HPV DNA) of 
affected lymph nodes with outcome was investigated retrospectively.
1.7.6. What is the prognostic value of lymph node metastases in HPV-
positive TSCCs and to what extend do the 7th and the 8th edition of the UICC 
classification system take this into account? Which parameters besides 
TNM enhance reliability in predicting prognosis and should be considered 
for risk stratification in therapeutic decision-making in the future?
The aim of this study was to contribute to a better tumor classification system for HPV-
associated TSCCs. We focused on a large series of 368 TSCCs, which were subjected to 
HPV-analysis using p16-overexpression, HPV-specific PCR and/or FISH. All cases were 
staged with the 7th and the 8th edition of OPSCC and the prognostic value of T-, N- and 
M-status was then examined. Then additional parameters (age, smoking behavior, 
alcohol consumption, tumor differentiation grade, and treatment) were included in 
the analysis. It was shown that the addition of some of those parameters could improve 
the prognostic value of the latest (8th) TNM staging system for TSCCs.
1
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1.7.7. Does HPV-related tumor biology in head and neck offer new targets 
for therapy?
In a review clinical and molecular characteristics of HPV-positive and – negative HNSCC 
were studied and possible ways to target specifically the HPV-infected cells were 
explored to elucidate possible new therapeutic strategies for these tumors.
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2.1. ABSTRACT
Objective/Hypothesis: Assessment of the prognostic value of nodal status in relation 
to human papillomavirus (HPV) status and the various treatment modalities in tonsillar 
squamous cell carcinomas (TSCC).
Study design: Retrospective 5-year survival-analysis
Methods: A 5-year follow-up of disease-free, disease-specific and overall survival in 
a group of 81 patients with TSCC was conducted. The nodal status and integration of 
HPV-DNA in the genome (detected with fluorescence in situ hybridization) as prognostic 
indicators was examined while correcting for other clinical parameters (smoking habits, 
alcohol consumption, treatment modality, differentiation, TNM-classification).
Results: Of TSCCs, 41% were positive for HPV type 16. In these TSCCs, the primary tumor 
was significantly smaller when compared to HVP-negative TSCCs (p=0.04), whereas 
the percentage of cases with cervical metastases was identical. In the total tumor 
population, it was not nodal involvement , but rather HPV manifestation, which was 
related to patient prognosis. Within the treatment modalities (surgery combined with 
radiotherapy and radiotherapy alone), neither nodal status nor HPV were prognostic 
indicators.
Conclusion: Since a substantial percentage of TSCCs is HPV-positive and metastasizes 
to cervical lymph nodes in less advanced primary tumors, the N-status is an unreliable 
prognostic indicator in TSCCs. HPV is only prognostically relevant in the total tumor 
population, but loses its value within patient groups receiving a single treatment 
modality. The value of HPV for prognosis of patients with TSCC requires further 
study.
Key words: Human papillomavirus, tonsil, carcinoma, nodal involvement, treatment, 
survival
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2.2. INTRODUCTION
During the past decades numerous investigations have shown an etiologic relationship 
between oncogenic or high-risk human papillomavirus (HPV) and squamous cell 
carcinomas of the tonsil (TSCC).1–4 The incidence of HPV in TSCC is increasing, possibly 
related to changes in sexual behavior, and ranges from 20% to 80% in different studies 
depending on the detection approach used.5–8 There is increasing evidence that the 
pathogenesis of HPV-positive tumors is different from their HPV-negative counterparts, 
which is confirmed by molecular and clinical differences between the two subgroups. 
Therefore, a different clinical approach may be advisable for both TSCC groups.2–4,7,9
Weinberger et al. proposed a model for the development of HPV-positive carcinomas, 
in which three classes are differentiated and divided into two arms.9 In the first arm, 
tumorigenesis is induced by alcohol consumption and/or smoking tobacco (class I). In 
this group, HPV superinfection of the tumor site may occur, resulting in an HPV-positive 
tumor with biological features that resemble alcohol/tobacco-related tumors (class 
II). In the second arm, the inducer of tumorigenesis is HPV (class III), independent of 
smoking tobacco and alcohol consumption. Many studies suggest a better prognosis 
for patients with HPV-associated head and neck carcinomas,7 as a consequence of an 
improved response to treatment when compared to HPV-negative tumors.10,11 Therefore 
HPV testing has recently been proposed to be included in the standard diagnostic work-
up for oropharyngeal carcinomas.8,10
Another factor influencing prognosis is tumor spread to cervical lymph nodes. For 
head and neck tumors in general, a positive N-status is considered the most reliable 
prognostic marker for an unfavorable prognosis.12-14 However, TSCC literature is not 
consistent in confirming the prognostic value of N-status in TSCC .15-17 The present study 
aims to examine the prognostic value of N-status in a series of 81 TSCC, while also taking 
into consideration the HPV-status, clinicopathological features (age, gender, TNM-
classification, tumor differentiation grade, smoking tobacco and alcohol consumption), 
as well as treatment of the tumor.
2.3. MATERIALS AND METHODS
2.3.1. Tumor material and patient data
The study population consists of 81 TSCC patients (mean age 58,9 yrs; range 39-87 yrs; 
73% male)2, diagnosed between 1992 and 2001 at the Maastricht university Medical 
Centre. The formaldehyde-fixed, paraffin-embedded archival biopsy and resection 
materials of these patients had been classified by histopathology at the Department 
of Pathology, University Hospital Maastricht, The Netherlands and analyzed for the 
presence of oncogenic HPV16 DNA by means of polyùerase chain reaction (PCR), 
fluorescence in situ hybridisation (FISH) as well as p16 immunostaining.17 Data on age, 
gender, TNM classification, tumor differentiation grade, smoking habits, amount of 
2
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alcohol consumption, treatment modality, and follow-up were collected from the head 
and neck tumor database of our institute and from reviewing clinical, pathological, 
radiological and surgical reports. Tumors of patients treated before 1997 were re-
classified according to the UICC classification. Data on tumor differentiation grade were 
unavailable for three patients.
Patients were classified as smokers (> 1 cigarette, pipe, and/or cigar per day) (n=69) 
or non-smokers (n=12). The latter group consisted of patients who had never smoked 
(n=10) and former smokers (n=2), who had stopped smoking more than 10 years before 
diagnosis of TSCC. Patients were also classified as drinkers (consumption of > 2 whiskey 
equivalents (~10g alcohol) per day) or non-drinkers (0-2 whiskey equivalents per day). All 
patients were treated irrespective of their HPV status by multimodal regimens including 
local resection (LR), combined resection (CR): neck dissection plus local resection, i.e. 
tonsillectomy or combined mandibular operation (command-procedure), radiotherapy 
(RT), local resection plus radiotherapy (LR/RT), combined resection plus radiotherapy 
(CR/RT), chemotherapy (ChT) or chemotherapy in combination with previous other 
treatment modalities.
Patients with tumors feasible for resection without unacceptable compromising organ 
functionality were treated with radical resection and elective neck dissection and 
postoperative radiotherapy if indicated. In patients who where primarily treated with 
radiotherapy the neck was also treated with radiotherapy.
During multidisciplinary counseling, treatment plans were designed dependent on tumor 
size, neck staging, presence of distant metastases, feasibility of surgery, histopathology 
of resection specimens, clinical condition and comorbidities. With the exception of 
microcarcinomas, elective treatment of the neck was performed routinely, including 
in the N0 neck, because of the high incidence of occult metastases in TSCC.14, 18-20
For patients treated with radiotherapy alone, histopathological data from surgical 
neck dissection were consequently unavailable. Therefore clinical staging (including 
panendoscopy, magnetic resonance imaging of the neck, ultrasound with fine-needle 
aspiration, and X-thorax) was used in this study. In the CR/RT group, there was one 
patient with a N0 neck according to diagnostic work-up, where a positive lymph node 
was observed in histopathological analysis after ipsilateral elective neck dissection. This 
patient was considered as N0 in this study.
Follow-up data were collected with a minimum of 5 years after treatment for all 
patients.
The investigation was conducted in accordance with the declaration with the 18th 
meeting of the World Medical Association in Helsinki 1964 and the subsequent 
revisions. The study protocol was approved by the institutional ethical committee. 
Written consent was obtained from all the patients included in this study.
2.3.2. Statistical analysis
The association of N-status and HPV status with other factors associated with prognosis, 
including age at time of diagnosis, gender, TNM-status, tumor differentiation grade, 
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smoking habits and amount of alcohol consumption, were analyzed by cross-tabulations 
using the 2-tailed χ²-test or 2-tailed Fisher exact test adhering to a significance level 
of p< 0.05.
Survival curves for disease-free survival (DSF), disease-specific survival (DSS) and overall 
survival (OS), were calculated using the Kaplan-Meier method.21 Five-year survival was 
calculated from the date of diagnosis until death or until discharge from follow-up. DFS 
was calculated from the date of diagnosis until the date of recurrence (local, regional 
or distant). Patients without recurrence were censored at the date of the last follow-up 
or the date of death. Differences between survival times was determined by the log 
rank test in univariate analyses (significance level of p < 0.05).21 Four patients initially 
presented with distant metastases were excluded from the survival analysis.
Multivariate analyses were performed using the Cox proportional hazards model. 
Variables included were HPV, smoking tobacco, alcohol consumption and T-classification. 
The inclusion of treatment modality as a variable depended on the number of patients 
within each treatment group. Variables remained in the model if their p-values were 
below 0.10.2
SPSS Base System version 12.0 was used for the statistical analysis.
2.4. RESULTS
2.4.1. N-status and HPV-status in relation to patient characteristics.
A positive N-status, as determined in the diagnostic work-up by the clinical investigation 
and radiology, was more frequently observed in non- and former-smokers (p=0.048). 
Other clinico-pathological factors (age, alcohol consumption, TNM-stage and tumor 
differentiation grade) and HPV-status did not appear to be associated with N-status 
(Table 1).
HPV-status, however, correlated with a poor tumor differentiation grade (p=0.015), 
as did less or no smoking of tobacco (p=0.011) and alcohol consumption (p=0.003) 
(Table 1). Primary tumor size at time of presentation was found to be significantly 
smaller in the HPV-positive group than in the HPV-negative group (p = 0.041) in spite 
of comparable frequencies of nodal involvement in both groups. Moreover, in case of 
nodal involvement, a swelling in the neck was the main reason for visiting the ENT-
outpatient department for 15 of the 24 patients with HPV-positive TSCC, compared to 
only 6 of the 30 patients with HPV-negative TSCC (p=0.001).
2.4.2 N-status and HPV-status in relation to patient treatment.
The different treatment modalities for TSCC are listed in Table 2. The two largest patient 
groups receiving a single treatment modality included thirty patients treated with 
combined surgery and radiotherapy (CR/RT) and 30 patients received radiotherapy 
(RT). The other treatment modalities were not taken into consideration in this analysis 
because of the limited number of patients in these groups. Functional resectable tumors 
2
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were preferably treated with CR/RT, whereas patients with functional irresectable 
tumors or other contra-indications for surgery were treated with RT alone.
T-status was significantly lower in the CR/RT group than in the RT-group (p=0.001), 
whereas nodal involvement did not differ. HPV-positive TSCC were more often treated 
with CR/RT (p=0.035), whereas HPV-negative TSCC were more often treated with RT 
(p=0.048). In the CR/RT group, all HPV-positive patients had a positive N-status whereas 
in HPV-negative patients significantly less nodal involvement was present (p=0.003).
Patients treated with CR/RT (resectable tumors) smoked significantly less than patients 
treated with RT (p=0.001). Smoking habits observed in both treatment modality groups 
were HPV-dependent. Nine of the 16 HPV-positive patients who were treated with 
CR/RT were nonsmokers, whereas the eight HPV-positive patients treated with RT 
(irresectable tumors) all smoked (p=0.007). In patients with HPV-negative tumors, no 
significant differences in smoking habits were found between the treatment modality 
groups. Alcohol consumption did not differ between treatment modality groups. 
Patients treated with CR/RT had a far more favorable 5-year overall, disease-specific 
and disease-free survival compared to patients treated with RT (log rank, p<0.001) 
(Figure 3: A-C). This outcome based on patient treatment dod not differ between the 
HPV-positive and HPV-negative patients with TSCC (OS, DSS, log rank p<0.001; DFS, log 
rank p=0.001). Moreover, in both treatment modality groups, there were no differences 
notied for the development of local and regional recurrence or for the development of 
distant metastases between HPV-positive and HPV-negative patients with TSS (Fisher 
exact test).
2.4.3. N-status and HPV-status in relation to outcome.
Nodal involvement did not correlate with survival in either the entire group of TSCC (Fig. 
1A–C) or in the treatment subgroups CR/RT and RT. Remarkably, a trend for a favorable 
5-year DFS rate was observed in patients with a lymph node metastasis (P=0.067) (Fig. 
1C).
A statistically significant difference between the prognosis of HPV-positive and HPV-
negative TSCCs was not found in the univariate analysis. However, there was a trend 
for a better DSS in the HPV-positive group (log rank, p=0.094) (Figure 2: A-C). Also 
within the treatment sub-groups CR/RT and RT, HPV-status proved to be an unreliable 
prognostic indicator.
The influence of N-status on prognosis was also analyzed in patients with HPV-positive 
and HPV-negative TSCC. In the HPV-negative group, the presence of nodal involvement 
seemed to be a related to an unfavorable 5-year OS, DSS and DFS (Fig. 3). In the HPV-
positive group, however, the presence of nodal involvement seemed to be related with 
a better OS, DSS and DFS.
In multivariate analysis neither N-status, nor gender, age and tumor differentiation 
grade, appeared to have a statistically significant influence on survival. For HPV-negative 
TSCCs a 2 times higher risk of cancer death was found (95% confidence interval (CI) = 0.9-
4.2) compared to patients with HPV-positive tumors. Patients with a tumor staged T3 
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or T4 had a 2.6 times increased risk of cancer death (95% CI = 1.4-4.9) compared to 
patients with tumor staged T1 or T2. However, the strongest prognostic factor was 
smoking: smokers had a 5.5 fold higher risk (95% CI = 1.3-23.6) of dying from cancer 
when compared to non-smokers.17
Multivariate analysis within treatment modality groups CR/RT and RT were not 
performed, due to the limited number of patients in each of these groups (n=30).
2.5. DISCUSSION
In head and neck squamous cell carcinoma (HNSCC), N-status is known to be an 
important prognostic factor.22-27 Nodal involvement reduces survival by more than 50% 
in patients with HNSCCs.22-27 However in recent years, the prognostic value of nodal 
involvement in TSCC is becoming increasingly controversial.15-17 A possible explanation 
for this finding is the heterogeneity in etiological factors underlying tumorigenesis in 
different head and neck mucosa areas. For example, HPV appears to play a much more 
prominent etiological role in TSCC than in other head and neck tumors.28,29 Moreover, 
the incidence of HPV in TSCC has increased substantially in the past few decades.5-8 
Therefore, investigation into whether the presence of HPV underlies the decreased 
prognostic value of nodal involvement is warranted.
In our study we noticed that the only clinical parameter associated with a positive 
neck status in TSCCs was absence of tobacco smoking. This parameter, however, was 
found to correlate much stronger with the presence of HPV in the tumor (41% of cases). 
This observation has also been described in other studies.7-9 Additional parameters 
correlating to HPV included less or no alcohol consumption, a poor tumor differentiation 
grade and a smaller T-stage. The latter finding suggests a different tumor biology for 
HPV-positive TSCCs with regional spreading occurring at smaller primary tumor sizes.
Possibly, HPV-positive tumors were detected in smaller T-stages because of an 
earlier clinical presentation of a lymph node metastasis in this group. We observed a 
relationship between a swelling in the neck as presenting symptom and the presence 
of HPV in the primary tumor. This has also been described in literature.17 This pattern 
of regional tumor spreading in smaller primary tumor sizes may contribute to an earlier 
detection of a so far “unknown” primary tumor at a smaller size. According to this 
hypothesis, the tumor biology of HPV-positive tumors would result in the detection of 
tumors with smaller T-stages.
In this study patients with tumors feasible for resection with respect to organ 
functionality were treated with CR/RT, and (functionally) inoperable tumors were 
treated with RT. As a consequence, the CR/RT group showed a significantly better 
outcome. Because of their smaller primary tumor sizes, HPV-positive TSCCs were more 
often feasible for resection and subsequently more often treated with CR/RT. We would 
like to stress that conclusions with respect to the efficacy of these treatment modalities 
should not be extracted from the data presented here.
2
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To what extent patient-dependent factors as life-style and co-morbidities influence 
clinical choice and treatment outcome remains to be studied. A favorable performance 
status appears to be related to HPV-positive tumors.11 The inverse relation between 
tobacco smoking, alcohol consumption and HPV-status, suggests also that the difference 
in life-style may result in a decreased prevalence of co-morbidities in the HPV-positive 
tumor population.
N-status was not found to be of prognostic value in TSCC. Patients with HPV-negative 
TSCC were found to have a 2 times greater risk of cancer death. Separate analysis 
of the CR/RT- and RT did not indicate that these two parameters had an effect on 
prognosis. HPV-positive tumors, thus, show no significant improvement of response 
to therapy within the different modality groups. Although this could be caused by 
the relatively limited number of patients in the different treatment groups, a recent 
study also showed no significantly favorable prognosis of HPV-positive oropharyngeal 
tumors when treated with combined radio/chemotherapy.11 Multiple hypotheses for a 
better outcome of HPV-positive tumors have been put forward. They are all based on 
factors related to therapy-outcome: absence of field cancerization as a consequence 
of the inverse relation of HPV and tobacco smoking and alcohol consumption, an intact 
apoptotic tumor response to radiation and an immune surveillance to viral-specific 
tumor antigens.30-33 However, in most cases multimodal treatment modalities have 
been used.
In our study, the presence of nodal involvement in HPV-negative TSCC, seemed to 
expose a negative influence on the prognosis. However in HPV-positive TSCC, nodal 
involvement even appeared to ameliorate outcome. This suggests that the tumor 
biology of HPV-positive TSCC is not only different from the HPV-negative TSCC but 
also has a great influences on the clinical presenation and outcome. As mentioned, 
nodal involvement in HPV-positive TSCCs is often the presenting symptom and seems 
to indicate the presence of a smaller primary tumor in HPV-positive TSCCs (squealer 
node in unknow primary tumors). Subsequently, these HPV-positive TSCCs are more 
feasible for a radical therapeutic approach. This indicates that the outcome of HPV-
positive tumors is not only dependent on a better response to different (multimodal) 
treatment modalities, but more importantly, the presence of HPV in TSCCs seems to 
determine the choice of treatment as a result of its biology. As a consequence of the 
controversial prognostic value of nodal involvement, we advise the implementation of 
testing HPV diagnostically to stratify in TSCC tumor staging.
2.6. CONCLUSION
HPV-positive tumors, which are associated with less smoking and alcohol, have a 
different tumor biology. They have smaller primary tumor sizes while regional lymph 
node involvement is comparable to HPV-negative tumors. Our data indicate that 
the relatively favorable prognosis of HPV-related TSCC is determined by the choice 
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of treatment as a result of its biology. The prognostic value of nodal involvement is 
reduced by the presence of HPV. HPV-testing in the diagnostic work-up is therefore 
advised in TSCC tumor staging.
2
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Figure 1. A) N-status-dependent 5-year Overall Survival, B) N-status-dependent 5-year Disease 
Specific Survival, C) N-status-dependent 5-year Disease Free Survival.
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Figure 2. A) HPV-dependent 5-year Overall Survival, B) HPV-dependent 5-year Disease Specific 
Survival, C) HPV-dependent 5-year Disease Free Survival.
2
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Figure 3. A) N-status-dependent 5-year Disease Specific Survival in patients with HPV-positive 
TSCCs and B) N-status-dependent 5-year Disease Specific Survival in patients with HPV-negative 
TSCCs.
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Table 2. HPV in correlation with treatment.
Treatment HPV+ HPV− Total
Local resection (LR) 0 1 1
Combined resection (CR) 3 3 6
LR/RT 3 2 5
CR/RT 16 14 30
Radiotherapy (RT) 8 22 30
Chemotherapy (ChT) 2 1 3
CR/RT/ChT 1 0 1
RT/ChT 0 3 3
None 0 2 2
Total 33 48 81
2
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P16INK4A immunostaining is a strong indicator for high-
risk-HPV-associated oropharyngeal carcinomas and 
dysplasias, but is unreliable to predict low-risk-HPV-
infection in head and neck papillomas and laryngeal 
dysplasias.
Published: Mooren JJ, Gültekin SE, Straetmans JM, Haesevoets A, Peutz-Kootstra CJ, 
Huebbers CU, Dienes HP, Wieland U, Ramaekers FC, Kremer B, Speel EJ, Klussmann 
JP. P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated 
oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-
HPV-infection in head and neck papillomas and laryngeal dysplasias. Int J Cancer 
2014;134:2108-2117.
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3.1. ABSTRACT
Human papillomavirus (HPV) is a risk factor for the development of benign and 
malignant mucosal head and neck lesions. P16INK4A is often used as a surrogate marker 
for HPV-infection, although there is still controversy with respect its reliability. Our 
aim was to determine if p16INK4A overexpression can accurately predict both high-
risk and low-risk-HPV-presence in (pre)malignant and benign head and neck lesions. 
P16INK4A immunohistochemistry was performed on paraffin-embedded tissue sections 
of 162 oropharyngeal squamous cell carcinomas (OPSCC), 14 tonsillar and 23 laryngeal 
dysplasias, and 20 tonsillar and 27 laryngeal papillomas. PCR, enzyme-immunoassay 
and FISH analysis were used to assess HPV-presence and type. Of the 162 OPSCC and 
14 tonsillar dysplasias, 51 (31%) and 10 (71%) were HPV16-positive, respectively. All 
tonsillar papillomas were HPV-negative and four laryngeal dysplasias and 26 laryngeal 
papillomas were positive for HPV6 or −11. P16INK4A immunohistochemistry revealed a 
strong nuclear and cytoplasmic staining in 50 out of 51 HPV16-positive and 5 out of 
111 HPV-negative OPSCC (p < 0.0001) and in all HPV16-positive tonsillar dysplasias, 
whereas highly variable staining patterns were detected in the papillomas and laryngeal 
dysplasias, irrespective of the HPV-status. In addition, the latter lesions generally showed 
a higher nuclear than cytoplasmic p16INK4A immunostaining intensity. In conclusion, our 
data show that strong nuclear and cytoplasmic p16INK4A overexpression is a reliable 
surrogate indicator for HPV16 in OPSCC and (adjacent) dysplasias. For HPV6 or −11-
positive and HPV-negative benign and premalignant lesions of the tonsil and larynx, 
however, p16INK4A immunostaining is highly variable and cannot be recommended to 
predict HPV-presence.
Keywords: human papillomavirus, immunohistochemistry, FISH, PCR
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3.2. INTRODUCTION
Human papillomavirus (HPV)-infections may lead to the development of head and 
neck mucosal lesions. High-risk (HR)-HPV16 is involved in the carcinogenesis of 
oropharyngeal squamous cell carcinomas (OPSCC) and is an indicator of favorable 
prognosis, independent of the applied treatment modality. The reported incidence 
of HPV16 in OPSCC ranges from 25% to 93% in different studies, and appears to have 
increased during the last decade. Also the incidence of OPSCC and its proportion within 
the total head and neck squamous cell carcinoma (HNSCC) population are increasing.1, 2 
Low-risk (LR)-HPV6 and −11 especially play a role in the development of benign laryngeal 
lesions. HPV-positivity may help in these lesions to predict a higher risk for recurrence 
and a lower risk for malignant progression in relation to HPV-negative, smoking-induced 
laryngeal lesions.3
In general, two methods are used for the detection of HPV-DNA in clinical diagnosis 
and biomedical research, i.e ., polymerase chain reaction (PCR)-based methods and 
fluorescence in situ hybridization (FISH). PCR is a highly sensitive method, but may not 
be able to distinguish biologically and clinically relevant HPV-containing lesions from 
cases with an extracellular virus contamination. Although FISH is a less sensitive method, 
it is highly specific and has the advantage to visualise the virus-DNA in situ and allows 
the distinction between an episomal and integrated status. Because both techniques 
are relatively costly, technically demanding and requiring sophisticated laboratory 
facilities as well as experienced personnel,4 practical alternatives or complementary 
procedures for HPV-testing have been explored, including the immunohistochemical 
detection of p16INK4A.5
HPV-positive carcinomas are characterized by overexpression of viral oncoproteins E6 
and E7 leading to inactivation of p53 and the retinoblastoma protein (pRb), respectively, 
thereby inducing cell cycle deregulation and inhibition of apoptosis. As a result, 
cyclin-dependent kinase (CDK) inhibitors, including p16INK4A and p21Cip1/WAF1, and 
the MDM2 inhibitor p14ARF are generally upregulated, which subsequently leads to 
downregulation of cyclin D1 and inhibition of its complex formation with CDK4.6-9 
Of these HPV-associated changes in protein expression, p16INK4A overexpression has 
been reported to be the most reliable surrogate marker for the presence of HR-HPV 
in OPSCC.6, 10-12 In contrast, HPV-negative carcinomas, induced by smoking and 
alcohol consumption, are generally characterized by inactivation of the p16INK4A gene 
through loss of 9p21. Therefore, the choice of p16INK4A immunostaining to distinguish 
HPV-positive and -negative malignancies is most obvious.6, 7, 13, 14
P16INK4A immunostaining has long been identified as an objective biomarker for HR-HPV-
positive (pre)malignancies of the uterine cervix, allowing the unambiguous identification 
of truly dysplastic cells in biopsies, thereby reducing interobserver disagreement 
and improving diagnostic specificity.6, 15, 16 In contrast, normal cervical epithelium 
and inflammatory or metaplastic lesions are usually p16INK4A negative, while genital 
lesions containing LR-HPV6 or −11 often show only weak p16INK4A immunostaining.14, 
3
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17-19 Moreover, several studies reported a strong correlation between p16INK4A 
immunostaining intensity and frequency of positive cells with increasing severity of 
the cervical lesion.18, 20-22 The College of American Pathologists and the American Society 
for Colposcopy and Cervical Pathology has recently published their recommendations 
on using p16INK4A immunostaining as a biomarker in lower anogenital squamous lesions, 
introducing the concept of “block-positivity,” defined as continuous strong nuclear or 
nuclear plus cytoplasmic p16INK4A staining of the basal cell layer with upward extension. 
The authors state that this scoring method allows a categorization of precancerous 
disease when the differential diagnosis is between a premalignancy [-intraepithelial 
neoplasia (IN) 2 or -IN 3] and a mimic of a premalignancy known to be not related to 
neoplastic risk. Furthermore, it can be used when -IN 2 is in the differential diagnosis 
to distinguish between a premalignant disease and a low-grade lesion/a non-HPV-
associated pathology. As such, the method is used as an adjudication tool for cases in 
which there is a professional disagreement in histologic specimen interpretation.23
Despite the fact that p16INK4A immunohistochemistry is a low-cost test that can easily 
be implemented in daily diagnostic practice, its reliability as a surrogate marker for 
the presence of HR-HPV has been subject of debate.18, 24 HPV-negative but p16INK4A 
positive cases, although small in number, have been described in many series. It has 
been suggested that this p16INK4A positivity results from pRb inactivation by means 
of mechanisms independent of HPV-infection.4-9, 25, 26 Also the lack of standardization 
of p16INK4A immunohistochemistry and its evaluation criteria may be a source of 
misinterpretations. The foregoing arguments have been a reason for hesitation to 
introduce the p16INK4A test into the clinic.15
Although numerous studies analyzed the expression of p16INK4A in HR- and LR-HPV-
associated cervical premalignancies, these data are scarce for premalignant and benign 
head and neck lesions, and therefore the aim of the present study was to determine 
the usefulness of this biomarker in neoplasms of the oropharynx and larynx. For this 
purpose we analysed a series of 162 OPSCC as well as a range of tonsillar and laryngeal 
dysplasias and papillomas, part of which was expected to harbor HR- and LR-HPV-
types.
3.3. MATERIAL AND METHODS
3.3.1. Tumor material and patient data
Biopsy and resection material was obtained from 227 patients resulting in 246 samples, 
taken at different moments in time. Since our main goal was to evaluate the potential 
of p16INK4A immunostaining patterns as a surrogate marker for HPV in daily routine 
diagnostic practice, i.e ., in every single biopsy sample a pathologist receives from the 
clinic, we present the analyses in the total number of samples in the main text (Table 
1 and Figs. 1a and 1b). For comparison we have included the analyses per patient in 
Supporting Information Table 1 and Supporting Information Figs. 1a and 1b.
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Formaldehyde-fixed and paraffin-embedded tissues were selected from the archives of 
the Departments of Pathology of the University of Cologne, Germany and the Maastricht 
University Medical Centre, The Netherlands. Patients were diagnosed between 1986 
and 2007.
Table 1 summarizes the clinicopathological features of the cases used in this study.
Patient age at first diagnosis ranged from 39–87 years (mean 60) in the OPSCC group 
with no significant difference between the HPV-positive and the HPV-negative cases. In 
the papilloma group, the age ranged from 1 to 72 years (mean 43) and in the dysplasia 
group from 36 to 82 years (mean 62). The specimens included 162 OPSCC (from 162 
patients) and 84 benign and premalignant samples (from 65 patients), i.e ., 14 tonsillar 
dysplasias from 12 patients, 13 of which were adjacent to an invasive carcinoma, 20 
tonsillar papillomas (from 20 patients), 23 laryngeal dysplasias (from 19 patients) and 
27 laryngeal papillomas (from 14 patients).
A correlation of the HPV16 status with the disease-free survival (DFS) data with a 
maximum follow-up time up to 180 months and a mean of 36 months revealed that the 
after 5 years was 55% for patients with an HPV-negative carcinoma and 74% for patients 
with an HPV-positive carcinoma (Hazard ratio = 0.4; 95% Confidence Interval = 0.2–0.8), 
indicating that we used a representative OPSCC patient group.
The OPSCC and dysplasias were histologically classified according to the criteria of the 
World Health Organization (C.J.P.-K. and H.P.D.).27 Eleven out of 14 tonsillar dysplasias 
were graded as severe and three as moderate. From the laryngeal dysplasias six were 
graded as mild, eight as moderate and nine cases as severe (see Table 1).
3.3.2. P16INK4A immunohistochemistry
Immunostaining of p16INK4A was performed on 4-µm-thick formaldehyde fixed, paraffin-
embedded tissue sections, which were deparrafinized using xylol. As a primary p16INK4a 
antibody clone E6H4 (Roche, Almere, The Netherlands) was used and detected using 
Powervision (DAKO A/S, Glostrup, Denmark) and peroxidase-DAB visualisation, as 
previously described.7
Three independent observers (J.J.M., S.E.G., E.-J.S.) performed evaluations of the 
immunostained samples and consensus was acquired about the scores.
P16INK4A immunostaining patterns were first scored on a semiquantative scale, using the 
following evaluation criteria: Score 0 indicates that the majority of the cells are negative 
and that only up to 5% of the cells show nuclear immunoreactivity with or without 
cytoplasmic staining; Score 1 indicates that 5–10% of the cells show a nuclear reactivity 
with or without cytoplasmic positivity; Score 2 indicates a focal staining pattern with 
10–25% of the cells showing nuclear reactivity with or without cytoplasmic positivity; 
Score 3 indicates that >25% cells show a strong nuclear staining reaction with or without 
cytoplasmic positivity.14
The proportion of positive cells is the primary parameter, with the intensity as 
a secondary scoring parameter. All cases scored as 2 and 3 showed a strong 
immunostaining intensity, while few cases scored as 1 stained less intensely positive.
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In addition, we scored the p16INK4A staining patterns according to the “block-type” 
immunopositivity approach, defined as p16INK4A only being block positive if continuous 
(>70%) strong nuclear with or without cytoplasmic staining is present (in all head and 
neck lesions) and staining is observed in the basal cell layer with extension upwards (in 
the benign and premalignant lesions).23 Controls included sections of uterine cervical 
IN grade 2 and 3 (positive controls) and sections from the same cases on which the 
p16INK4A antibody was substituted by a monoclonal mouse IgG2a antibody to Aspergillus 
Niger or by buffer without a primary antibody (negative controls).
3.3.3. DNA isolation and HPV typing by PCR
For DNA isolation, tissues were processed with the QIAamp Tissue Kit (Qiagen, Hilden, 
Germany) according to the manufacturers’ instructions. Total cellular DNA was eluted 
with 250 μl of the AE-buffer (Qiagen) and 5 μl were used in each of the PCR analyses.
To test the quantity and quality of the DNA samples and to demonstrate that the 
samples were free from inhibitory substances, PCR was performed for the ß-Globin 
gene, resulting in a 268 bp PCO4/GH20 PCR product.28 As negative controls water and 
as positive controls human placental DNA were included in each PCR run.
HPV sequences were detected by highly sensitive group-specific nested PCR protocols 
with degenerate primers A5/A10 and A6/A8 for HPV as previously described.29 PCR 
products (5 µl) were separated on 2% agarose gels and visualized by ethidium bromide 
staining. For HPV typing internal biotinylated A6/A8-PCR products (270 bp) were 
hybridized with 37 type-specific digoxigenin-labeled oligonucleotide probes in an 
enzyme-immunoassay as described earlier.30, 31
3.3.4. Detection of HPV6-, 11-, 16- and 18 by FISH
FISH was performed on 4-µm thick formaldehyde fixed and paraffin-embedded tissue 
sections tissue as described previously.32-34 Briefly, sections were deparaffinized, 
pre-treated with 85% formic acid/0.3% H2O2, 1 M NaSCN and 4 mg/ml pepsin, post-
fixed in 1% formaldehyde in PBS, dehydrated in an ethanol series and hybridized 
with digoxigenin-labeled HPV6-, 11-, 16- and 18-specific probes (PanPath, Budel, The 
Netherlands), respectively, depending on PCR results, according to the manufacturer’s 
instructions. After hybridization the preparations were washed stringently in 50% 
formamide, 2× SSC at 42°C (two times 5 min). The probes were detected by subsequent 
application of mouse anti-digoxigenin (Sigma, St. Louis, MO), peroxidase-conjugated 
rabbit anti-mouse and peroxidase-conjugated swine anti-rabbit (both DAKO), and 
visualized by a peroxidase based amplification reaction using rhodamine-labeled 
tyramide.35, 36 Preparations were mounted in Vectashield (Vector Laboratories, 
Burlingame, CA) containing 4,6-diamidino-2-phenyl indole (DAPI; Sigma: 0.2 g/ml). 
Microscope images were recorded with the Metasystems Image Pro System (black 
and white CCD camera; Sandhausen, Germany) mounted on top of a Leica DM-RE 
fluorescence microscope equipped with DAPI and rhodamine filters.
Jos_Binnenwerk_v3.indd   48 24/09/2020   17:04:13
49
P16INK4A and HPV in head and neck lesions
Evaluation of nuclear hybridization signals was performed by two investigators (J.J.M., 
E.-J.M.S.) according to the criteria described by Mooren et al .,37 i.e ., nuclear punctate 
signals were considered to indicate integrated HPV-DNA and diffuse signals to indicate 
episomal HPV-DNA. Controls included hybridizations on HPV6-, −11-, −16- and 18-
positive formaldehyde-fixed, paraffin-embedded tissues of known human uterine 
cervical and head and neck (pre)malignancies. Negative controls consisted of HPV-
negative tissue sections as determined by PCR and hybridizations omitting the viral 
probe.
3.3.5. Statistical analysis
HPV-status and p16INK4A immunostaining were correlated using cross-tabulations and 
the two-tailed Fisher exact test and/or Chi-square test. We regarded a p -value ≤ 0.05 as 
level of significance. DFS in the OPSCC group was calculated from the date of diagnosis 
until the date of recurrence (local, regional or distant, whichever occurred first). Patients 
without recurrence were censored at the date of the last follow-up or the date of death. 
The statistical significance of differences between survival times was determined by 
the log rank test in univariate analysis. All statistical analyses were performed by PASW 
Statistics version 18.0.
3.4. RESULTS
3.4.1. HPV-status of the head and neck lesions examined in this study
The HPV-status of the OPSCC, the premalignant and the benign head and neck lesions 
is presented in Table 1. Only when the presence of HPV was detected by both PCR and 
FISH the sample was judged to be HPV-positive.
Of the 162 OPSCC 51 (31%) were found to be positive for HPV16. All 51 cases showed 
integrated HPV16, as concluded from the FISH-analyses. No other HPV-subtypes were 
detected in these lesions.
Forty of the 84 benign and premalignant lesions (48%) were HPV-positive: 10 (71%) 
of the 14 tonsillar dysplasias harbored HPV16; 4 (16%) of the 23 laryngeal dysplasias 
harbored HPV6, of which two also contained HPV11; of the 27 laryngeal papillomas 
17 (63%) were positive for HPV6, and nine (33%) for HPV11. The frequency of HPV-
infections in these lesions is in accordance with previous studies.38-41 Remarkably, all 
20 samples of tonsillar papillomas were HPV-negative.
In all HPV16-positive tonsillar dysplasias the virus was integrated (Fig. 2b ), whereas 
in one sample additionally an episomal FISH pattern was detected in the cell nuclei 
surrounding tonsillar crypts (data not shown). In all, except one sample, of the HPV6- or 
11-positive laryngeal lesions the virus was episomal (Fig. 2h ).
In the Supporting Information Table 1, the HPV-positivity per patient is presented, for 
comparison, showing only a slightly difference in the frequency of HPV-positivity in the 
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tonsillar dysplasias (83% per patient vs . 71% per sample) and the laryngeal papillomas 
(93% vs . 96%).
3.4.2. Strong correlation between p16INK4A overexpression and HR-HPV16 in 
OPSCC and tonsillar dysplasias
The p16INK4A scores in the HPV-positive and -negative lesions, using the two different 
scoring methods, are shown per subgroup in Figs. 1a and 1b . The analyses per patient 
are presented in Supporting Information Figures 1a and 1b.
The presence of HR-HPV16 in the OPSCC was significantly associated (p < 0.0001) with 
a strong p16INK4A immunostaining reaction (staining Score 3) and with a block positive 
p16INK4A immunostaining: 50 of 51 HPV16-positive OPSCC showed strong nuclear and 
cytoplasmic p16INK4A immunopositivity in more than 70% of the tumor cells, whereas 
only five of the 111 HPV16-negative tumors were p16INK4A positive.
Also all 10 HPV16-positive tonsillar dysplasia samples showed strong (Score 3) p16INK4A 
expression (Fig. 2a). In eight of these an equally strong staining intensity in the nuclei 
and cytoplasm could be observed in more than 70% of the dysplastic cells and these 
were scored as block positive. The remaining two HPV16-positive samples showed a 
strong (Score 3) p16INK4A immunostaining reaction in 40–50% of the lesion, being block 
negative.
Of the 4 HPV-negative tonsillar dysplasia samples, two showed an intermediate p16INK4A 
staining pattern (Score 2) and two samples from one patient were negative (Score 0), 
implying that these were all block negative.
3.4.3. Highly variable p16INK4A immunostaining patterns in the tonsillar 
papillomas and laryngeal lesions
In the 20 HPV-negative tonsillar papillomas, the p16INK4A immunostaining patterns 
were highly variable and ranged from a negative score to a strong staining intensity 
in 30–80% of the cells (Figs. 2d –2f and Fig. 1a). Only one sample was p16INK4A block 
positive (Fig. 1b). In 12 (86%) out of the 14 p16INK4A positive tonsillar papillomas, the 
immunostaining intensity of the nucleus was stronger than that of the cytoplasm.
Of the 23 laryngeal dysplasias, four samples (two from one patient) showed a strong, 
four a low to intermediate and 15 (two from one patient) no p16INK4A expression (Fig. 
1a ). Three of the four HPV6-positive lesions, of which two samples from the same 
patient harbored HPV11-DNA, were p16INK4A negative. The remaining HPV6-positive 
dysplasia sample showed a strong p16INK4A immunostaining (Score 3) and was also 
block positive (Figs. 2c and 2g and Figs. 1a and 1b ). There was no association between 
p16INK4A score and the degree of dysplasia. Although all five mild dysplasias were also 
p16INK4A negative, the moderate and severe dysplasias showed negative to strong p16INK4A 
staining patterns.
P16INK4A staining patterns in the HPV6 and-11-positive laryngeal papillomas varied from 
negative to strongly positive. Five out of the 26 HPV-positive laryngeal papillomas were 
p16INK4A block positive, three of these being from the same patient. Similar to most 
Jos_Binnenwerk_v3.indd   50 24/09/2020   17:04:13
51
P16INK4A and HPV in head and neck lesions
tonsillar papillomas, all of the p16INK4A positive laryngeal lesions showed a stronger 
nuclear than cytoplasmic staining intensity.
In the Supporting Information Figures 1a and 1b , the p16INK4A-positivity per patient is 
presented, showing only minor differences in the frequencies of p16INK4A-immunostaining 
scores, compared to those presented in Figures 1a and 1b (analyses per sample).
3.5. DISCUSSION
Overexpression of p16INK4A has been put forward as a specific surrogate biomarker for 
the presence of HR-HPV, in particular in (pre)malignancies of the uterine cervix, as well 
as those in the head and neck region.6, 7, 13, 14 However, there still exists controversy on 
the reliability of p16INK4A expression as indicator for the presence of HPV, particularly in 
the latter group. In our study, we analysed the relationship between HR- and LR-HPV-
status and p16INK4A immunostaining patterns in 246 samples of benign, premalignant 
and malignant head and neck lesions. A strong (Score 3) and block positive nuclear 
and cytoplasmic p16INK4A staining pattern was predominantly found to correlate with 
HPV16-containing OPSCC and tonsillar dysplasias. In contrast, the tonsillar and laryngeal 
papillomas, as well as the laryngeal dysplasias showed a highly variable p16INK4A staining 
pattern, independent of the HPV-status. By using the block-type scoring approach, 
however, most of these lesions were interpreted as being p16INK4A block negative.
It is now well established that HPV-associated HNSCC represent a separate entity, 
which is clinically and molecularly distinct from its tobacco- and/or alcohol-induced 
counterpart.2, 7, 37 The upregulation of p16INK4A results from inactivation of pRb by the 
HPV-E7 oncoprotein, or alternatively through E7-mediated epigenetic induction of 
KDM6B, subsequently leading to activation of the p16INK4A gene.6, 16
Although several studies have reported a high interobserver conformity in the evaluation 
of p16INK4A immunostaining patterns,4, 14, 18, 19, 42 others have indicated limitations in this 
procedure. The immunohistochemical p16INK4A staining procedure is subject to variations 
in the protocol and to difficulties in the interpretation of the staining patterns as a result 
of different scoring criteria.17 There is an emerging consensus that only samples showing 
strong nuclear and cytoplasmic p16INK4A immunostaining, observed in more than 25% 
of tumor cells, should be considered HPV-positive.5, 13, 14, 18, 20-22 Recent studies even 
suggest to use 70% immunopositivity of the carcinoma tissue as a cut-off point.4, 11, 12 In 
our study, we indeed observed the strong and block positive p16INK4A immunostaining in 
all except one HPV16-positive OPSCC. Despite the fact that a small fraction of the HPV-
negative OPSCC did show p16INK4A positivity, the correlation of this surrogate marker 
with HPV16-presence is highly significant.
Also in all HPV16-positive tonsillar dysplasias of the present study a strong, and in most 
cases block positive, p16INK4A immunostaining pattern could be detected, which is in 
accordance with the results in cervical dysplasias.14, 19 Similar to OPSCC, also in these 
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lesions we identified p16INK4A positive staining in two HPV-negative samples, albeit with 
an intermediate score and being block negative.
The use of p16INK4A immunostaining as surrogate marker for HPV-presence in laryngeal 
dysplasias and head and neck papillomas, however, is unreliable. In the HPV6/11-positive 
laryngeal dysplasia samples the majority of cases was p16INK4A negative, while 1/3 of the 
HPV-negative samples did show p16INK4A positivity. LR-HPV-integration seldomly occurs 
and the only laryngeal papilloma sample harboring nuclear punctate HPV6-FISH signals 
only showed weak p16INK4A immunostaining. In a recent study on juvenile onset laryngeal 
papillomatosis progressing to carcinoma in one patient, the papilloma with episomal 
and the carcinoma with integrated HPV6 were all p16INK4A negative.43
All our tonsillar papilloma samples were HPV-negative, whereas 70% of the samples 
showed variable p16INK4A positivity, indicating that p16INK4A immunostaining appears 
of no use for predicting HPV-presence in these lesions. This is in accordance with 
a previous study on tumor-free palatine tonsils, all proven to be negative for HPV, 
but showing p16INK4A overexpression in a quarter of these normal cases.25 By using 
the block-type scoring system, however, most tonsillar and laryngeal papillomas and 
laryngeal dysplasias were interpreted as being p16INK4A block negative. This fits with 
the fact that these head and neck lesions are usually HPV-negative or contain LR-HPV 
types. Block-positivity is used to identify HR-HPV-containing precancerous anogenital 
lesions, which is in accordance with the block-positivity observed in our study in OPSCC 
and tonsillar dysplasias, being associated with HR-HPV.23
Also at a subcellular level variability in p16INK4A immunostaining patterns could be 
observed: in the HPV16-positive OPSCC and tonsillar dysplasias we predominantly 
found an equally strong p16INK4A staining intensity in nuclei and cytoplasm, whereas in 
the other head and neck lesions the nuclear intensity was generally stronger than that 
of the cytoplasm.
The fact that studies on oral papillomas showed an HPV-positivity in 13–60%, 
predominantly HPV6 or −11,44-46 makes the absence of HPV in the tonsillar papillomas 
in our series remarkable. The lack of HPV in these samples might be explained by 
elimination of the virus by the immune system with persistence of the lesions, or by the 
fact that other viruses, yet to be discovered, play an etiological role in the development 
of the tonsillar papillomas. Also the mechanisms underlying the predilection of different 
HPV-types for different anatomical head and neck lesions remain to be further 
explored.
The highly variable p16INK4A immunostaining patterns in the benign and premalignant 
head and neck lesions may be explained by several other factors. It is well described in 
the literature that in uterine cervical lesions LR-HPV6 results in a less intense p16INK4A 
immunostaining pattern as compared to HPV16, which is caused by the fact that the 
affinity of the HPV6 E7 protein for cellular pRb is 10-fold lower than that of HPV16 E7.19, 47, 
48 Therefore, it is surprising that our HPV6/11-containing benign and premalignant head 
and neck samples were often strongly positive, or completely negative for p16INK4A.
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Since a subgroup of HPV-negative lesions also shows overexpression of p16INK4A, several 
factors have been proposed to explain this observation, which remain to be studied. 
These include infection with other viruses (i.e ., cytomegalovirus and adenovirus), which 
functionally inactivate pRb in a similar fashion as the HPV-oncogene E7,49, 50 physiological 
stress, oncogene-driven senescence by functional overactivation of (proto)oncogenes 
including Ras, Raf, MEK and E2F or replicative senescence due to DNA-damage or 
oxidative stress.51-54
In summary, our results indicate that a strong nuclear and cytoplasmic p16INK4A 
immunostaining pattern can accurately predict the presence of HR-HPV16 in OPSCC 
and tonsillar dysplasias. Our data underscore the proposed cut-off level of 70% p16INK4A 
positive cells, corresponding to block positive p16INK4A immunopositivity, in these lesions 
as indicator for HR-HPV16-presence. In the other premalignant and benign head and 
neck lesions, however, caution is recommended when using this surrogate marker for 
HPV-infection.
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Table 1. HPV-status and clinicopathological features of all head and neck lesion studied
 OPSCC Tonsillar 
dysplasia
Tonsillar 
papilloma
Laryngeal 
dysplasia
Laryngeal 
papilloma
 (n  = 162) (n  = 14) (n  = 20) (n  = 23) (n  = 27)
Number of different 
patients
162 12 20 19 14
Gender
Male 117 (72%) 9 (75%) 12 (60%) 18 (95%) 12 (86%)
Female 45 (28%) 3 (25%) 8 (40%) 1 (5%) 2 (14%)
Mean age at first 
diagnosis (range)
60 (39–87) 60 (36–79) 42 (5–66) 63 (43–82) 44 (1–72)
TNM status
T1 23 (14%)
T2 54 (33%)
T3 46 (29%)
T4 39 (24%)
N0 51 (31%)
N1 29 (18%)
N2 64 (39%)
N3 15 (9%)
Missing 3 (3%)
M+ 4 (3%)
Histology grade (all samples)
Mild 0 (0%) 6 (26%)
Moderate 3 (21%) 8 (35%)
Severe 11 (79%) 9 (39%)
Number of HPV-
positive samples
51 (31%) 10 (71%) 0 (0%) 4 (17%) 26 (96%)
HPV–PCR (all samples)
HPV 6 4a 17
HPV 11 2 9
HPV 16 51 10
HPV–FISH (all samples)
Integrated 51 9 1b
Episomal 1 4 26
a Two out of these four HPV6-positive samples were also positive for HPV11.
b This sample showed both episomal and integrated HPV6.
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Figure 1
 (a) P16INK4A immunostaining scores in all (pre)malignant and benign head and neck lesions. 
Scoring criteria: Score 0 negative; Score 1: 5–10% of the cells show a nuclear reactivity with or 
without cytoplasmic positivity; Score 2: focal staining pattern with 10–25% of the cells showing 
nuclear reactivity with or without cytoplasmic positivity; Score 3: >25% cells show a strong 
nuclear staining reaction with or without cytoplasmic positivity.14 (b) Immunostaining results 
for p16INK4A in all (pre)malignant and benign head and neck lesions based on the block-type 
scoring approach, defined as p16INK4A only being interpreted as positive if continuous (>70%) 
strong nuclear with or without cytoplasmic staining is present (in all head and neck lesions) 
and is observed in the basal cell layer with extension upwards (in the benign and premalignant 
lesions).23
3
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Figure 2
Representative examples of p16INK4A immunohistochemistry (a , c–g) and HPV-specific FISH 
analysis (b , h) in head and neck lesions. (a ) Strong nuclear and cytoplasmic p16INK4A immunostaing 
(Score 3) and also block-positive p16INK4A staining pattern in a tonsillar dysplasia; (b) Punctate 
signal (red) per nucleus (blue DAPI) indicating integrated HPV16 in a tonsillar dysplasia; (c) Strong 
nuclear and cytoplasmic p16INK4A immunostaining (Score 3) and also block-positive p16INK4A 
staining pattern in a laryngeal dysplasia sample; (d) Tonsillar papilloma sample showing strong 
nuclear and weaker cytoplasmic p16INK4A immunostaining (Score 3), but scored as being block-
negative. (e , f) Tonsillar papilloma samples showing a focal staining pattern with 10–25% of the 
cells showing nuclear and cytoplasmic positivity (Score 2; e), and showing 5–10% of the cells with 
a nuclear and cytoplasmic positivity (Score 1; f). (g) Laryngeal dysplasia sample showing 0–5% of 
the cells showing nuclear and cytoplasmic p16INK4A immunopositivity (Score 0); (h) Diffusely (red) 
stained nuclei (blue DAPI) indicating episomal presence of HPV6 in a laryngeal papilloma.
Jos_Binnenwerk_v3.indd   60 24/09/2020   17:04:13
61
P16INK4A and HPV in head and neck lesions
3
Jos_Binnenwerk_v3.indd   61 24/09/2020   17:04:13
Jos_Binnenwerk_v3.indd   62 24/09/2020   17:04:13
4
Value of human papillomavirus testing in the 
diagnostic workup of lymph node metastases from an 
unknown primary tumor to the neck.
Published: Straetmans JM, Speel EJ, Kremer B. Value of human papillomavirus 
testing in the diagnostic workup of lymph node metastases from an unknown 
primary tumor to the neck. Head Neck 2012;34:1819-1821.
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In their article, Strojan et al1 promote human papillomavirus (HPV) testing in patients 
with metastases of unknown primary tumors to the neck (CUP). This advice is merely 
based on retrospective studies on patients with CUP in which the HPV status of the 
metastasis was compared with that of the primary tumor identified during diagnostic 
workup, suggesting that HPV positivity is indicating an origin in the oropharynx.2–6 If the 
authors are right, HPV testing could improve the sensitivity of current extensive diagnostic 
workup protocols applied to patients with true CUP by identifying “missed” (or formerly 
undetected) oropharyngeal primary tumors.
However, studies on the prevalence of HPV in lymph node metastases of which the 
primary tumor could not be detected after diagnostic workup so-called “true” CUPs are 
scarce and contradictory. HPV prevalence rates range from 0% to 100% and were tested 
in very small sample numbers: Weiss et al7 0/1 (0%), Armas et al8 0/4 (0% in N3 necks; 4/4 
Epstein Barr virus–positive), Begum et al5 3/10 (30%), Barwad et al9 9/17 (53%), Hofmann 
et al10 2/3 (66%), Desai et al11 4/6 (66%), and Goldenberg et al3 2/2 (100%). Compton et 
al12 investigated HPV16 presence by DNA in situ hybridization in a cohort of resected, 
nonirradiated true CUPs: of 11/25 p16-positive, there were 7/25 HPV-positive (28%) 
tumors. However, a relationship with survival was not found. So far, no studies have 
been reported in which additional HPV testing has led to the discovery of the primary 
tumor in case the regular diagnostic workup revealed a true CUP.
In our institute, 29 true CUPs (all squamous cell carcinomas) were analyzed with no prior 
history of head and neck carcinoma. Diagnostic workup consisted of MRI or CT of the head 
and neck, CT of the thorax, and ultrasonography with fine-needle aspiration cytologic 
study in all patients. In 18 patients, positron emission tomography–CT of the whole body 
was executed. Panendoscopy was routinely performed with biopsy of the base of the 
tongue, epipharynx, and ipsilateral tonsillectomy. After treatment with ipsilateral neck 
dissection (29/29) and ipsilateral radiotherapy of the neck (27/29), without radiation of 
pharyngeal axis and contralateral neck (21/27), 5-year follow-up revealed no primary 
tumors. HPV was tested on all (nonirradiated) surgical specimens (paraffin-embedded): 
5/29 were p16-positive without association with survival. However, in none of the 
specimens was HPV-DNA detected by fluorescence in situ hybridization and polymerase 
chain reaction (HPV16-DNA), or GP5 /6 PCR (0%). Therefore, in our cohort, HPV testing 
did not add value to the described diagnostic workup and did not influence therapeutic 
decision-making, for example, additional postsurgical radiotherapy of the oropharynx.
Currently, the prevalence of HPV in true CUPs seems insignificant despite the relationship 
of oropharyngeal viral carcinogenesis and its pattern of lymph node metastasis. The 
prognostic and therapeutic implications of HPV in true CUPs are therefore limited until 
now. Probably, most HPV-positive primary tumors of the oropharynx are detected by 
tonsillectomy or “blind biopsies” of the oropharyngeal region, resulting in low percentages 
of HPV- positive true CUPs. A prospective study is warranted to investigate the value of 
HPV presence in lymph node metastases of true CUPs regarding the detection of the 
primary oropharygneal tumor and to explore whether de-escalation of therapy in HPV-
positive true CUPs can be considered.
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5.1. ABSTRACT
Combined analysis of diagnostic and therapeutic management of neck metastases of 
carcinoma of unknown primary origin (‘true CUP’) in two European tertiary referral 
centers (University Medical centers of Maastricht, NL and cologne, D) to contribute to 
the ongoing discussion on management in CUP. Retrospective analysis of 29 (Maastricht) 
and 22 (cologne) true cervical CUP syndrome patients (squamous cell carcinoma). The 
diagnostic and therapeutic approaches were correlated with clinical follow-up data 
and HPV status. In total, 48 out of 51 true CUP patients received postsurgical adjuvant 
radio- therapy. In eight patients from cologne, this was combined with concomitant 
platin-based chemotherapy. neither in cologne nor in Maastricht, radiotherapy of the 
pharyngeal mucosa was commonly performed (n=6, 12.5%). The percentage of patients 
who were irradiated ipsilaterally or bilaterally did not differ between both institutes 
(N= 21/27 in Maastricht vs. 11/21 in Cologne), nor did the 5-year overall survival differ 
significantly. Oncogenic HPV was only found in 4 out of 51 CUPs (7, 8 %). Therefore, no 
relation with overall and recurrence-free survival could be detected. no occult primary 
tumors were revealed during follow-up despite de-escalation of therapy by abandoning 
irradiation of the pharyngeal mucosa in both institutes. There were no significant 
differences between ipsilateral and bilaterally irradiated patients regarding overall and 
recurrence-free survival. The occurrence of distant metastases was more often noticed 
in ipsilaterally treated patients as compared to bilaterally radiated patients (8 vs. 2, 
p=0.099). Those patients all had been classified N2b or higher. International guidelines 
still are not unified and there is an urgent need for a consented therapeutic regimen. 
Comparison of two international strategies on the management of CUP patients is 
presented and further research is recommended regarding the role of radiotherapy 
of the pharyngeal axis, the value of unilateral and bilateral radiotherapy and the role 
of concomitant or induction chemotherapy in CUP patients, particularly in N2b or 
higher-staged neck disease. The prevalence and role of HPV in true CUP after thorough 
diagnostic work-up seem limited in our case series, particularly when compared to the 
role in oropharyngeal carcinomas.
Keywords cervical carcinoma of unknown primary (CUP) · neck · Diagnosis · Treatment 
· Outcome
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5.2. INTRODUCTION
Carcinoma of unknown primary cancer (CUP) is defined as a metastatic disease with 
its origin remaining unknown despite extensive clinical, laboratory and imaging 
examinations.1 Up to 10 % of all cervical lymph node metastases present without a 
known primary site.1 The histopathology is most commonly squamous cell carcinoma, 
but CUP lymph nodes can also consist of adenocarcinoma, as reported in a review of 
223 patients by Lee et al.2
A unified strategy for CUP management is desirable, not only to optimize diagnostics 
and therapy, but also to minimize side effects and finally to improve the outcome 
and survival of those patients. However, for CUP syndrome, no joined diagnostic 
or treatment strategies have yet been determined. In multiple countries, national 
consensus guidelines (e.g., German Oncologic Society3, Dutch national Guidelines4) 
recommend diagnosis and treatment strategies of cervical CUP. However, they vary,5–7 
and no unified regimen has yet been established.1, 8, 9
Rodel et al.10 already in 2009 called for a unified treatment strategy in cervical CUP 
syndrome, and outlined in a heterogeneously treated group of 58 patients that the 
treatment needs to be unified and optimized.
In Germany, ultrasonography of the neck, in some centers including fine needle 
aspiration cytology (USgFNAC) of the suspected lesion, is generally recommended.11 
Fluoro-deoxy-glucose positron emission tomography (FDG-PET) may be helpful to 
identify a primary cancer due to its enhanced glucose metabolism.12, 13 However, in 
Germany, it is not universally conducted – be it for financial and insurance aspects (high 
costs which are not always covered by insurances) or for availability (not every hospital 
has a positron tomogram). Thus, variations in diagnostic and therapeutic approaches 
to patients presenting with CUP syndrome may lead to differences in prognosis and 
outcome within one country and even between centers.
In the Netherlands, general diagnostic approaches in patients with suspected cervical 
CUP syndrome include ultrasonography of the neck with guided fine needle aspiration 
cytology, CT and/or MRI of the head and neck, as well as chest X-ray.11, 14, 15 In the last 
decade, PET-CT scanning has been introduced and has established an important role 
in detecting occult tumor sites.14, 16 Therefore, a combined FGD-PET-CT of the whole 
body is currently recommended as stated in the Dutch national guidelines.8, 14, 15, 17–22
In case of squamous cell carcinoma (SCC), there is international consensus that the 
above-mentioned diagnostic approaches should be completed with panendoscopy 
(pharyngeal and laryngeal endoscopy, combined with cervical esophagoscopy and a 
bronchoscopy under general anesthesia), to search for a potential primary tumor in the 
mucosal alignment of the larynx, pharynx, trachea and upper esophagus.16 Systematic 
biopsies of suspected regions, biopsies of the nasopharynx and base of the tongue, as 
well as an ipsilateral tonsillectomy are routinely performed to detect occult primary 
tumors. If a tonsillectomy was performed in the past, biopsies of the tonsillar fossa 
should be obtained.
5
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Retrospective studies on patients with CUP syndrome, in which the HPV status of the 
neck lymph node metastasis was compared to that of the eventually identified primary 
tumor, showed that HPV positivity is an indicator for a primary cancer originating in 
the oropharynx.23–26 HPV testing could, therefore, improve the sensitivity of current 
extensive diagnostic work-up protocols applied to true CUP patients by indicating an 
occult oropharyngeal primary tumor in HPV-positive metastasis. Thus, the addition 
of HPV testing to the diagnostic work-up in patients with CUP is recommended by 
some authors23–27 and the recommendations particularly concern the investigation 
of HPV status in true CUP patients to detect potential HPV-positive primary cancers 
which were missed during the regular diagnostic work-up in CUP.28, 29 However, it is 
questionable whether HPV-positive primary tumors of the tonsil or base of tongue are 
not already detected by tonsillectomy, biopsies of the base of tongue and/or biopsies 
during panendoscopy.24, 25, 28–32
After the diagnosis of a ‘true CUP syndrome’ with exclusion of a primary cancer, an 
appropriate treatment modality should be established. To achieve loco-regional 
control, a combination of surgery (tonsillectomy as a diagnostic tool to exclude a 
primary cancer and ipsilateral neck dissection) and adjuvant radiotherapy are most 
commonly performed in CUP syndrome.14, 18, 33 Singular treatment modalities, such 
as neck dissection or radiotherapy alone, may be appropriate for patients with more 
favorable clinical N-stages.14, 18, 34 Also, adjuvant chemoradiation (with or without a 
neck dissection) can be applied in patients with CUP, but may be associated with an 
increased toxicity.35, 36
There is a current debate on most efficient therapies regarding oncologic results and 
associated toxicity of more aggressive treatment protocols. The extent of radiotherapy, 
in particular whether administered ipsilaterally or bilaterally in the neck and with or 
without additional radiation of the pharyngeal mucosa, is subject of controversies; and 
a general consensus is yet to be established.37
In the literature, depending on the used treatment modalities and patient characteristics, 
5-year loco-regional disease-free (LR-DF) survival rates vary from 44.0 to 66.0 %.20, 33, 38, 
39 Five-year overall survival rates vary from 27.0 to 66.0 %.14, 16, 18–20, 33, 36, 39, 40
5.2.1. Hypothesis and aim
This present study aimed at analyzing the current therapeutic regimen conducted in 
two European oncologic centers. The two collaborating head and neck cancer centers, 
both tertiary referral hospitals in University medical centers (Maastricht, Netherlands, 
121,050 inhabitants with a referral area containing about 1,500,000 inhabitants, and 
Cologne, Germany, 1,000,000 inhabitants) united in this retrospective analysis of patient 
records to analyze and compare their data.
Patient data were evaluated regarding the role for HPV testing and the influence of HPV 
prevalence on outcome was explored, as well as the value of irradiating the pharyngeal 
mucosa to treat occult primary tumor sites. Lastly, regional control rates were described 
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and compared in patients treated with bilateral versus ipsilateral postsurgical radiation, 
with or without concomitant chemotherapy.
5.3. MATERIALS AND METHODS
5.3.1. Patient population
The data of patients presenting with CUP syndrome to the Department of 
Otorhinolaryngology, Head and neck Surgery of the University of Cologne and 
Maastricht Medical Centre, from 1997 to 2010 were retrospectively assessed. Patients 
were included if no primary tumor was detected during thorough staging examinations 
(‘true CUP’) and if histopathological material was available (Cologne: n = 22; Maastricht: 
n = 29). Thus, patients who only received radiation without surgical therapy were 
excluded. This retrospective investigation was approved by the ethics committees of 
the University of Cologne as well as Maastricht Medical Centre.
5.3.2. Diagnostic work-up in both centers
In Cologne, all patients underwent ultrasound of the neck with ultrasound guided fine 
needle aspiration cytology (USgFNAC) of the suspected mass, computed tomography 
(CT) or magnetic resonance imaging (MRI) of the head and neck, CT of the abdomen 
and thorax, abdominal ultrasonography, skeletal scintigraphy and positron emission 
tomography (FDG-PET, since 2008).
In Maastricht, patients underwent ultrasonography of the neck and USgFNAC of the 
suspected lesion, MRI or/CT of head and neck, chest X-ray or CT-thorax and combined 
PET/CT scanning (whole body, since 2002).
In both institutes, a panendoscopy was performed: In Cologne, patients underwent 
panendoscopy of the upper aerodigestive tract (pharyngeal and laryngeal endoscopy 
combined with rigid esophago-(gastroduodeno-)scopy and a rigid bronchoscopy under 
general anesthesia. If no primary tumor was found in these staging examinations, 
bilateral tonsillectomy and biopsies of the base of tongue as well as curettage of the 
nasopharynx for histopathological evaluation were executed.
In Maastricht, patients underwent a panendoscopy similarly, during which biopsies of 
base of tongue and nasopharynx and an ipsilateral tonsillectomy were performed. The 
contralateral tonsil was not removed.
5.3.3. Patient collective
In Maastricht, true CUP Syndrome is classified as no known primary cancer found—
when a primary cancer can be identified, patients are registered by tumor location. 
It was, therefore, not possible to investigate retrospectively how many patients 
initially presented with a neck mass suspicious of CUP. In Cologne, similarly, patients 
presenting with a neck mass are treated with intensive staging, however, we were able 
to retrospectively show in how many patients a primary cancer could be found in this 
5
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patient collective (in 20 out of 47 patients, 30 %).41. Only the 27 true CUP patients were 
analyzed in the presented study.
Of all neck dissections in Cologne, the resection margins were classified by the 
pathologist as resected radically (R0). In Maastricht, the width of resection margins 
was specified in mm (Table 3).
5.3.4. Histopathology: additional HPV testing in the diagnostic work-up
In both institutes, HPV testing was assessed as follows: the lymph node metastases 
obtained via neck dissection were investigated retrospectively for HPV-DNA using PCR, 
and HPV typing was subsequently performed, as well as p16-immunohistochemistry. 
Since our two cancer centers collaborate, the HPV-investigations, including HPV-
analysis, were performed at the same laboratories to exclude inter-investigator 
variations. Tissue biopsies from lymph node metastases were analyzed according to 
the following protocols. HPV-16-FISH (fluorescence in situ hybridization) analyses were 
performed retrospectively in 2011, as previously described by Hafkamp et al.42, 43
5.3.5. Treatment protocols in both centers
Cologne
In Cologne, patients underwent a neck dissection of the ipsilateral neck: lymph nodes 
of levels I to V, as classified by Robbins,44, 45 were dissected with intended preservation 
of the jugular vein, the sternocleidomastoid muscle and the accessory nerve. The tissue 
from each level was placed in a separate pathology jar, submersed in 4 % formaldehyde 
and then submitted for histopathological investigation, where the lymph nodes were 
dissected, embedded and sectioned as described by Schroeder et al.46 Regarding 
adjuvant radio- and chemotherapy, no standard protocol was used for determining 
the choice between ipsi- and bilateral radiotherapy whether or not combined with 
chemotherapy. Adjuvant radiotherapy was performed with linear accelerators (6 MeV) 
after three-dimensional treatment planning. The clinical target volume included the 
involved lymph node area, ipsi- or contralateral cervical and supraclavicular lymph 
nodes. The pharyngeal mucosa was not irradiated as such. Total dose to this volume was 
in the mean 50.4 Gy. Macroscopically involved lymph nodes were boosted to 59.4–63 
Gy. Chemotherapy consisted of carboplatin administration (20 mg/m2 body surface daily 
in week one and five, n = 8 in Cologne). no standard protocol was used for the choice 
of administering concomitant chemotherapy. In general, the decision for adjuvant 
therapy was made in consensus with the patient: after surgery, in an interdisciplinary 
informative discussion with the patient, all advantages and risks and side effects of 
chemoradiation were explained. The patient could then decide on the adjuvant therapy 
he desired, and in case of lymph nodes larger than N1, the general recommendation 
for adjuvant chemoradiation was given.
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Maastricht
Regarding the treatment protocol in Maastricht, a modified radical neck dissection was 
performed (levels I to V), in which the jugular vein and sternocleidomastoid muscle 
routinely were resected.9, 47 The accessory nerve was preserved if feasible. Patients 
treated before 2002 in general underwent an ipsilateral neck dissection and post-
operative radiotherapy of the pharyngeal mucosa and the bilateral neck. The elective 
radiation dose to the uninvolved neck regions and the pharyngeal mucosa was 46–50 
Gy. The regions of the involved nodes were treated up to 60–66 Gy. After 2002, the 
treatment protocol was changed with abandoning radiation treatment of the pharyngeal 
mucosa and the contralateral neck, only performing post-operative ipsilateral radiation 
of the neck following ipsilateral neck dissection.
Also, after 2002, in the N1 (single metastatic lymph node <3 cm) without radiographic 
signs of extracapsular growth in the staging examinations, single treatment modalities, 
e.g. ipsilateral surgery or radiotherapy alone, were occasionally performed in Maastricht 
(in 25 % of CUP patients in Maastricht in the decade). In patients with neck dissection, 
radiological findings were verified by histopathology. Patients not undergoing surgical 
therapy were thus excluded because their lymph node state was not pathologically 
confirmed and HPV status could not be examined. Concurrent chemotherapy during 
radiation was not used in the Maastricht cohort.
5.3.6. Statistical analysis
Statistical analysis was performed using SPSS® (Statistical Package for the Social Sciences, 
USA, Versions 18.0 and 19.0). Disease-free survival (DFS) and overall survival (OS) rates 
were estimated using the Kaplan–Meier algorithm for incomplete observations. The 
overall survival time was defined as the interval between the date of diagnosis and the 
last date when the patient was known to be alive (censored) or date of death for any 
reason (uncensored). The disease-free survival rate was measured as the period of time 
between the date of diagnosis and the date of the last follow-up examination in which 
the patient was disease free (censored), or the date of first recurrence independently 
if it was a local, regional, or distant recurrence (uncensored). The log-rank test was 
used to test for differences between subgroups. Statistical correlation was performed 
with the Chi-square test. A p value <0.05 was considered statistically significant in 
two-sided tests.
5.4. RESULTS
5.4.1. Demography: comparison of patient groups between Maastricht and 
Cologne
There were no significant differences concerning age, tobacco smoking behavior, alcohol 
consumption and tumor differentiation grade between the patients of Maastricht 
and Cologne. Regarding gender, the Maastricht-group consisted of 22 men and 7 
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women whereas in the Cologne-group, there were only men (n = 22, p < 0.001). No 
differences were found in both institutions comparing the clinical N-status determined 
after radiology with the pathological N-status determined after neck dissection. Both 
clinical and pathological N-status were distributed equally in both study groups (Table 
1). In the Maastricht-group, however, nine pN3-neck lymph node metastases were 
included, compared to three pN3-metastases in Cologne [31 % (9/29) and 13.63 % 
(3/22), p = 0.147].
None of the patients presented with contemporary distant metastases at 
the time of diagnosis.
Prior to panendoscopy and neck dissection, two patients from Maastricht underwent a 
diagnostic nodal excision at the neck at other hospitals as compared to seven patients 
from Cologne (p = 0.021). The average time from first presentation of disease until 
neck dissection at the University Medical Centers was 40 days in Maastricht and 26 
days in Cologne (p = 0.005). In histopathological analysis, extracapsular growth of 
the metastases was found in 22 patients from Maastricht (75.9 %) as compared to 18 
patients from Cologne (81.8 %, p value: NS).
5.4.2. Treatment of CUP patients
Out of the 51 included patients, 48 patients received adjuvant radiotherapy. 
Concomitant chemotherapy was administered to eight patients in Cologne (carboplatin 
20 mg/m2 body surface daily in week 1 and 5). Three patients were not irradiated: two 
patients refused further treatment and in the third patient, a distant metastasis was 
discovered at the planning PET-CT of the whole body, as it has become routine work-up 
in Holland in recent years.
Two patients received adjuvant radiotherapy elsewhere and the records were unclear 
whether treatment was administered ipsi- or bilaterally. Those patients were excluded 
from the analysis when comparing the extension of adjuvant radiotherapy.
Thirty-two patients received postsurgical radiotherapy in the ipsilateral neck and 14 
patients bilaterally. Eight patients received concomitant chemotherapy (ipsilateral 
RT: n = 2; bilateral RT: n = 6) and another six patients were treated with additional 
radiotherapy of the pharyngeal mucosa (bilateral RT: n = 6).
No differences were noted between adjuvantly treated groups regarding age, gender, 
institute of inclusion in Maastricht or Cologne, smoking and alcohol behavior. Patients 
treated with adjuvant bilateral radiotherapy were all but two (pN2a) staged with pN2b 
or higher involved lymph nodes.
5.4.3. Five-year overall survival and disease-free survival rates related to 
adjuvant radiation strategy
The 5-year overall survival (5-year OS) was 54.9 % in our patient population (n = 51). 
For patients treated with ipsilateral adjuvant radiotherapy, the 5-year OS was 67.6 
% as compared to 35.7 % for the bilateral RT-group (log rank, p < 0.001, Fig. 1). This 
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difference is caused by the difference in pN-status between both groups, as patients 
treated with neck dissection and adjuvant bilateral radiotherapy were all —but two 
(pN2a)— staged with pN2b or higher involved lymph nodes. The 5-year OS for patients 
with a pathologically staged neck pN1-N2a was 81.8 % as compared to 46.2 % for 
pN2b or higher. In the latter group, however, 5-year OS also did not differ significantly 
between both adjuvant radiotherapy-groups.
5.4.4. Local control: the value of radiotherapy of the pharyngeal mucosa 
in treating possibly missed primary tumors
Only six patients in our patient population of n = 51 received radiotherapy of the 
pharyngeal mucosa. There was only one oropharyngeal tumor found during follow-up 
presenting 52 months after therapy. This tumor was treated as a second primary cancer 
considering the period of more than 4 years after the initial CUP syndrome (Table 2; Fig. 
1). Table 2 shows tumor characteristics and clinical follow-up data.
5.4.5. Regional control: the value of adjuvant ipsilateral versus bilateral 
radiotherapy
Nine patients experienced regional recurrence during follow-up and in one patient, 
there was residual disease after treatment. All recurrences were seen in patients with 
a maximum nodal size of >3 cm or a conglomerate of lymph nodes.
Regarding regional recurrence rates, there was no significant difference between 
the ipsilaterally or bilaterally adjuvant RT-group (6 vs. 2 recurrences in resp. 32 and 
14 patients). There was also no difference in sidedness of the recurrence between 
both groups: 50 % of recurrences in both groups were found in the contralateral neck. 
However, in two patients with recurrent disease in the contralateral neck, remission 
of disease could be established after dissection of the contralateral lymph nodes.
In one patient, staged pN3, PET/CT scanning after radiotherapy revealed incomplete 
response to therapy after R2 resection and also a contralateral recurrence and a newly 
diagnosed distant metastasis to the lung.
5.4.6. Occurrence of distant metastases
In total, nine patients developed distant metastases. They were all initially treated for 
pN2b or higher-staged lymph node involvement.
There was no significant difference in the occurrence of distant metastases between 
patients treated with adjuvant ipsilateral radiotherapy (8/32) and patients treated with 
bilateral radiotherapy (1/14) or with concomitant chemotherapy (1/8). There were no 
further patient characteristics associated with the occurrence of distant metastases.
5.4.7. Disease-free survival
In total, 13 patients presented with recurrence of disease. All recurrences or distant 
metastases were found within 2 years after therapy. For ipsilateral radiotherapy, the 
2-year disease-free survival was 68.8 % (n = 32). When comparing pN1-N2a with pN2b 
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or higher-staged neck, the 2 year-DFS was 88.9 % compared to 60.9 %. For bilateral 
radiotherapy, the 2-year disease-free survival was 78.6 % only (n = 14: all but two pN2a 
necks were pN2b or higher).
One patient experienced residual disease after adjuvant radiotherapy together with a 
contralateral recurrence and distant metastasis (mainly to the lung, but also bone and 
liver). Interestingly, six patients experienced recurrent regional disease within 6 months 
after radiotherapy, five of which simultaneously showed distant metastases.
Table 3 shows the different diagnostic and treatment strategies of CUP patients in 
Maastricht and Cologne.
5.4.8. The role of HPV testing in CUP syndrome
In none of the 29 tested samples of Maastricht, HPV could be found when tested for 
p16-/HPV-PCR and HPV-FISH. In the 22 tested neck dissection samples of Cologne, 
four samples were identified as HPV-positive (18.2 %). In one of the four HPV-positive 
patients, an oropharyngeal tumor originating from the base of tongue was found after 
52 months of follow-up. In Maastricht, no HPV-positive tumor was found.
In this total investigated population, the prevalence of HPV was 7.8 %. The relationship 
of HPV association with local control, regional control and the 5-year OS was absent as 
a consequence of the low prevalence. In Maastricht, no HPV-positive tumor was found. 
Table 2 shows the results of HPV testing in Cologne, related with tumor characteristics 
and clinical follow-up.
In comparison to oropharyngeal cancers, in which percentages of HPV infection are 
reported to be as high as 30– 70 %, this appears to be a different tumor entity.41, 48
5.5. DISCUSSION
The diagnostic and therapeutic approach of cervical metastases of unknown primary 
tumors is debated in the current literature.16, 17, 19
International guidelines still are scarce and diverse and there is an urgent need for a 
unified regime. This current description of treatment strategies in two European tertiary 
medical centers highlights the international diversity in therapeutic approaches, despite 
the high medical and scientific standards. Most international guidelines focus on CUP 
syndrome in general (also inguinal and para-aortal, published by hemato-oncological 
societies) and are not specific for the management of cervical CUP (e.g. http://www.
NICE.org.uk, http://www.dgho-onkopedia.de).
Comprehensive guidelines for the management of cervical CUP syndrome have been 
published by the national comprehensive cancer network (NCCN, http://www.NCC.org 
guidelines) and also by the Dutch head and neck society (NWHHT). These guidelines 
are similar, but allow multiple treatment modalities for the different N-status. For N1-
status, monotherapy is suggested (neck dissection or radiotherapy). N2-N3-staged 
neck statuses are preferably treated with neck dissection of levels I to V. Postsurgical 
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treatment consists of ipsilateral radiotherapy and its extension is dependent on the 
size and number of affected lymph nodes, the presence of extracapsular spread and 
the resection status (R0/R1). The possibility to treat the neck bilaterally is mentioned, 
but not explicitly recommended.
Also, the addition of concomitant chemoradiation or induction chemotherapy is 
indicated as optional in guidelines, and needs consideration in the presence of 
extracapsular spread. Discussion on the role of chemotherapy in the guidelines is based 
upon findings in studies on patients with neck metastases in known primary head and 
neck carcinomas rather than upon results in studies on CUP patients.
Regarding the role of radiotherapy of the pharyngeal mucosa, guidelines include this in 
the discussion for consideration, and mention a possible restriction of radiotherapy only 
to the oropharyngeal and nasopharyngeal mucosa when HPV or EGFR is detected.
HPV-associated oropharyngeal carcinomas are present with smaller primary tumors and 
often bulky neck disease.49 The HPV prevalence in ‘true CUP syndromes’ can, therefore, 
be related with occult and missed primary tumors of the oropharynx. Moreover, in the 
Dutch guideline, one can consider primary
(chemo-)radiation instead of surgery as a consequence of probable relation of CUP-
disease with a primary tumor of Waldeyer’s ring.50, 51 A positive HPV association could 
support this change of treatment protocol in the affected CUP patients.
This study combines the treatment strategies in two European tertiary referral centers 
(University Medical centers of Cologne and Maastricht). To attribute to the voids in 
the described guidelines, the prevalence of HPV and the postsurgical management 
of CUP patients in both institutes were retrospectively assessed comparing ipsilateral 
and bilateral radiotherapy, radiotherapy of the pharyngeal axis and the addition of 
chemotherapy. Therefore, the presented data included only true CUP patients who 
were primarily treated surgically and excluded all cases in which a primary cancer was 
found. In both institutes, patients routinely underwent neck dissection levels I to V and 
all but three patients were treated with postsurgical radiotherapy. From all patients, 
histopathologic samples were available for analysis of the prevalence of HPV.
The pitfalls of this retrospective analysis are the low case number and the diverse 
approaches to cervical CUP syndrome in diagnostics and therapies — the broad variety 
prohibits any statistical evaluation or conclusion. However, it does indicate the need 
for a unified regimen and calls for clear guidelines on the background of the ongoing 
discussions.
The diagnostic work-up in both institutes was similar, however, in Cologne, a bilateral 
tonsillectomy was performed as compared to a unilateral tonsillectomy in Maastricht. 
This might have led to selection bias as possible contralateral occult primary tumors 
can be missed. Nevertheless, no occult primary tumor revealed during follow-up or 
that HPV prevalence was 0 % in the Maastricht population.
As described, neck dissections were performed through levels I to V in both institutions, 
however, in contrast to Maastricht, the sternocleidomastoid muscle was routinely 
preserved in Cologne.
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5.5.1. Role of additional HPV testing in CUP patients
Studies on the prevalence of HPV in lymph node metastases, of which the primary 
tumor could not be detected after diagnostic work-up — so-called true CUPs — are 
scarce and contradicting. HPV prevalence rates range from 0 until 100 % tested in 
very small samples, ranging from n = 2 to n = 25.23–25, 27, 52 In none of these studies, a 
relation between HPV status and survival was found. Moreover, in the current literature, 
no study reports of HPV testing during diagnostic work-up leading to the discovery 
of the primary tumor, in case the regular diagnostic work-up revealed no primary 
cancer, i.e., a true CUP syndrome. In this study, no HPV was detected in 29 true CUPs 
of Maastricht. In Cologne, only four HPV-positive CUP patients were found. Therefore, 
HPV positivity in those patients did not result in different outcome, although it has to 
be acknowledged that the number of patients is very limited for implications of HPV 
in true CUPs in this group of patients. This stands in great contrast to oropharyngeal 
tumors, in which HPV prevalence rates range from 20 to 90 % 48 and they appear to be a 
different tumor entity.41, 48 This seems important, as some institutes treat CUP syndrome 
akin to oropharyngeal tumors. Probably, most HPV-positive occult primary tumors 
of the oropharynx are detected by tonsillectomy or biopsies of the base of tongue 
resulting in low percentages of HPV-positive ‘true CUPs’. However, in the diagnostic 
work-up of patients referred with the clinical diagnosis ‘CUP syndrome’, HPV detection 
in USgFNA could show an important role in helping to identify a primary tumor in the 
oropharynx.41
A prospective study is suggested, in which the removed tonsils and oropharyngeal 
biopsies are thoroughly inspected for the presence of small (microscopic) primary 
tumors in case of HPV presence detected during the diagnostic work-up of CUP. It 
seems, however, that after a thorough diagnostic work-up, the prevalence, which in 
this study is only 7.8 %, and consequently the role of HPV in true CUP is very limited.
5.5.2. Therapeutic decision making in CUP
As in recent years, multiple institutes down-regulated the treatment of CUP patients 
from adjuvant bilateral radiotherapy including the pharyngeal mucosa towards adjuvant 
ipsilateral radiotherapy, studies offering a clear comparison are lacking in literature. 
Both collaborating institutes have undergone a similar down regulation of therapy, 
as it was observed that morbidity in the first group was high and the occurrence of 
recurrent, mostly contralateral, disease most often was curable and did not affect the 
mortality rates. This resulted in a comparison between patients adjuvantly treated 
with ipsilateral radiotherapy (n = 32) and contralateral radiotherapy (n = 14). There 
was, however, a prolonged time from initial diagnosis until treatment in Maastricht 
as compared to Cologne (40 vs. 26 days). Whether this difference affected outcome 
remains unclear. Moreover, there was no significant difference in distribution between 
pN1-2a and pN2b-3 staged necks in both institutes. The latter group of patients more 
frequently developed recurrent disease and distant metastasis during follow-up.
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5.5.3. Adjuvant radiotherapy of the pharyngeal mucosa
During follow-up, only one oropharyngeal tumor manifested after 52 months, located 
in the base of the tongue. Regarding the period after first presentation, this tumor was 
considered as a second primary cancer. One possible explanation for the fact that no 
primary cancer manifested during follow-up after therapy might be that small primary 
tumors of the base of the tongue or other pharyngeal subsides could be combated by 
the patient’s immuno-system.53 Another reason could be that unintended radiation 
dose to the mucosa, especially when not applying conformal radiotherapy, may result 
in successful eradication of a microscopic, initially undetected primary tumor in the 
pharyngeal region, although no radiotherapy of the pharyngeal mucosa is given. A 
third reason could be that histopathologically undetected micro carcinomas have been 
resected during diagnostic tonsillectomy and biopsies.
5.5.4. Overall and disease-free survival: postsurgical ipsilateral versus 
bilateral radiotherapy of the neck with or without chemotherapy
Patients with pN2b or higher-staged necks experience a worse overall and disease-
free survival. Bilateral radiotherapy was administered in only pN2b or higher-staged 
necks. The overall survival rate of bilaterally treated patients was worse as compared to 
ipsilaterally treated patients. This difference disappeared after stratification for lymph 
nodes staged pN2b or higher.
Neither were there differences between patients treated with ipsilateral nor bilateral 
radiotherapy regarding a recurrence-free survival rate, nor regarding the occurrence of 
distant metastases between patients treated with ipsilateral or bilateral radiotherapy 
with or/without chemotherapy.54
Regarding total disease-free survival, it was noted that all recurred during the first 2 
years after treatment. The disease-free survival for ipsilaterally treated patients was 
almost 90 % in lymph nodes staged lower than pN2b. When comparing lymph nodes 
staged pN2b or higher, the DFS was just over 60 % for ipsilaterally treated patients 
compared to almost 80 % for bilaterally treated patients. This was, however, not 
significant.
Despite the similar recurrence rates in both ipsilaterally and bilaterally treated patients, 
for higher-staged necks (or maximum nodal size more than 3 cm), additional treatment 
could be considered. Bilateral radiotherapy showed to be associated with a slightly 
better disease-specific survival (p = NS), but on the other hand increased radiotherapy-
associated morbidity. Moreover, in case of contralateral recurrences, initial ipsilateral 
treatment offered the potential of salvage surgery in combination with radiotherapy. 
We, therefore, suggest a large prospective multicenter study in which subgroups can 
be expanded since in the current literature these data are lacking but are crucial.
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5.6. CONCLUSION
This study united patient data from two European institutes to compare the therapeutic 
strategy for cervical metastasis of unknown primary squamous cell carcinoma. The 
presented data support the ongoing discussion in a call for a consensus strategy for the 
management in diagnostics and therapy of cervical CUP syndrome, particularly regarding 
the role of omission of radiotherapy of the pharyngeal axis, ipsilateral as compared to 
bilateral postsurgical radiotherapy and the role of concomitant chemotherapy and 
the prevalence of HPV in true CUPs. To increase evidence and to unify the treatment 
strategies for patients with CUP syndrome, a systematic (international) multicenter 
comparative study is needed.
Regarding HPV prevalence in true CUPs, in only four patients presenting with CUP, 
association with HPV was found (7.8 %) and data, therefore, did not provide insight 
in the influence of HPV presence on outcome after therapy in this patient population. 
The value of HPV testing in neck metastases of unknown primary tumors seems, in the 
presented patient collective, to be of limited value particularly when compared with 
prevalence rates in oropharyngeal carcinomas. Further investigation is advised.
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Figure 1. Five-year disease-free survival in patients treated with adju- vant ipsilateral (a) and 
bilateral (only n2b or higher) (b) radiotherapy
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Table 1. Comparison of N-status in the Maastricht- and in the Cologne-group
 Maastricht Cologne p value
 n = 29 n = 22  
pN statusa    
N1 2 2  
N2a 3 4  
N2b 15 13  
N3 9 3 0.147
a Diagnostic work-up did not reveal any cN2c-staged neck. Therefore, no bilateral neck dissections 
were performed in both institutes
Table 2. Results of HPV testing in Cologne, related with tumor characteristics and clinical follow-
up
 HPV-positive CUPs (n = 4) HPV-negative CUPs (n = 18) p value
Primary tumor 1 (base of tongue: 52 
month)
0 NS
N-status    
pN1 1 1  
pN2a 0 4  
pN2ba 2 11  
pN3 1 2 NS
Regional recurrence 0 2 NS
Distant metastases 0 2 NS
Five-year overall 
survival
3 (75 %) 12 (66.7 %) NS
   NS (log 
rank)
a n = 1: 24 months
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Table 3. Treatment of CUP patients in Maastricht and Cologne
 Maastricht Cologne p value
 (n = 29) (n = 22)  
Nodus extirpation 2 7 0.021
Neck dissection 29 22 NS
Extracapsular growth 22 18 NS
Radical resection (R0)  18  
Resection margin < 1 mm 18 Unknown  
Resection margin 1–5 mm 4 Unknown  
Resection margins ≤ 5 mm 7 Unknown  
Angio-invasive growth 9 Unknown  
Perineural growth 4 Unknown  
Adjuvant RT 27 21 NS
Unilateral 21 11 NS
Bilateral 6 8 NS
Pharyngeal axis 6 0 NS
Unknown 0 2 NS
Plus chemotherapy 0 8 0.000
Time until OR (days)    
Average 40 26 0.005
Jos_Binnenwerk_v3.indd   86 24/09/2020   17:04:15
87
Management of CUP in 2 European centers
5
Jos_Binnenwerk_v3.indd   87 24/09/2020   17:04:15
Jos_Binnenwerk_v3.indd   88 24/09/2020   17:04:15
6
Tumor control of cervical lymph node metastases 
of unknown primary origin: the impact of the 
radiotherapy target volume.
Published: Straetmans JMJAA, Stuut M, Wagemakers S, et al. Tumor control of 
cervical lymph node metastases of unknown primary origin: the impact of the 
radiotherapy target volume. Eur Arch Otorhinolaryngol 2020;277:1753-1761.
Jos_Binnenwerk_v3.indd   89 24/09/2020   17:04:15
90
Chapter 6
6.1. ABSTRACT
Purpose: Debate on the extent of treatment of neck metastasis of cancer of unknown 
primary tumors (CUPs) is still ongoing. In two Dutch tertiary referral centers, the 
post-surgical radiation target volume changed from the bilateral neck including the 
pharyngeal axis to the unilateral neck only, in the course of the last decade. This study 
aims to investigate the outcome of patients with CUP before and after de-escalation 
of post-surgical radiotherapy.
Methods: Data of two Dutch tertiary referral centers were merged. Disease-free survival 
(DFS), overall survival (OS), and regional control rate (RCR) of 80 patients diagnosed 
with CUP (squamous cell and undifferentiated carcinomas) between 1990 and 2009 
were retrospectively analyzed.
Results: Thirty patients received bilateral neck and pharyngeal axis radiotherapy and 
42 patients ipsilateral radiotherapy only. In another eight patients, the postsurgical 
radiation target volume was expanded to the contralateral neck or to the pharyngeal 
axis, due to suspicious lesions on imaging. The 5-year DFS, OS and RCR were 60%, 51.2%, 
and 80% respectively, in the total patient population. RCR did not differ in patients 
treated with ipsilateral as compared to bilateral radiotherapy, nor did 5-year OS and 
DFS. No tumors occurred in the pharyngeal axis.
Conclusion: In this study, omitting elective treatment of the contralateral neck and 
pharyngeal axis did not lead to a decrease in locoregional control or survival rates when 
treating patients with CUP.
Keywords: [Lymph node, *pathology], [Neoplasms, Unknown primary], [Neck dissection], 
[Radiotherapy], [Survival Rate]
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6.2. INTRODUCTION
Cervical lymph node metastases of carcinomas of unknown primary origin (CUP) 
represent 2-5% of all malignancies in the head and neck region [1]. Diagnostic 
approaches in patients with CUP are comprehensive, including a full history, a physical 
examination, ultrasonography (US) of the neck combined with fine needle aspiration 
cytology (FNAC), magnetic resonance imaging (MRI) of the head and neck region and/
or computed tomography (CT) with (whole body) FDG-PET scan. The latter has been 
introduced in the last decades. Next, a panendoscopy is performed together with 
systematic biopsies of suspect regions and blind biopsies of the nasopharynx and base 
of the tongue, as well as an ipsilateral or bilateral tonsillectomy.1, 2
Human papillomavirus (HPV)-positivity in the lymph node metastasis is an indicator for 
a primary cancer originating in the oropharynx.3 Sensitivity of diagnostic work-up may 
therefore be improved by testing on p16INK4A-immunohistochemistry and HPV-16 DNA 
polymerase chain reaction (PCR).4 Correspondingly, detection of Epstein-Barr virus (EBV) 
nucleic acids in lymph node metastases of unknown origin suggests a nasopharyngeal 
primary tumor.5 Current TNM-classification (Eight Edition) has adopted special staging 
systems for HPV and EBV-associated lymph node metastases in CUP in which these 
entities have been classified as oropharyngeal or nasopharyngeal carcinoma respectively 
(T-stage as T0).6
In literature, 5-year loco-regional disease-free survival rates and 5-year overall survival 
(OS) rates vary from 17-85 and 22-79%, respectively, dependent on the treatment 
modalities applied and patient characteristics.2, 7-10 Generally, treatment consists of 
primary surgery (with or without postoperative radiotherapy) or primary radiotherapy. 
Radiotherapy comprises uni- or bilateral neck radiation, with or without radiation of 
the pharyngeal axis. In the last years, chemoradiotherapy has also been applied as a 
treatment option for selected cases.11 However, the optimal treatment for CUP and 
which tumor- and patient characteristics should steer treatment decision-making, is 
still a matter of debate.10 A particular issue is whether radiotherapy should include 
the bilateral neck and pharyngeal mucosa or only the unilateral neck. Extensive 
radiotherapy may prevent recurrence in the contralateral neck and outgrowth of the 
occult primary tumor at the mucosal site but this is at the cost of significant increase 
of acute and late morbidity.7, 12-15 Some studies suggest that there is no difference in OS 
between patients treated with unilateral or bilateral radiotherapy and that patients can 
be spared the morbidity of bilateral treatment.12,13 Recently, two reviews on treatment 
modalities in CUP also concluded that more evidence is needed regarding the extent 
of radiotherapy.9,10
The aim of this study is to determine the outcome of patients with cervical CUP 
in relation to the applied treatment in two Dutch head and neck clinics. Results of 
post-surgical unilateral versus bilateral post-operative irradiation and radiotherapy 
of the pharyngeal axis are compared in terms of disease-free survival (DFS), regional 
6
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recurrence rate (RCR) and OS. Also, the relation of HPV-detection in affected lymph 
nodes with outcome was investigated retrospectively.
6.3. MATERIAL AND METHODS
6.3.1. Patients
Data of patients presenting with cervical CUP at the departments of Otorhinolaryngology, 
Head and Neck Surgery of the Maastricht University Medical Centre (Maastricht UMC: 
Center 1) (n=60) and the Radboud University Medical Center Nijmegen (Radboud UMC: 
Center 2) (n=64), the Netherlands, from 1990 until 2009 were retrospectively assessed. 
In- and exclusion of patients with CUP are described in Figure 1. Approval by the ethics 
committee of both institutes was obtained.
All patients with CUP were discussed in the centers’ multidisciplinary head and neck 
tumor boards: the most actual edition of the TNM-classification of the International 
Union Against Cancer was used to determine treatment plans. In the included era, HPV 
and EBV were not routinely tested.
Diagnostic work‐up
The diagnostic work-up included a full history, a physical examination, ultrasonography 
(US) of the neck combined with fine needle aspiration cytology (FNAC), magnetic 
resonance imaging (MRI) of the head and neck region and/or computed tomography 
(CT) with (whole body) FDG-PET scan, introduced in the last decade. Also, a 
panendoscopy was performed together with systematic biopsies of suspect regions 
and blind biopsies of the nasopharynx and base of the tongue, as well as an ipsilateral 
or bilateral tonsillectomy. The contralateral tonsil was not removed routinely. If the 
patient had undergone tonsillectomy in the past, only biopsies of the tonsillar fossa 
were obtained.
6.3.2. Treatment
In both centers, the protocol for treatment of CUP syndrome is based on the Dutch 
national guideline: “Primary tumor unknown”.16 Initially, treatment of CUP involved an 
ipsilateral neck dissection with adjuvant bilateral radiotherapy including radiotherapy 
of the pharyngeal axis. In the course of the last decade, the radiation target volume 
was reduced. The practice of adjuvant radiotherapy of the contralateral N0-neck, and 
radiotherapy of the pharyngeal axis were abandoned, and changed to post-operative 
ipsilateral radiation only.
Radiotherapy in Maastricht UMC: The elective radiation dose to the uninvolved neck 
regions and the pharyngeal axis was 46-50 Gy. The regions of the involved nodes were 
treated up to 66 Gy. Radiotherapy in Radboudumc: The median elective radiation 
dose to the uninvolved neck regions and pharyngeal axis was 50 Gy and the median 
dose delivered to the pathologically involved node level(s), was 64 Gy, range 56-70 Gy, 
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depending on histopathological criteria (higher dose if extranodal growth or close or 
positive resection margins).
Radiation therapy was administered using techniques that were available in those 
periods: in the beginning of the study, patients, undergoing bilateral neck irradiation 
including the mucosal axis, were treated with 2-D radiation with parallel opposing 
beams for the upper neck and a matching anterior lower neck field. Unilateral radiation 
for patients receiving ipsilateral neck radiation only was given by oblique wedge-pair 
beams. These techniques evolved into 3-D radiation and ultimately Intensity Modulated 
Radiation Therapy (IMRT).
Chemoradiation as part of the treatment protocol of CUP, was not used in both centers 
during the period of inclusion of this study. None of the included patients were therefore 
treated with adjuvant and/or concomitant chemotherapy.
6.3.3. Follow-up
Follow-up consisted of a periodic history and physical examination during five years in 
all patients and was scheduled every 2 months in the first year and extended to every 
6 months during the fifth year after treatment of CUP. In case of suspect local, regional 
and/or distant failure, additional imaging tests and/or panendoscopy were performed, 
when considered necessary and when further treatment options were still present.
6.3.4. Statistics
Statistical analysis of the data was performed using SPSS software (v17.0). When 
comparing groups, the Pearson Chi-square test was used. Survival rates and data 
on disease-specific control in patients were calculated from the date of the first 
pathological confirmation of disease. There were no patients lost to follow-up. DFS, 
OS, RCR were computed with Kaplan Meier survival analysis.
DFS was defined as the survival until recurrence of disease locally, regionally and/or 
distantly. In order to report on the value of ipsilateral versus bilateral radiotherapy 
of the neck, the RCR is used. OS was defined as the survival until death. The log-rank 
test was used for univariate comparisons of the survival functions. Nominal two-sided 
p-values are reported, the significance level was set at p ≤.05.
6.3.5. HPV-status
The presence of HPV was retrospectively determined according to the algorithm 
described by Smeets et al.17 Thirty-two tumor samples in the center 1 and 40 samples 
in the center 2 were available in which immunohistochemical (IHC) detection of p16INK4A, 
and/or HPV16 DNA polymerase chain reaction (PCR) were performed.
6
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6.4. RESULTS
6.4.1. Study population
No differences were noted regarding the diagnostic work-up in the two centers. In 
total, 80 patients with CUP were analyzed in this study (Table 1). They all underwent a 
neck dissection followed by post-operative radiotherapy with curative intent (Table 2). 
Bilateral radiotherapy combined with irradiation of the pharyngeal axis was performed 
in 30 patients (38%) and ipsilateral radiotherapy without irradiation of the pharyngeal 
axis in 42 (52%).
Due to suspicious lesions found on imaging - but not histologically or cytologically 
confirmed, postoperative ipsilateral radiotherapy was combined with treatment of 
the pharyngeal axis in 2 patients, and another 5 patients received radiotherapy of 
the bilateral neck without irradiation of the pharyngeal axis. Finally, one patient with 
limited pN1-disease did not receive additional radiotherapy of the ipsilateral neck, but 
instead the pharyngeal axis was irradiated because of a suspected lesion found by 
imaging (Table 2).
6.4.2. Outcome
Five-year DFS, OS and RCR were 60%, 51.2% and 80%, respectively (Table 3). There 
were no significant differences in survival between the group of patients irradiated 
ipsilaterally and those treated bilaterally. Also, the 5-year regional control rates did 
not differ between both groups, resp. 77.3% and 82.9% (p=.54) (Figure 2), nor did the 
5-year contralateral recurrence rate (p=.23).
In both groups, no primary tumors occurred in the pharyngeal axis during follow-up. 
Two primary tumors, both located in the floor of the mouth outside the pharyngeal 
axis, emerged during follow-up in the total population (in both patients 31 months after 
initial treatment). The first patient was initially treated with bilateral neck irradiation 
without the pharyngeal axis. The second patient was treated with radiotherapy of the 
bilateral neck and pharyngeal axis.
Twenty-three patients developed distant metastases during follow-up. This was not 
related to the extent of radiotherapy used.
6.4.3. HPV-status
In total, 4 out of 72 histopathological samples of cervical metastases tested positive for 
both p16INK4A-expression and HPV DNA (5.7%), 3 patients of which were treated with 
radiotherapy of the pharyngeal axis, including the oropharyngeal mucosa. Five-year 
DFS, OS and RCR in the four HPV-positive patients were all 100%.
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6.5. DISCUSSION
The objective of this study was to investigate the outcome of patients with CUP 
before and after de-escalation of post-surgical radiotherapy applied in two Dutch 
tertiary referral centers. In this study, no differences were found regarding survival 
and regional control rate in patients with CUP treated with neck dissection and post-
operative bilateral radiotherapy including radiation of the pharyngeal axis (n=30) 
compared to patients with CUP treated with neck dissection and post-operative 
ipsilateral radiotherapy solely (n=42). Eight patients received additional therapy of the 
contralateral neck or the pharyngeal axis as a consequence of radiological suspicion of 
disease although this was not pathologically confirmed. In addition, no primary tumors 
occurred in the pharyngeal axis, even though radiotherapy to the pharyngeal axis was 
abandoned in 47 out of 80 patients.
6.5.1. Unilateral versus bilateral radiotherapy
In our study, no differences in survival rates and moreover no differences in regional 
control rates were found between the group of CUP-patients treated ipsilaterally and 
those treated with bilateral radiotherapy of the neck.
These results correspond with previous research by our group in which 29 patients of 
our cohort were compared with 22 patients with CUP in a German tertiary head and 
neck cancer referral center.18 In that study significant more contralateral recurrences 
were seen in the ipsilateral radiated patients compared to the bilateral radiated patients. 
In the current study, the above mentioned cohort of 29 patients was expanded to 80 
patients which were homogeneously treated; the regional recurrence rate concerning 
contralateral relapses did not significantly differ.
In an early review of literature by Nieder et al. (2001), a median nodal relapse of 19% 
(rang 8-45%) after comprehensive radiotherapy compared to 51.5% (range 31-63%) after 
ipsilateral radiotherapy was described.13 However, regarding 5-year overall survival rates 
no differences were noted between both groups (resp. 50%, range 34-63%, compared 
to 36.5%, range 22-41%). In a more recent meta-analysis by Liu et al (2016) of 16 studies 
that report outcome between bilateral versus ipsilateral radiotherapy,9 a significant 
reduced relative risk of 0.61 was described for nodal recurrence in patients treated 
with more comprehensive radiotherapy, however no differences between both groups 
were found for 5-year OS and DFS. This lack of difference in overall survival between 
both treatment groups was confirmed in a recent review of Müller von der Grün et al 
(2017).10 Our study also shows no significant differences regarding 5-year DFS and OS. 
Moreover, no differences were found regarding (ipsilateral and contralateral) regional 
control rates between both groups. In our study, the inclusion of the contralateral neck 
in 5 patients in which radiologically suspected lesions were found during radiation 
treatment planning without histologically or cytologically confirmation, may have 
contributed to the lack of differences in 5-year RCR between both groups. The strict 
evaluation criteria of CUP and uniform treatment (all patients underwent unilateral 
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neck dissection combined with post-operative radiotherapy) may have contributed to 
this favorable RCR when compared to other studies. Altogether, in our study metastatic 
disease (n=23) was a more common reason of disease failure than locoregional failure 
(n=18). The radiotherapy target volume was not related to the occurrence of distant 
metastases. This supports the current findings in literature that the possible benefit of 
extended volume radiotherapy on a slightly improved locoregional control, if present, 
cannot be translated into improved overall survival rates. 10,19
6.5.2. Radiotherapy of the pharyngeal axis
In our study, no primary tumors occurred in the pharyngeal axis regardless of inclusion 
of the pharyngeal mucosa in the radiation target volume. Two out of 80 patients 
developed a primary tumor during follow-up, both located in the oral cavity, which is 
generally not included in the target volume of pharyngeal axis irradiation. In a review of 
literature by Reddy et al (2001), a higher local (mucosal) failure is reported in patients 
who received treatment to the neck alone (44%) compared to those who received 
radiotherapy to the pharyngeal axis (8%).14 Also, lower primary tumor emergence rates 
were described for patients treated with bilateral radiotherapy when compared to 
patients treated with ipsilateral radiotherapy.7,14 A recent meta-analysis also reported 
a significantly lower 5-year primary tumor emergence rate (12%; RR=0.44) and a lower 
5-year DFS rate when comprehensive radiation volumes were used.9 Again, the 5-year 
overall survival did not differ significantly for ipsilateral and comprehensive radiated 
patients, whereas acute severe toxicity and xerostomia were significantly increased in 
the latter group.
Contributing factors to the current reported low primary emergence rate might be 
the strict evaluation criteria of CUP in which only true-CUP-patients are selected, 
the comprehensive diagnostic work-up used in both centers in this study and the 
addition of radiotherapy of the pharyngeal axis in 3 patients in which lesions were 
suspected on imaging studies. The importance of a comprehensive diagnostic work-
up is illustrated by the significant decrease of primary tumor emergence rates in 
literature after the introduction of PET-CT in the radiation treatment planning in CUP-
patients.7,10,13Nevertheless, the additional value of PET remains hard to quantify next 
to panendoscopy with blind biopsies of the base of tongue and tonsillectomy.20
Furthermore in literature, the importance of selecting of irradiation volumes regarding 
the treatment of the primary site is emphasized with the introduction of IMRT, which 
allows preserving organs at risk (salivary tissue in particular), but on the other hand 
can miss the primary tumor that coincidently would have been treated with older less 
sophisticated techniques.
6.5.3. HPV and CUP
In the 8th edition of the UICC’s TNM-classification for CUP-patients, HPV- and EBV-
associated lymph node involvement is staged separately corresponding to N-staging 
in HPV-associated oropharyngeal and EBV-associated nasopharyngeal carcinomas. 
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Inclusion of HPV- and EBV-testing in CUP may support prediction of the prognosis and 
the location of the primary tumor in the oropharynx and/or nasopharynx respectively.21 
The prevalence of HPV-associated head and neck carcinomas still rises and the prognosis 
remains more favorable as in non-HPV-associated carcinomas. As patients treated with 
radiotherapy of the ipsilateral neck only were more often included in the second half 
of this study, it was interesting to investigate the possible presence of an HPV-endemic 
in this group and its influence on the presented outcome. Patients in our study cohort 
were treated before the introduction of HPV- and EBV-assessment to the routine 
diagnostic work-up and a retrospective analysis for HPV-presence could be performed 
in 72 out of 80 patients. Nevertheless only in 4 patients HPV/p16INK4a-presence. Possibly, 
most HPV-positive primary tumor of the oropharynx were detected by tonsillectomy or 
blind biopsies of the oropharyngeal region resulting in low percentages of HPV-positive 
true CUPs.22
6.5.4. Study design
In previous research we compared 29 patients of the currently presented cohort with 
22 patients from a cohort in Germany.22 Due to a relative heterogenous treatment 
strategy in both centers, this study aimed to collect a larger patient group with a 
more homogenous therapeutic approach. Therefore, data was merged from two 
Dutch tertiary referral centers in which the diagnostic and therapeutic development 
evolved almost identically, in the period of inclusion of more than two decades. This 
retrospective study still encountered possible limitations to investigate the impact of 
radiotherapy target volume of the neck and pharyngeal axis on tumor control in CUP. 
The number of included patients is rather small (n=80). However the selected study 
group was derived from a collection of 2 cohorts which were homogenously treated in 
2 Dutch tertiary referral centers, and was the result of a meticulous exclusion of non-
true-CUP. The inclusion period was extended over 2 decades: in the first decade of 
inclusion, radiotherapy of the bilateral neck and the pharyngeal axis was predominantly 
performed, whereas post-surgical ipsilateral radiotherapy was more often applied in 
the second decade of inclusion. This latter group, experienced a higher availability of 
IMRT compared to 2DRT in the first group, and was also more prone to have PET-CT 
included in the diagnostic work-up. The chance to coincidently radiate a missed primary 
tumor with IMRT is nevertheless smaller then with older less sophisticated techniques. 
Regarding the role of PET, de Bree et al (2010) already mentioned the inability to 
quantify the additional value of PET next to a comprehensive diagnostic work-up 
including panendoscopy, tonsillectomy and blind biopsies of the base of tongue.19 The 
influence of a possible HPV-endemic in the latter half of the study, was also minimalized 
as only 4 (out of 72) patients turned out to have HPV-associated disease. Again, the role 
of a comprehensive diagnostic work-up, particularly of the oropharyngeal region, may 
have led to this low prevalence of HPV in CUP.
In order to create the ideal world to compare the outcome of ipsilateral radiotherapy 
only with a comprehensive radiotherapeutic regime in CUP-patients, Nieder et al 
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recommended in 2001 a randomized controlled trial.13 It is reported that a similar trial 
which started in 2002, was never accomplished (EORTC-24001-22005) as a consequence 
of very limited patient enrollment.10 The low prevalence of patients with CUP and the 
heterogeneous treatment strategies as a consequence of the lack of well-designed 
studies, are important limiting factors to create a study design with an acceptable 
methodological work-up regarding this subject. A prospective multicenter approach in 
which homogenous therapeutic strategies are applied, are considered to be feasible.
6.6. CONCLUSION
In this study, omitting irradiation of the pharyngeal axis in patients with cervical 
lymph node metastases of unknown primary origin after performing a comprehensive 
diagnostic work-up, including PET-CT and pandendoscopy with tonsillectomy and blind 
biopsies of the base of tongue, did not result in the emergence of a primary tumor 
in the pharyngeal axis during five years of follow-up. This can avoid acute and late 
toxicity of comprehensive radiotherapy of the pharyngeal mucosa with significant 
improvement of long-term quality of lifer of these patients. Also, the absence of post-
surgical radiotherapy of the contralateral neck in CUP did not lead to a decrease of 
regional control rates nor of survival rates. The occurrence of distant metastases was 
the most important reason for failure of disease-free survival in this study. The true 
impact of radiotherapy target volume in CUP-patients still needs further investigation 
and at least requires a prospective multicenter approach.
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Figure 1. In- and exclusion criteria used for selecting patients with CUP in both participating 
centers.
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Figure 2. Regional control rate comparing patients treated with post-operative ipsilateral (n=44) 
versus bilateral radiotherapy of the neck (n=35)
Log-rank: p-value = NS
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Table 1. Demographic data
  Total 
patient 
population
Center 1 Center 2 p-value
  n= 80 n= 43 n= 37  
Follow-up time (months) mean 43.1 45.3 40.6 NS
 range 3-200 4-200 3-116  
Age (years) mean 63.1 62,9 63.2 NS
 range 41-86 41-83 46-86 NS
Male/female  59/21 35/8 24/13 NS
Non-smoker n (%) 1 (1.25) 1 (2,3) 0 (0) NS
alcohol consumption ≤2 
U/day
n (%) 36 (45) 18 (41,86) 16 (43.2) NS
Histopathological data squamous cell 
carcinoma
71 36 35  
 undifferentiated 
carcinoma
9 7 2  
pN-status pN1 3 3 0 NS
(UICC version 7) pN2a 17 8 9  
 pN2b 40 20 20  
 pN3 20 12 8  
Abbreviations: NS: not significant.
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Table 2. Type of treatment based on pN-status
  number 
of 
patients
% pN1 pN2a pN2b pN3 p-value
Type of neck 
dissection
Radical neck 
dissection
43 54 1 8 22 12  
 Modified radical 
neck dissection
22 28 1 6 12 3  
 Extended radical 
neck dissection
10 12 0 1 4 5  
 Selective neck 
dissection 
(regions I/II/III)
5 6 1 2 2 0  NS
Type of 
postoperative 
radiotherapy 
Ipsilateral 
radiotherapy of 
the neck
44 55 2 11 21 10 NS
 Bilateral 
radiotherapy of 
the neck
35 44 0 6 19 10 NS
 Radiotherapy of 
the pharyngeal 
axis
33 41 2 6 16 9 NS
Type of 
combined 
therapeutical 
strategy
ND + RT-ipsi 42 52 1 11 20 10  
 ND + RT-bilat + 
RT-PA
30 38 0 6 15 9  
 ND + RT-ipsi + 
RT-PA
2 3 1 0 1 0  
 ND + RT-bilat 5 6 0 0 4 1  
 ND + RT-PA 1 1 1 0 0 0 NS 
Total patient 
population
 80 100 3 17 40 20  
Abbreviations: NS: not significant; ND: neck dissection; RT-bilat: radiotherapy of the bilateral 
neck; RT-PA: radiotherapy of the pharyngeal axis.
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Table 3. Five-year overall survival, disease-free survival and regional control rate in the total 
patient population and in relation wih pN-status and therapy
   Disease-
free 
survival
Overall 
survival
Regional 
control 
rate
  N % % %
Total patient 
population
 80 60 51.2 80
pN-status pN1 3 100 66.7 100
 pN2a 17 88.2 76.5 88.2
 pN2b 40 45 45 80
 pN3 20 60 40 70
  p-value .014 NS NS
Type of neck dissection Radical neck dissection 43 53.5 41.9 76.7
 Modified radical neck 
dissection
22 72.7 63.6 86.4
 Extended radical neck 
dissection
10 40 50 70
 Selective neck dissection 
(regions I/II/III)
5 100 80 100
  p-value .047 NS NS
Post-operative 
ispilateral
Post-operative 
ipsilateral RT
44 61.4 47.7 77.3
versus bilateral 
radiotherapy
Post-operative bilateral 
RT
35 57.1 54.3 82.9
  p-value NS NS NS
Post-operative RT of Included 33 60.6 54.5 81.8
the pharyngeal axis Not included 47 59.6 48.9 78.7
  p-value NS NS NS
Therapy strategy ND + RT-ipsi* 42 61.9 50 78.6
 ND + RT-bilat-PA** 30 60 56.7 83.3
  p-value NS NS NS
*ND + RT-ipsi: neck dissection and post-operative ipsilateral radiotherapy without radiation of 
the pharyngeal axis
 **ND + RT-bilat-PA: neck dissection with post-operative radiotherapy including radiation of 
the pharyngeal axis.
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8.1. SUMMARY
Oncogenic human papillomavirus (HPV) is currently recognised as a major risk factor for 
the development of head and neck squamous cell carcinomas (HNSCC). HPV is mostly 
detected in tumours arising from the oropharynx and more specifically from the tonsil. 
HPV-related tumours display clinical and molecular characteristics that are distinct from 
HPV-unrelated tumours, which are generally induced by alcohol and tobacco abuse. 
Detection of biologically active HPV in HNSCC has prognostic relevance, which warrants 
the separate classification of HPV-induced tumours and is a prerequisite for further 
optimisation of treatment protocols for this distinct group. Current guidelines for the 
treatment of oropharyngeal squamous cell carcinoma (OPSCC) have not incorporated 
specific treatment modalities for HPV-related tumours. The development of such 
treatment options is still in a preclinical phase or in early clinical trials. Recent data 
on treatment response of OPSCC have been obtained by retrospectively analysing 
HPV-status and indicate that patients with HPV-related tumours show a favourable 
prognosis, independent of the type of treatment. These patients may benefit from 
de-intensified treatment, which should be assessed in prospective clinical trials. The 
development and future use of new antiviral and immunomodulatory therapeutics 
may be instrumental in this approach to improve survival rates and decrease disease-
and-treatment-related morbidity. In this review we will focus on present therapeutic 
HPV-targeting strategies and discuss future directions for de-intensified treatment of 
HPV-positive HNSCC.
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8.2.INTRODUCTION
Head and neck cancer is a serious health care problem in many parts of the world.1 The 
vast majority of head and neck cancers are squamous cell carcinomas originating from 
the mucosal epithelium lining the oral cavity, nasal cavity, pharynx and larynx.2 In 2008, 
head and neck squamous cell carcinomas (HNSCC) were estimated to cause 480 000 
new cancer cases and 273 000 cancer deaths worldwide.1 Despite the fact that advances 
have been made in diagnosis and treatment, mortality rates have only marginally 
decreased over the last decades and the 5-year survival rate currently ranges between 
40%–60%.3 Approximately 80%–90% of HNSCC develop in patients with a history of 
alcohol and tobacco abuse, including tobacco and betel quid chewing and snuff dipping.4 
These factors are also responsible for the process of ‘field cancerisation’ in the entire 
head and neck region,5 leading to multiple primary tumours in up to 40% of patients.6 
Patients without exposure to these risk factors account for 10%–20% of HNSCC. These 
tumours are predominantly associated with viral carcinogenesis, including infection with 
EBV in nasopharyngeal carcinomas 7 and, to a greater extent, infection with oncogenic 
human papillomavirus (HPV) in the oropharynx, in particular in the lingual and palatine 
tonsils. In the last decade, the incidence of HPV-related oropharyngeal squamous cell 
carcinoma (OPSCC) has increased relative to the total group of HNSCC.4, 8 Infection 
rates in OPSCC range from 20% to more than 90% in different studies, depending on 
geographical factors and the detection method used.9-12
In this review, we will present the clinical and molecular features of HPV-positive HNSCC. 
Subsequently we will focus on the current knowledge of potential anti-HPV strategies 
and discuss the most promising modalities for the treatment of HPV-positive HNSCC.
8.3. METHODS
Besides relevant articles selected from the general literature concerning HPV-related 
carcinogenesis and references therein, specific literature on treatment options for 
HPV-related HNSCC was obtained by a bibliographical search in PubMed, Medline and 
Embase, from inception to May 2011, using the search term (HPV OR papillomavirus OR 
papilloma) AND (HNSCC OR ‘head and neck cancer’ OR oropharyngeal OR oropharynx 
OR oral OR pharyngeal OR pharynx OR buccal OR base of tongue OR tongue OR tonsillar 
OR tonsil OR floor of mouth OR mouth OR vallecula) AND (treatment OR antiviral OR 
therapy) AND (cancer OR carcinoma OR tumour OR tumour OR neoplasm). This search 
yielded 1246 results in PubMed, 137 in Medline and 309 in Embase. Based on inspection 
of the title and/or abstract of these publications, 63 relevant papers on treatment 
options and some references therein were included in this review. Moreover, ongoing 
clinical trials concerning new therapeutic options for HPV-related HNSCC were identified 
from the Cochrane Controlled Trial Register and from the US National Institute of Health 
Clinical Trials (www.clinicaltrials.gov), yielding five relevant results.
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8.4. HUMAN PAPILLOMAVIRUS AND 
TUMOURIGENESIS
8.4.1. Human papillomavirus
Human papillomaviruses are non-enveloped viruses, containing circular double-stranded 
DNA of approximately 8 kb, that are highly epitheliotropic and known to infect both 
mucosal and cutaneous epithelia.13 Papillomaviruses are species-specific and the human 
papillomavirus family can be classified into five genera and subdivided into 31 species 
and 120 types.14 A subgroup of 15 HPV types is linked to the development of malignant 
lesions of mucosal and cutaneous epithelia, and is considered to comprise high-risk (HR) 
HPVs.15 All HR-HPVs belong to the alpha-genus, including HPV-16 and HPV-18, which 
are found in ~50% and ~20% of cervical malignancies, respectively.16 Differences in the 
capacity to deregulate cellular protein function by viral oncogenes E6 and E7 account 
for the carcinogenic properties of HR-HPV in comparison with low risk (LR) HPVs.17, 18 
LR-HPV types, such as HPV-6 and HPV-11, are often found in benign mucosal lesions and 
are only sporadically associated with carcinomas. Human lesions in which HPV types of 
the alpha-genus appear to be involved are summarised in Table 1.
8.4.2. Human papillomavirus replication and integration
The HPV life cycle is linked to the differentiation of the infected epithelial cell. HPV 
infection is initiated by binding of the virion L1 protein to heparan sulphate proteoglycans 
(HSPG) on segments of the basement membrane, which are exposed at sites of 
(micro)injury. This induces conformational changes and L2 cleavage finally resulting in 
binding of the L1 capsid protein to a so far undetermined cell surface receptor.19 The 
cell adhesion receptor α6-integrin has been implicated to be this receptor,20 but does 
not seem to be essential for HPV infection. However, α6-integrin might be a matrix 
component closely associated with HSPG.21 The circular HPV DNA comprises 8 genes, 
coding for six early (E) and two late (L) proteins (Figure 1). The E-proteins regulate and 
facilitate virus-replication and are expressed early after infection.22 Oncoproteins E6 
and E7 have a direct effect on several essential cellular processes, such as cell cycle 
and apoptosis regulation. E6 promotes degradation of p53 through interaction with 
E6-associated protein (E6AP), an E3 ubiquitin ligase, and subsequent ubiquitination 
and proteasomal degradation. Amongst others, this alters transcription of p53 target 
genes and activates human telomerase reverse transcriptase (hTERT), resulting in 
cell survival and ultimately in genetic instability.23, 24 The oncoprotein E7 binds to the 
unphosphorylated retinoblastoma tumour suppressor protein (pRb), which promotes 
the release of transcription factor E2F, leading to activation of the cell cycle and 
transition through the G1/S-phase, needed for DNA-replication.25-27 As a consequence, 
p16INK4A is upregulated but is unable to properly inhibit the cell cycle. Expression 
of oncoproteins E6 and E7 is tightly regulated by E2, the main regulator of viral gene 
transcription.28 Molecular studies have shown that integration of HPV often leads to a 
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disruption in the E1/E2 open reading frame and concurrent loss of the E4 and E5 and 
parts of the E2 and L2 genes.29 E2 function can moreover be abrogated by epigenetic 
alterations of the viral genome such as methylation of the E2 binding site in the long 
control region.30 Absence of E2 function results in upregulation of the expression of 
oncoproteins E6 and E7, which in turn leads to uncontrolled cell cycle progression (see 
Figure 1).
The major structural protein L1 of the HPV capsid is sufficient for self-assembly into a 
capsid, but entry of the virus into the cell is co-dependent on L2, the minor structural 
protein.19, 31
Under normal circumstances, HPV maintains an episomal state, and infection with HPV 
is transient. In a recent prospective cohort study, the reported average duration of 
active episomal infection in the uterine cervix appears to be approximately 8 months.32 
Although uterine cervical HPV infection prevalence decreases with increasing age,33 it 
is unclear whether age affects the duration of infection. Persistent infection, however, 
might lead to integration of the virus.34, 35 Numerous investigations have shown an 
etiological relationship between infection with HR-HPV infection and the development 
of uterine cervical squamous cell carcinomas (UCSCC) and other anogenital squamous 
cell carcinomas.36, 37 More than 90% of UCSCC contain and express HR-HPV sequences, 
which are predominantly present in an integrated form.38, 39 HPV-16 is the most common 
HPV type and is detected in more than 50% of UCSCC, followed by HPV-18, HPV-33 and 
HPV-45 (Table 1).37, 40
The precise relationship between HR-HPV integration and head and neck carcinogenesis 
is less clear, partly because primary premalignant lesions of the oropharynx are seldom 
detected. Although controversial data have been reported,41-44 integration of HR-HPV 
in OPSCC is a prevailing finding.
8.4.3. High-risk human papillomavirus in head and neck squamous cell 
carcinoma
Patients with a history of HPV-related anogenital carcinomas, patients seropositive 
for HPV-16, and husbands of patients diagnosed with uterine cervical dysplasia or 
carcinoma in situ all show increased risk rates for developing OPSCC.45-47
The involvement of HPV in head and neck tumourigenesis was first proposed by 
Syrjänen et al.,48 who showed histopathological features of HPV infections in 40% of 
patients, and HPV-positive nuclei in 20% of patients using immunohistochemistry. 
Since then many studies have provided evidence that infection with HR-HPV is a 
significant independent risk factor for HNSCC and is associated with high-risk sexual 
behaviour.9, 10, 49-51 HR-HPV positive tumours are most frequently found in the oropharynx 
and are associated with HPV-16 in >90% of cases.9, 49, 52, 53 Because patients with OPSCC 
often present with metastatic disease at first diagnosis, information on the persistence 
of oropharyngeal HPV infections and premalignant lesions in this region is scarce.54-56 
HPV prevalences of less than 1% have been found in tumour-negative tonsillar tissue 
samples, screened for HPV with PCR.51, 57, 58
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8.4.4. HR-HPV detection and tumour characteristics
The reported overall incidence of HPV in OPSCC ranges from less than 20% to more 
than 90% in different studies. This variation depends on several factors, including 
geographical features, sample preparation and detection methods used but also 
the amount and manner of tobacco consumption depending on geographical 
location.9, 12, 54, 59-61 It has been shown that not all tumours tested positive for HPV DNA 
can be regarded as etiologically HPV-related.50, 62 A clinically relevant infection, that is, 
a transcriptionally active infection should be present, which can be demonstrated by 
detectable expression of the viral oncogenes E6 and E7.63 This correlates strongly with 
overexpression of the CDK inhibitor p16INK4A, which is considered a reliable surrogate 
marker for HR-HPV infection in most cases.41, 64 A reliable algorithm for HPV detection 
should thus start with p16INK4A detection, followed by in situ hybridisation (ISH) and/
or RT-PCR analysis of E6/E7 transcripts after HPV typing,41 as suggested by two recent 
reports.59, 65 A representative example of these analyses is shown in Figure 2.
The HPV-associated OPSCC are now considered to comprise a separate entity with 
typical clinical and molecular features. Table 2 summarises the major differences 
between HPV-positive and HPV-negative OPSCC.
The HPV-positive OPSCC are characterised by overexpression of oncoproteins E6 and 
E7 leading to degradation of p53 and pRb, thereby inducing cell cycle and apoptosis 
deregulation. As a result, CDK inhibitors including p16INK4A, p14ARF, p18INK4C and 
p21Cip1/WAF1 are upregulated, which subsequently leads to downregulation of cyclin 
D1 and inhibition of complex formation with CDK4.22, 62, 66, 67 In HPV-negative tumours, 
cell cycle deregulation is established by p53 and pRb gene mutations, or alternatively 
by inactivation of p16INK4A and p14ARF gene expression through mutation, promoter 
hypermethylation or homozygous deletion,22 or activation of cyclin D1 expression via 
11q13 amplification 68. High expression of EGFR by transcriptional upregulation is 
generally present in this OPSCC subgroup.22, 56, 62, 66-68 Upregulation of EGFR expression 
is usually not seen in HPV-positive OPSCC.56, 67, 69-71
In addition, global genome and protein scanning approaches have been and are being 
used to unravel DNA, mRNA, microRNA, and protein signatures specific for HPV-
positive and HPV-negative OPSCC. So far, these studies revealed that HPV-positive 
tumours exhibit a relatively stable genome with 11q and 16q loss,72-74 and upregulate 
transcriptional activity of cell cycle regulators (as mentioned previously), transcription 
factors (e.g. TFDP2, ZNF238, TAF7L and RPA2) and DNA repair proteins (e.g. RFC4 
and RFC5). Also, HPV-positive tumours show decreased expression of genes involved 
in immune responses (e.g. IFIT1, IFITM1-3, IFI6-16, IFI44L, OAS2 and IFN-κ).68, 75-79 In 
addition, these tumours differentially express microRNAs, and for example upregulate 
miR-363 (belonging to the oncogenic miR-106a-363 cluster) and downregulate miR-218. 
A recent proteome analysis comparing HPV-positive and HPV-negative oral squamous 
cell carcinomas (OSCC) reported upregulation of thioredoxin and epidermal-fatty acid 
binding protein.80 Thioredoxin is an important redox-mediator that stimulates cell 
growth and inhibits apoptosis under adverse conditions, apparently including HPV 
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infections, as also seen in cervical carcinomas. Epidermal fatty-acid binding protein, 
although, mainly involved in fatty acid uptake, transport and metabolism, also functions 
in cellular signalling, affecting differentiation, growth regulation and gene expression.80 
Although expression of 3q-specific genes has been reported as being specific for HPV-
positive OPSCC, this finding remains to be confirmed, because extra copies of 3q-genes 
have been found in both HPV-positive and HPV-negative tumours.68, 77
8.5. CURRENT TREATMENT OF OPSCC AND 
EFFECT OF HR-HPV STATUS ON TREATMENT 
RESPONSE
8.5.1. Current treatment modalities
Current international clinical guidelines for HNSCC treatment mention HPV as a risk 
factor for OPSCC. The American National Comprehensive Cancer Network has suggested 
to include HPV detection in the diagnostic work-up of these tumours.81 However, the 
treatment guidelines do not offer therapeutic modalities specific for HPV-related 
tumours. Current therapeutic options include surgery, radiotherapy, chemotherapy 
(CT), immunomodulatory therapies or combinations of the foregoing. Surgery as 
primary treatment avoids toxicity caused by radiotherapy and CT but causes loss 
of function, particularly in patients with larger tumours. The development of laser 
surgery and transoral robotic surgery (TORS) for OPSCC reduces functional morbidity 
as a consequence of three-dimensional visualisation and the ability to manipulate 
and perform reconstruction of the oropharynx without the need for an open surgical 
approach.82, 83 Regional infiltration of critical structures and unacceptable loss of function 
after surgery can classify a tumour as functionally or technically unresectable. In those 
cases, radiotherapy and/or CT is the treatment of choice84 when aiming at restoring 
function, however with the disadvantage of therapy-related local and systemic side 
effects.85 The final choice of treatment is based upon clinical variables such as tumour 
type, localisation and stage,86 age of the patient, general medical and psychomedical 
condition 81 and individual preferences of the patient.
8.5.2. Effect of HR-HPV status on outcome
In retrospective studies, HR-HPV- and/or p16INK4a positive tumours have been found to 
respond better to multimodal therapies as compared to HPV-negative tumours, thereby 
favouring patient survival.41, 42, 53, 64, 87, 88 More recent retrospective studies have shown 
that this favourable outcome is independent of treatment modalities.89-95 However, the 
heterogeneity of the HNSCC patient populations and consequent variability with regard 
to the HPV and/or p16INK4A status, as well as applied treatment protocols, has most 
probably negatively influenced the association between HR-HPV status and outcome 
in these studies. It can be anticipated that the actual difference in clinical outcome 
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between HPV-positive and HPV-negative cases will become even more pronounced 
when comparing a homogeneous population of OPSCC and application of reliable 
detection methods for clinically relevant HPV-infections. Prospective clinical trials are 
required to further validate HR-HPV presence as predictive factor for therapy outcome 
and to determine whether treatment de-intensification might improve quality of life 
while preserving the favourable clinical outcome in HPV-positive OPSCC patients.96, 97
An explanation for the favourable response may lie in the fact that, although the pRb-
pathway and p53-pathway are compromised in HPV-positive tumours, they retain 
some function, such that under the pressure of radiotherapy and/or CT, p53-mediated 
apoptotic pathways may still function. The presence of wild-type p53 in combination 
with low levels of Bcl-2/Bcl-xL and EGFR, which are features of HPV-positive tumours 
in non-smokers, may enhance this treatment advantage.9, 53, 63, 67, 69, 71 Moreover, limited 
tobacco and/or alcohol use reduces field cancerisation and the chance of developing 
a second primary tumour or distant metastasis in HPV-positive tumours,41, 53, 93 which 
underscores the need to investigate the effect of tobacco and alcohol exposure on the 
biological behaviour of HPV-positive OPSCC, as recently proposed.41, 94
Besides the overall better survival of patients with HPV-positive tumours, their 
treatment may be further improved by the implementation of strategies that either 1) 
promote the immune response to eradicate the virus, 2) inhibit viral DNA replication, 
3) specifically target viral oncoproteins or 4) have an effect on deregulated signal 
transduction pathways specific for HPV-positive tumour cells. In the following section, 
we review these strategies, their mode of action and possible benefits for patients with 
HPV-induced HNSCC.
8.6. PROPHYLACTIC AND THERAPEUTIC 
ALTERNATIVES FOR HPV-POSITIVE OPSCC
8.6.1. Immunomodulating therapies
Vaccination
Two prophylactic vaccines, containing recombinant virus-like particles (VLP) composed 
of the L1 proteins of the respective HPV types31 have been marketed recently, which 
are Cervarix® (GlaxoSmithKline, Brentford, Middlesex, TW8 9GS, United Kingdom) and 
Gardasil® (Merck, NJ, USA). Both vaccines have been FDA-approved for use in girls and 
young women 98, 99 and Gardasil® has also been approved for use in men.100
Cervarix® is a bivalent vaccine that protects against infection with HPV-16 and HPV-18, 
whereas the quadrivalent vaccine Gardasil® provides protection against HPV-6, HPV-11, 
HPV-16 and HPV-18. Reports indicate that Cervarix® also offers cross-protection against 
HPV-31, HPV-45 and HPV-52,101, 102 and Gardasil® possibly against HPV-31.103 More robust 
cross-protection may be induced by adding L2 minor capsid proteins to the vaccine.104 
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Both vaccines induce high antibody titers and seem to be well-tolerated and safe and 
provide >90% protection in HPV-16 and HPV-18 in naïve females when given in three 
doses within six months.102, 105 Currently, only young HPV-naïve females are vaccinated 
because vaccination of women actively expressing HPV-16 or HPV-18 at study entry 
did not result in decreased development of cervical intraepithelial neoplasia (CIN) 
lesions.102, 105 However, vaccination with Gardasil® also provided >90% protection in 
women with evidence of past infection (seropositive and HPV DNA negative) with one or 
more of the HPV-types against which the vaccine is directed.106, 107 Long-term benefits of 
vaccination are not yet known, but it is hypothesised that vaccination could also strongly 
reduce the number of HPV-related OPSCC. This would indicate that HPV-naïve boys and 
young men should be vaccinated as well, because HPV-related OPSCC is diagnosed in 
males more often than in females.61, 69 However, seeing that patients usually present 
with HPV-related head and neck tumours from the fifth decennium of life onwards, 
the efficiency of vaccination in these patients will only become evident within a few 
decades.
Patients with HPV-related disease may benefit from the development 
of therapeutic vaccines. These vaccines are designed to induce cell-mediated immunity 
against the overexpressed foreign viral oncoproteins, particularly E6 and E7. There are 
four classes of therapeutic vaccines: 1) live-vector based; 2) peptide/protein based; 
3) nucleic acid based; and 4) whole cell vaccines (for a comprehensive review see 108). 
In anogenital and uterine cervical lesions therapeutic vaccination has been shown to 
generate specific immunological and clinical responses, including complete regression 
of the lesion in 22% of patients with CIN III lesions as reported in a study using a fusion 
protein-based vaccine.109-111 A preclinical study using a DNA-based vaccine demonstrated 
that such an approach for therapeutic vaccination was efficacious in a mouse model 
of HPV-related HNSCC.112 Clinical trials to evaluate the effectiveness of therapeutic 
vaccination in HPV-related HNSCC are ongoing.113, 114
Interferon
Interferons are cytokines that are produced by many cell types in response to infection 
with bacteria, viruses and parasites.115 Two classes of IFNs can be distinguished: Class I 
consists of IFN-α and IFN-β, and Class II consists of IFNγ. Class I IFNs are secreted from 
infected cells and bind to the ubiquitously expressed heterodimeric interferon receptor. 
Binding of IFNα/β to the interferon receptor induces the transcription of several host cell 
proteins that inhibit viral replication in the infected epithelial cell, and leads to activation 
and the production of IFNγ in dendritic cells. IFNγ can also be produced by activated 
Th1 cells. Both classes of IFNs possess antiviral and antiproliferative properties. IFNγ 
can also activate macrophages and natural killer lymphocytes, and induce translocation 
of the major histocompatibility complex Classes I and II to the cell membrane.115 The 
interferon response, however, is suppressed upon HPV infection because several HPV 
proteins (E1, E6 and E7) interfere with the IFN signal transduction cascade by binding 
to, for example, Tyk2 kinase, IRF-1 and IRF-3, p48 and p56 leading to downregulation of 
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the levels of IFN-inducible genes, such as TNSFS10, IFIT1 and IFI54.78, 116, 117
Despite this, a successful immune response to HPV is generally seen in healthy 
individuals, as for example reported in the studies of van der Burg and co-workers,118, 119 
showing high frequencies of circulating CD4+ T-helper cells reacting with HPV16 E2 and 
E6, indicating a cell-mediated Th1 immune response. In persisting lesions, application 
of IFN therapy may restore antiviral defence mechanisms, thereby supporting effective 
treatment of HPV-infected lesions. IFN therapy proved to be beneficial in HPV infections 
such as condylomata acuminate,119, 120 whereas the use of IFN therapy in HPV-associated 
anogenital intraepithelial neoplasia has been assessed in several studies with 
contradicting results. Improved outcome for IFN-treated patients was shown in some 
studies,121, 122 whereas others reported no change in response rates between treated 
patients and controls.123, 124 This might be attributed to the fact that local application 
seems to achieve better responses than systemic application.120 In addition, it seems 
that IFN therapy can eradicate episomal HPV infection but leads to growth advantage 
for cells containing integrated HPV.125, 126 IFN-induced upregulation of p56, which 
blocks HPV replication by binding to the E1 protein and inhibits its helicase activity, 
may explain this effect on episomal infection.127, 128 Loss of (parts of) E1 and E2 by viral 
integration, resulting in upregulation of E6 and E7 as stated previously could explain 
the lack of effect of IFN treatment in these cells and their selective growth advantage. 
On the contrary, IFN was also shown to increase viral early gene transcription in a 
cell model.129 In recurrent respiratory papillomatosis (RRP) a long-term response to 
IFN-α therapy was seen in patients with HPV-6-related papillomas, but patients with 
HPV-11-related papillomas were much less responsive to IFN therapy.130 In conclusion, 
the beneficial effects of IFN therapy seem to be limited to episomal infections, which 
limits the applicability of this therapy in HPV-positive carcinomas.
8.6.2. Antiviral therapy
Cidofovir
Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] (HPMPC) is a 
nucleoside analogue of deoxycitidine monophosphate with a remarkably broad 
spectrum of antiviral activities directed against DNA viruses, including HPV and 
polyoma.131 After intracellular double phosphorylation, the structure resembles dCTP 
and can act as a competitive substrate. After removal of the diphosphate group cidofovir 
can be incorporated into viral DNA during replication, resulting in selective antiviral 
activity for those viruses encoding their own DNA polymerase. Viral DNA polymerases, 
for instance cytomegalovirus, display greater affinity for cidofovir than human cellular 
DNA polymerases. Although HPVs do not produce viral DNA polymerases, cells infected 
with HPV show enhanced susceptibility to cidofovir-induced apoptosis as compared to 
non-infected cells for a yet unknown reason.132, 133
In 1998, it was shown by Andrei et al . that acyclic nucleoside phosphonate (ANP) 
analogues, such as cidofovir, show a selective antiproliferative effect in HPV-bearing 
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tumour cell lines CK-1, SiHa, CaSki and HeLa.134 This effect is partly induced by its non-
selective toxicity to rapidly dividing cells.134, 135 Apoptosis might also be induced by 
accumulation of the tumour suppressor proteins p53 and p21Cip1/WAF1,132, 133 although 
an increase in p53 expression was not found in the HNSCC cell line UPCI:SCC090.136 
However, by combining cidofovir with radiotherapy, the radiosensitivity of UPCI:SCC090 
and other HPV-containing cell lines could be enhanced in vitro, 132, 136 as well as in vivo in 
nude mouse xenografts.132 CT combined with cidofovir also yielded a synergistic effect 
in an HNSCC cell line model.137 One study expressed concern about using cidofovir for 
the treatment of RRP,138 as it demonstrated high malignancy transformation rates in 
rats and cell lines. In humans, this effect has not been reported, and cidofovir is already 
applied as an effective adjuvant therapy for HPV-induced RRP in humans.139
For the treatment of various HPV-related lesions the route of administration may 
be an important factor. Cidofovir can be applied systemically or topically or injected 
intralesionally. Although concern was raised about possible nephrotoxicity in systemic 
use, this side-effect can be greatly diminished by administration of probenecid and 
prehydration with saline solution.140
In a clinical setting, it was shown that local therapy with cidofovir gel resulted in 
complete or partial regression of uterine CIN II and III lesions 141, 142 as well as vulvar 
and other intraepithelial neoplasms.143, 144 On the other hand, intralesional treatment 
with cidofovir of one patient with an invasive carcinoma in the respiratory tract and a 
history of RRP only lead to minor clinical effects, limited to the superficial portion of 
the tumour.145
Clinical trials using cidofovir as an adjuvant therapy in cervical cancer have started,146 
but trials for its application in HNSCC have to be initiated.
Interfering RNAs
The RNA interference (RNAi) can be used to inactivate gene expression and so far 
encouraging results have been reported for the treatment of HPV-related carcinomas in 
vitro as well as in vivo . Chen and co-workers, for example, reported a 50% reduction of 
E7 mRNA expression in HPV-6b/11 E7-expressing mouse tumour models.147 RNAi against 
HPV-16 E6 and/or E7 has been shown to degrade these mRNAs leading to decreased 
expression of the gene products in both cervical as well as HNSCC cell line models. This 
resulted in restoration of pRb function and upregulation of p53 and p21Cip1/WAF1, 
leading to substantial apoptotic cell death.148-150 RNAi against HPV-18 E6 and E7 has also 
seemed to possess antitumour activity by retarding the growth of HeLa-cell induced 
tumours in NOD-SCID mice 151 and to enhance the chemotherapeutic effect of cisplatin 
in HeLa cells in vitro.152
8.6.3. Molecular therapy based on cellular targets
Because inactivated tumour suppressor gene products such as p53 and p16INK4A are 
difficult to restore by molecular therapy, many studies have focussed on the 
identification of oncogenes and deregulated cell signalling pathways in HNSCC. Key 
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pathways involved in HNSCC include EGFR, PI3K-PTEN-AKT, TGFβ and NF-κB signalling 
for which inhibitors are available, for example, the anti-EGFR antibody cetuximab 153, 
or being tested in several clinical trials (for reviews, see 72, 73).
In cervical cancer EGFR overexpression has been shown to negatively affect overall 
survival in patients treated with radiotherapy.154 Anti-EGFR therapy using cetuximab 
lead to a therapeutic response in 12.5% of patients with uterine cervical SCC.155 Also 
in HNSCC, including HPV-positive OPSCC, overexpression of EGFR correlates with poor 
prognosis,67, 70, 71 although only a small subgroup of HPV-positive OPSCC exhibit EGFR 
protein accumulation.67, 71 Large prospective trials with anti-EGFR therapy in HPV-
positive HNSCC have been initiated,97 although its efficacy is most probably limited to 
the small subgroup of EGFR-expressing tumours.
Alternatively, the PI3K-PTEN-AKT pathway might be an efficient target because HPV-
positive OPSCC show extra copies of chromosome 3q in up to two-thirds of cases,68 
including the 3q26 locus, harbouring the PI3K gene.
Tumour angiogenesis and metastases are correlated to upregulation of the TGF-β 
and NFκB pathways.156, 157 HPV positive OPSCC have been shown to metastasise in an 
earlier stage compared to HPV negative OPSCC,158 indicating earlier endothelial-to-
mesenchymal transition (EMT), which is characterised by the expression of vimentin, 
downregulation of E-cadherin and upregulation of β-catenin.159 This suggests that EMT 
might be related to upregulation of these pathways and that particularly HPV-positive 
OPSCC might be a potentially interesting group for NFκB-inhibitors, for which a clinical 
trial has recently started.160
Increased degradation of cell cycle regulatory proteins p53 and pRb by the oncoproteins 
E6 and E7, can be inhibited by targeting the proteasomal pathway. Ritonavir, a protease 
inhibitor (PI) that is used in HIV-infected patients, inhibits the chemotryptic activity of 
the human cellular 20S proteasome while increasing the tryptic activity,161 resulting 
in reduced protein degradation. It was shown to enhance antitumour activity when 
combined with radiotherapy both in vitro and in vivo in a Hep-2 head and neck 
carcinoma model,161 later however shown to be contaminated with HeLa cells. The PI 
Lopinavir was shown to restore p53 expression and to induce apoptosis in SiHa cells.162 
Although several clinical trials have evaluated the effectiveness of PIs in the treatment 
of HIV, clinical trials in the treatment of HPV-related disease have not been initiated.
Finally, replication of the HPV virus can be targeted. In episomal HPV infection, replication 
is initiated by binding of E2 to its origin of replication.54 In human transcription factors, 
the most commonly found DNA binding motifs are zinc fingers. Recently, artificial zinc 
fingers (AZF) have been developed as a potent new inhibitor of HPV.163 When linked to 
a cell-penetrating peptide (CPP) these AZF were shown to inhibit HPV-18 for 97%.164 
However, because the CPP-AZF is designed to prevent E2 from binding to its origin of 
replication, they are only effective in episomal HV infection.
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8.7. DISCUSSION
The past decade has provided evidence for a biological association between oncogenic 
HPV and OPSCC. HPV-induced OPSCC show molecular and clinical features that are 
clearly different from tobacco-and-alcohol-induced tumours and these differences 
seem to underlie prognostic differences between both tumour subgroups. Independent 
of treatment modality, patients with HPV-positive tumours demonstrate up to 30% 
better survival rates. In the past decennia, intensification of treatment was the most 
important strategy to improve survival of patients with HNSCC. However intensification 
of treatment, combined with increased side effects, is finally reaching the maximum 
tolerance of the patient and this limits the intensity of treatment. Until now, no 
differentiation of therapeutic strategies has been made between the HPV-positive and 
HPV-negative subgroups in international guidelines on OPSCC treatment.81 Because 
of the clinical and molecular differences between both groups, the question arises 
whether HPV-positive tumours need equally intensive treatment protocols as their HPV-
negative counterparts. Moreover, additional antiviral therapeutic strategies can possibly 
improve survival without increasing therapy-related morbidity in HPV-positive tumours. 
In current and future studies. we should, therefore, aim at improving the quality of life 
in patients by de-intensification regimens in selected cases. Next-generation treatment 
strategies for HPV-associated cancers should focus on decreasing adjuvant radiotherapy 
and chemotherapy, whether or not combined with therapeutic options specifically 
targeting HPV. Assessing which therapy is most effective will finally lead to a more 
personalised approach for individual patients.
Immunomodulating therapies, such as IFN therapy, may have beneficial effects, but this 
seems to be limited to episomal infections. This conveys the need to reliably establish 
the integration status of HPV infection. That this criterion has not yet been met becomes 
apparent when observing the reported integration frequencies, which range from 0% 
to 100%, depending on the population studied and methods used.41, 42
Tumour-specific host responses could also be enhanced by depletion of CD4+/CD25+ 
regulatory T-cells (Tregs). Increased expression of Tregs was shown in patients with 
CIN and cervical cancer.165, 166 It is hypothesised that the enlarged population of 
Tregs suppresses HPV-specific immunity and inhibits tumour-specific T-cell responses. 
Upregulated Tregs have already been depleted using an anti-CD25 antibody, such as 
PC61.167
Other immunomodulating therapies such as imiquimod, a topical immune response 
modifier that has successfully been used in the treatment of anogenital lesions with 
episomal HPV infections,168 are thought to be unsuitable for application in HPV-related 
HNSCC and RRP. Application to cutaneous epithelia is known to induce local inflammatory 
responses and pain, which will be enhanced in mucosal epithelia. Moreover, the 
substance cannot be controlled to reach all tumour parts when topically applied, 
and, like IFN-therapy, will at best lead to eradication of only episomal HPV infections, 
whereas a large proportion of HPV-positive HNSCC show viral integration.169
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Antiviral therapies such as cidofovir and RNAi have already shown promising results 
and are expected to have progressive impact on the treatment of HPV-associated 
lesions. Cidofovir has been tested in cervical cancers and RRP, where it has been 
applied topically or intralesionally in most studies. It has been shown that combining IFN 
therapy with cidofovir could enhance the antiviral and antiproliferative effects of either 
substance alone, and it is postulated that adding IFN therapy could further improve the 
auspicious effects of cidofovir combined with CT and/or radiotherapy.170 Furthermore, it 
is recommended to assess the effects of cidofovir as adjuvant therapy in the treatment 
of HPV-associated HNSCC in a larger, prospective clinical trial.
The RNAi treatment, although tested in mouse models, has not yet been evaluated 
for use in human HPV-associated HNSCC. Such studies can, however, be expected in 
the near future, judging from patents referring to the use of oligonucleotides in the 
treatment of HPV infections (see for example 171).
Therapeutic approaches based on the molecular profile of the tumours are emerging in 
an adjuvant setting. However, one of the major drawbacks of such an approach is that 
the applicability should be assessed for each individual patient. For example, cetuximab 
can only be applied in a small subgroup of patients with HNSCC because HPV-positive 
tumours tend to show a low EGFR expression. In the current practice, Cetuximab is 
already used for larger non-resectable head and neck tumours, irrespective of HPV 
status. With regard to PIs and AZFs, no clinical studies have yet tested the applicability 
of these therapeutic options in the treatment of HPV-related carcinomas.
Because therapeutic vaccination is expected to have minimal side effects it can be 
combined with other therapeutic approaches, such as radiotherapy and/or CT, to obtain 
synergistic effects. However, therapeutic vaccines are still in a developmental stage.
Although a significant reduction in the burden of HPV-related diseases can be 
anticipated if prophylactic vaccination will live up to its promises, only HPV-naïve 
females are currently vaccinated. We firmly believe that young HPV-naïve boys should 
also be vaccinated in order to achieve optimal protection, although it needs to be 
validated whether vaccination is cost-effective.
In conclusion, we can state that although it has become evident that HPV-positive HNSCC 
have a better prognosis that their HPV-negative counterparts, the choice of therapy for 
these two subgroups of HNSCC will strongly depend on the outcome of ongoing clinical 
trials, including de-intensification protocols and implementation of treatment options 
based on new insights into the molecular biology of HPV-infection.
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Figure 1
Structure of circular episomal and linear integrated HPV DNA. The HPV genome is usually present 
in many episomal copies in the nucleus of infected cells. In the transition to cancer, viral DNA 
often integrates in 1 or more copies into the host genomic DNA. During this process, the ring 
structure of the HPV-DNA molecule is most often opened within the E2 reading frame, frequently 
leading to deletion of E4 and E5 and part of E2 and L2. The subsequent upregulation of E6 and 
E7 oncoproteins results in deregulation of cell signaling pathways, which, amongst others, leads 
to increased cellular proliferation and inhibition of apoptosis.172-175
Figure 2
Representative examples of strong nuclear and cytoplasmic p16INK4A immunostaining (A) and 
punctate nuclear HPV-16 FISH signals indicating viral integration (B) shown on paraffin embedded, 
formalin fixed tissue sections of oropharyngeal squamous cell carcinoma. An example of E6-
specific HPV-16 RT-PCR products on a 1% agarose gel, on RNA extracted from cell lines and 
fresh-frozen oropharyngeal squamous cell carcinoma tumour tissues, are shown in (C)
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Table 1. Involvement of human papillomavirus types of the alpha-genus in benign and malignant 
human lesions. The major human papillomavirus types for the different lesions are indicated 
in bold
Lesion HPV types found References
Head and neck benign   
Focal Epithelial Hyperplasia 13, 32 176, 177
Sinonasal papilloma 6, 11, 18 178, 179
Laryngeal papilloma and dysplasia 6 1), 11 , 16, 18 180, 181
Oral leukoplakia and lichen planus 6, 16, 18, 31, 33 182, 183
Head and neck malignant   
Oropharyngeal squamous cell 
carcinoma
6, 11, 16 , 18, 31, 33, 35 52, this 
review
Oral squamous cell carcinoma 16 , 18 52, 60
Laryngeal squamous cell carcinoma 6, 11, 16 , 30 52, 60
Sinonasal carcinoma 16 , 18 179
Anogenital   
Anogenital2) benign lesions3) 6, 11, 16 , 18, 31, 33, 53, 56, 58, 66, 83 36, 184
Anogenital§ (squamous cell) 
carcinoma
6, 11, 16 , 18, 31, 33, 45 36
Cervical intraepithelial neoplasia 
and uterine cervical squamous cell 
carcinoma
6, 11, 16, 18 , 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68, 70, 73, 82
16, 37
Adenocarcinoma in situ and 
uterine cervical adenocarcinoma
16 , 59 ,58 ,51 ,45 ,35 ,33 , 18 185, 186
Cutaneous   
Common skin warts 2, 3, 7, 10, 27, 28 15, 187
Periungual squamous cell 
carcinoma
16, 26, 33, 51, 56, 73 188, 189
1) The major HPV types for the different lesions are indicated in bold;
2) including anal, vulvar, vaginal and penile lesions;
3) including warts, lichen sclerosis, squamous cell carcinoma in situ , adenocarcinoma in situ and 
intraepithelial neoplasia.
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Table 2. Clinical and molecular differences between OPSCC with or without HR-HPV *
 HPV-positive HPV-negative
Clinical characteristics   
Preferred location oropharynx all sites
Degree of differentiation poorly 
differentiated
moderately to well 
differentiated
Baseloid appearance more often less often
T-stage at diagnosis T1-2 T3-4
Disease stage (TNM) more advanced less advanced
Average age slightly younger 
than 60 years
slightly older than 
60 years
Tobacco (ab)use low high
Alcohol (ab)use low high
5-year disease free survival 70-90% 30-60%
Second primary tumours within 5 years 0-10% 10-15%
Local recurrences within 5 years 10-20% 25-55%
Molecular characteristics   
E6/E7 expression + -
p53 downregulation + -
pRb downregulation + -
p16INK4A overexpression + - **
p14ARF overexpression + - **
p18INK4C overexpression + -
p21Cip1/WAF1 overexpression + -
Cyclin D1 overexpression - + ***
EGFR overexpression - + ***
* Summarised from 10, 22, 41, 56, 59, 62, 65-68, 92, 94, 158, 174, 190-192.
** Inactivated by gene mutation, hypermethylation or homozygous deletion.
*** Mainly induced by gene amplification or transcriptional upregulation.
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9.1. IMPLICATIONS OF HPV-RELATED 
TUMOR BIOLOGY ON TUMOR STAGING AND 
PROGNOSIS
In the past decade it has become clear that a biological association is present between 
oncogenic HPV and a subgroup of OPSCCs. HPV-induced OPSCCs show distinct molecular 
and clinical features that are different from tobacco-and- alcohol-induced tumors 
and these differences seem to underlie prognostic differences between both tumor 
subgroups.1,2 In chapter 2 we showed that HPV-positive tumors, which are associated 
with less smoking and alcohol consumption, have a different tumor biology. They have 
smaller primary tumor sizes, although regional lymph node involvement is comparable 
to HPV-negative tumors. In our study, this resulted in a different choice of treatment, but 
independent of treatment modality, HPV-positive tumors had a better prognosis.3
The prognostic value of nodal involvement is reduced by the presence of HPV. It was 
not until 2007 that the World Health Organization officially recognized HPV as causative 
agent in the development of head and neck cancer.4 Our study described in Chapter 
2 was the first to address that lymph node involvement and extent of nodal disease 
do not have a reliable predictive value when the seventh edition UICC staging system 
for OPSCCs is used. We therefore advised an HPV-dependent staging system for the 
diagnostic work-up in oropharyngeal tumor staging. Similar results to our findings were 
found by the groups of Klozar et al. and Fritsch et al.5-6 When reviewing literature 
reporting on the prognostic value of N-status in tonsillar squamous cell carcinomas 
(TSCCs), 10 studies were published prior to 1990, which all reported that N-status 
was of prognostic importance (although only 2 studies provided results based on 
statistical analysis). In contrast, from 1990 onwards, only 4 out of 12 studies showed 
N-status to be of prognostic relevance.7-28 This indicated that the prognostic shift of 
nodal status in TSCCs in literature runs parallel with the increase in HPV-prevalence in 
HNSCCs. In 2013, Dahlstrom et al. described in a US population of 3891 patients with 
OPSCCs collected between 1955 and 2004, a similar shift in prognostic reliability of 
TNM-status over time: compared to the previous study period, patients after 1995 
were more often of younger age, had more tongue base or tonsillar tumors, were 
more often never smokers or former smokers and died only half as often.29 The TNM-
classification predicted the survival of patients treated prior to 1995 accurately, but 
lost its predictive value for patients treated between 1995 and 2004. They also noted 
an unusually favorable outcome for stage III and IV disease in the most recent decade. 
In 2015, data of the Surveillance, Epidemiology, and End Results (SEER) database for 
OPSCC – also without knowledge of HPV status - described similar changes in prognostic 
significance.30 Similar to our results in chapter 2, the SEER-study noted a reduction of 
hazard ratio for survival for all N2 subcategories in the 7th edition UICC staging system 
compared with N0 disease.
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In this period, it was recognized that in OPSCCs HPV-positivity devalued the prognostic 
value of N-status described in the7th edition UICC staging system.29 Therefore, a new 
staging system for HPV-positive OPSCCs was the next step. First, Ang et al. presented 
a risk-model to predict survival for stage III and IV OPSCCs treated with concomitant 
chemoradiotherapy, in which smoking status was combined with N stages “N0-2a” and 
“N2b-3”.31 In the HPV-positive group, smoking status (more or less than 10 pack years) 
discriminated between mild and moderate risk. Within the HPV-positive smoking group, 
difference in outcome was based on nodal status “N0-2a” and “N2b-3”, respectively, 
resulting in mild and moderate risk-associated groups. Spector et al. subsequently, 
subdivided N-status on the basis of diameter and number of nodes in 3 risk groups: a 
single node <6cm ipsilaterally or contralaterally as “HPV+ N1”, a single node ≥ 6cm or 
≥ 2 nodes ipsilaterally/contralaterally or ≥3 nodes bilaterally as “HPV+ N2”. “HPV+ N3” 
was defined as neck node status with matted nodes.32 In 2015, Huang et al. studied a 
large group of 810 patients with OPSCCs and noted prognostic discrimination by using 
the 7th edition UICC staging system in HPV-positive tumors.33 Compared to the HPV-
negative tumors showing outcomes worsening from stage I to IV, their HPV-positive 
group showed no significantly different survival rates from stage I to IV. Two additional 
classifications were proposed using the existing T and N categories of the 7th edition 
UICC staging system for the HPV+ cohort. The first model, which was based on recursive 
partitioning (RPA), showed a better predictive value for prognosis (stage I: T1–3, N0–
N2b; stage II: T1–3, N2c; stage III: T4 or N3, stage IV: M1 as stage IV). Interestingly, 56% of 
patients classified as stage III or IV according to 7th edition UICC staging system, changed 
to stage I when using the new model. The second model proposed by Huang et al. was 
based on adjusted hazard ratios (AHR): 4 prognostic groups in HPV-associated OPSCCs 
without hematogenous metastases were discriminated, based on N status (N0-2c vs. 
N3), T status (T1-3 vs. T4), smoking behavior (fewer vs. more than 20 pack-years history) 
and age (younger vs. older than 70 years).33 Dahlstrom et al. (2016) were not able to 
validate Huang’s results; consequently, they proposed an own HPV-associated system, 
in which N status was staged corresponding to nasopharyngeal carcinomas.34 Finally, 
the classification system suggested by O’Sullivan et al. (ICON-S; 2016) was used for the 
clinical TNM-classification in the 8th edition of the UICC staging system for HPV-positive 
carcinomas.35 In this classification, N-status is based on the sidedness and maximum 
diameter of the nodes rather than on the number of nodes. It enhances the UICC 
staging system into more valid groups compared with the 7th edition to facilitate patient 
counseling, cancer surveillance, and translational research, and furthermore to optimize 
clinical trials design and outcome reporting.36 For this multi-institutional analysis, also 
the data on HPV-positive OPSCCs of our study group were included. Besides the clinical 
staging system, a pathological staging system has been introduced o establish prognosis 
and guide adjuvant therapy decision in surgically-managed HPV-positive OPSCCs.37 In 
contrast to clinical staging, the number of nodes (with a cut-off point of 4) determines 
N status (ranging from N0 to N2 without differentiation between N2a, N2b and N2c) 
for pathological staging.
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This newly introduced 8th edition UICC staging system for HPV-positive OPSCCs was 
validated by others.38-42 We also compared this 8th edition with the previous 7th edition 
UICC staging system for HPV-positive OPSCCs in this thesis. In our study only TSCCs were 
included, a very strict definition of HPV-positivity was used, and the added prognostic 
value of additional non-anatomical parameters was tested, as described in chapter 7 
and further on discussed in this chapter in 7.6.
9.2. ADEQUATE DETECTION OF BIOLOGICALLY 
RELEVANT HPV-POSITIVITY IN OPSCCS
In chapter 2 we showed that the impact of HPV on tumor biology, prognosis, and choice 
of treatment is large. Therefore, detection of biologically relevant HPV-positivity is of 
increasing importance. Literature has addressed the issue of more consensus on the 
exact definition of HPV-associated OPSCCs.44 HPV infection alone is not sufficient to 
classify an OPSCC as HPV-related, because the presence of HPV-DNA may only reflect 
a transient infection. In chapter 3, the reliability of p16INK4A immunohistochemistry 
(p16Ink4a-IHC) as surrogate marker for HPV was tested. We scored the p16Ink4a-
IHC staining patterns according to the “block-type” immunopositivity approach, 
defined as p16Ink4a -IHC only being block positive if continuous (>70%) strong nuclear 
with or without cytoplasmic staining is present (in all head and neck lesions) and 
staining is observed in the basal cell layer with extension upwards (in benign and 
premalignant lesions).45 Our results indicate that a strong nuclear and cytoplasmic 
p16Ink4a-IHC pattern can accurately predict the presence of HR-HPV16 in OPSCC and 
tonsillar dysplasias.46 In low-risk-HPV6/11-positive benign and premalignant tonsillar 
and laryngeal lesions, however, the predictive value of p16Ink4a-IHC was lower and 
therefore caution is recommended when using this surrogate marker for HPV-infection. 
More recent studies have shown that in tumors outside the oropharynx, p16Ink4a-IHC 
has also less predictive value for HPV-presence.46-48
Despite the good correlation between P16Ink4a and the presence of HR-HPV16 in 
OPSCC, the decision to use p16Ink4a-IHC as sole diagnosticum to identify a HPV-
positive OPSCC in the 8th edition UICC staging system may result in false-HPV-positive 
tumors. This was also recently emphasized by Bussu et al.49 Moreover, differences 
in geographical patterns of HPV-prevalence implicate, that the positive predictive 
value of p16Ink4a-IHC as solitary diagnostic tool will drop if the a priori probability 
of having a HPV-positive OPSCC is lowered by 30 to 40%, as is the case in Europe 
compared to the US.50 Throughout this thesis, therefore, p16Ink4a-IHC was combined 
with HPV-DNA PCR and/or Fluorescence In Situ Hybridization (FISH). We found that 14 
out of 124 p16Ink4a-positive patients were not HPV-positive (11.2%). Taberna et al. 
recently investigated the treatment outcome of HPV-positive OPSCCs depending on 
the definition of HPV-positivity.51 They confirmed that definitions of HPV-positivity have 
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impact on TNM-classification and patients’ prognosis and adequate testing with at least 
PCR for detecting HPV DNA next to p16Ink4a-IHC is emphasized.52, 53
Nevertheless, p16Ink4a-IHC is a widely available, low-cost test in the general pathology 
laboratory in contrast to more expensive HPV DNA PCR and HPV-in situ hybridization 
analyses, which require a specialized laboratory and expertise. Therefore, it has been 
adopted as surrogate marker for HPV in the since 2018 used 8th edition UICC staging 
system for OPSCCs.54
Prigge et al. suggested in their meta-analysis the most desirable technique to identify 
HPV-positive OPSCCs: the detection of HPV E6 and/or E7 oncogene transcripts 
of all HR-HPV types (a), in the form of all splice transcript variants (b), from fresh-
frozen tumor tissue (c), and performed on isolated tumor cells (d), e.g. by means of 
tumor microdissection.55 This “ideal” detection strategy is considerably laborious 
and, consequently, not realizable in the routine diagnostic setting.55 Therefore, the 
combined p16Ink4a-IHC and HPV-DNA PCR assay significantly enhances specificity 
while maintaining high sensitivity. This diagnostic test combination thus represents an 
attractive testing strategy for the reliable diagnosis of HPV-positive OPSCCs in the clinical 
setting and may constitute an inclusion criterion for future therapeutic trials.47
9.3. IS THERE ADDITIONAL VALUE FOR HPV-
TESTING IN CUP-SYNDROME?
Because HPV-positive OPSCCs often spread to the lymph nodes already at low T-stages, 
a clear role for HPV-detection in the diagnostic work-up of cervical metastases of 
unknown primary tumors (CUP), to identify primary tumors in the oropharynx, has 
been advocated.56 However, studies on the prevalence of HPV in lymph node metastases 
of which the primary tumor could not be detected after a comprehensive diagnostic 
workup, so-called “true” CUPs, are scarce and contradictory. In these studies, HPV 
prevalence rates range from 0% to 100% and were tested in very small sample numbers 
(range 1-25).56-62 In chapter 4, we collected 29 true-CUP patients, of which the primary 
tumor was not present within 6 months of follow-up after treatment. Treatment 
consisted of a neck dissection and/or (chemo)radiotherapy. In this patient group 5/29 
neck metastases were p16Ink4a-positive but in none of the specimen HPV DNA was 
detected by FISH and PCR (0%). No association between p16Ink4a-positivity and survival 
was found. All specimens were therefore regarded HPV-negative.63 This indicates that 
the additional value of HPV-testing, next to a thoroughly performed diagnostic work-
up, including panendoscopy, blind biopsies of tongue base and nasopharynx, bilateral 
tonsillectomy, and additional imaging, including PET-CT scanning, is limited.
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9.4. SHOULD PATIENTS WITH CUP SYNDROME 
WITH OR WITHOUT HPV ALWAYS BE TREATED 
EXTENSIVELY, OR IS DE-ESCALATION AN 
OPTION?
More than a decade ago in the Netherlands, patients with CUP were treated 
extensively with postoperative radiotherapy of the bilateral neck and radiotherapy 
of the pharyngeal axis, in some cases combined with concurrent chemotherapy. The 
question arose whether de-escalation of therapeutic regimes in patients with CUP with 
our without HPV is possible. To enlarge our CUP patient group (see 7.3), we united 
the patient collectives of two European University medical centers (Cologne, Germany 
and Maastricht, the Netherlands; n = 51) and compared their data (chapter 5). Only 
true CUP patients (no primary tumor found within 6 month of follow-up) whose neck 
metastases were primarily treated surgically were included. The prevalence of HPV in 
this Maastricht-Cologne cohort of true CUP-patients was 7.8% (4/51 HPV-positive true 
CUPs).64 No statistically significant difference of HPV-positivity between Maastricht and 
Cologne was found. Because of the low percentage of HPV-positivity, the influence of 
HPV positivity on outcome after therapy could not be assessed. Comparable to chapter 
4, the added value of HPV testing in neck metastases of CUPs was found to be limited 
in chapter 5, especially when compared with OPSCCs in which the prevalence of HPV 
is much higher.56
In the same study data about the therapeutic strategy for cervical metastasis of CUPs 
were retrospectively compared. All patients underwent a neck dissection, but the 
postsurgical management differed between patients and institutions. This enabled 
us to compare ipsilateral and bilateral radiotherapy, with or without radiation of the 
pharyngeal axis and with or without addition of chemotherapy. No significant differences 
in disease specific and overall survival between all subgroups was found, indicating that 
de-escalation might be a safe option in CUP-patients. Advanced nodal disease was, 
however, associated with a worse outcome, independent of treatment modality. The 
same was the case for the occurrence of regional recurrences after therapy: in almost 
half of the patients with regional recurrences during follow-up, distant metastases 
occurred (n = 6/13). Recently, also Sprave et al. found a high incidence of metachronous 
distant metastases in patients with regional recurrences.65 In that study, the combined 
radiochemotherapy of the pharyngeal axis and bilateral cervical lymph nodes led to 
good results in case of specific risk factors (extra nodal spread and residual tumors), 65 
which were not included in our study.
The presented data of the Maastricht-Cologne study contribute evidence to the ongoing 
discussion, in which the need for uniform international guidelines to treat patients 
with cervical CUP syndromes is claimed.66 Our data indicate that the omission of 
radiotherapy of the pharyngeal axis and the contralateral neck after neck dissection, 
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as well as the omission of concomitant chemotherapy, might be safe under certain 
conditions. However, the variety of therapeutic strategies in both institutes in this 
complex population of patients with cervical CUP syndrome, prohibited any statistical 
evaluation or definitive conclusion in our study. Therefore, further research in a more 
homogeneous patient population was needed, addressed in chapter 6.
9.5. FURTHER EVIDENCE FOR SAFE DE-
ESCALATION OF THERAPY FOR CUP PATIENT: 
NEED FOR TRIALS?
In order to homogenize treatment modalities of the neck and to exclude regional 
influences on the prevalence of HPV-positive CUPs, we merged our Maastricht database 
with a patient population collected at the Radboud University Medical center, Nijmegen, 
the Netherlands (n=80) (chapter 6). The protocols for diagnostics and treatment of 
CUP patients were similar in Nijmegen and Maastricht, and de-escalation of therapy in 
CUP patients was performed simultaneously in both institutes, starting in 2002. Again, 
in only 4 out of 72 neck dissection specimen presence of HPV DNA in tumor cells was 
found (6%) confirming previous results.67 Therefore, also in this merged patient cohort 
HPV testing did not add value to the described diagnostic workup and did not influence 
therapeutic decision-making, for example, additional postsurgical radiotherapy of 
the oropharynx. This might be unexpected taking into consideration that small (T1-2 
stage) HPV-positive OPSCC frequently are spreading to the lymph nodes and thus in 
principle could account for a substantial number of CUP. Probably, most HPV-positive 
primary tumors of the oropharynx are detected by tonsillectomy or “blind biopsies” 
of the oropharyngeal region, resulting in low percentages of HPV-positive true CUPs. 
Altogether, our studies in chapters 4-6 revealed that HPV-status was of insignificant 
importance to be used as in stratifying patients with CUP. Because of the low prevalence 
of HPV-positive CUPs, HPV-diagnostics improved neither the diagnostic and therapeutic 
work-up nor the outcome. As a result, the current treatment of patients with HPV-
related CUP does not differ from the standard of care treatment.66 Nevertheless, de-
intensification of therapy remains an interesting option to be examined in the (small) 
group of HPV-positive CUP-patients.56
Furthermore, in chapter 6, we confirmed our previous observation that omitting 
irradiation of the pharyngeal axis in patients with cervical true CUP syndrome does not 
result in the emergence of a primary tumor in the pharyngeal axis during five years of 
follow-up. This can avoid acute and late toxicity of comprehensive radiotherapy of the 
pharyngeal mucosa with significant improvement of long-term quality of life for these 
patients. Also, the absence of post-surgical radiotherapy of the contralateral neck in 
CUP did not lead to a decrease of regional control rates nor of survival rates.
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In order to compare the outcome of ipsilateral radiotherapy solely with a comprehensive 
radiotherapeutic regime in CUP-patients, Nieder et al. recommended a randomized 
controlled trial already in 2001.68 Only one randomized controlled trial was started 
since 2002, but was never completed (EORTC-24001-22005) as a consequence of limited 
patient enrollment.69 Still, a prospective multicenter approach to analyze the true impact 
of radiotherapy target volume in CUP-patients is needed. However, the low prevalence 
of patients with CUP and the heterogeneous treatment strategies in different countries 
and regions are important limiting factors to design a large international study providing 
sufficient evidence for an international guideline.
For that reason, the American Society of Clinical Oncology convened an Expert 
Panel of medical oncology, surgery, radiation oncology, radiology, pathology, and 
advocacy experts to conduct a literature search including 100 relevant studies 
published from 2008 through 2019 including our presented results in this thesis.70 
Available evidence and informal consensus was used to develop evidence-based 
guideline recommendations about appropriate pre-operative evaluation, appropriate 
surgical diagnostic and therapeutic procedures, treatment considerations for surgical 
management, radiotherapy and chemotherapy in patients with CUP. Regarding 
radiotherapy of the occult primary tumor site, it was stated that solely radiotherapy 
of the ipsilateral oropharynx (i.e. ipsilateral tonsillar bed, ipsilateral soft palate and the 
mucosa of the entire tongue base) is recommended in patients with CUP treated with 
primary radiotherapy for one or more unilaterally located lymph nodes, not greater 
than 6 cm (AJCC 8th N1 HPV+ve and AJCC 8th N1-N2b HPV-ve), and in case of available 
PET-CT scan and performed contralateral tonsillectomy. Patients with CUP presenting 
with bilateral located lymph nodes not greater than 6cm (AJCC 8th N2 HPV+ve and AJCC 
8th N2c HPV-ve), require bilateral treatment of the oropharyngeal mucosa. Patients 
with CUP presenting with nodes in the lower cervical stations (III and IV) should be 
considered for treatment of the larynx and hypopharynx, given the marginally higher 
risk of spread to stations III and IV from these organs.70
The following argumentation was offered regarding radiotherapy of the unilateral 
versus bilateral neck: as bilateral neck irradiation for CUP has been considered 
standard of care historically, this approach is accompanied with considerable toxicity, 
including increasing dose to salivary glands, larynx, pharyngeal constrictors, mandible, 
hypopharynx, and esophagus. Following high-resolution imaging, ipsilateral only 
radiotherapy has been demonstrated to results in very acceptable rates of contralateral 
failure and reduced doses to the above-named structures. Ipsilateral neck irradiation 
is recommended in patients with CUP with a unilateral single node without extranodal 
extension and preferably in lymph node level II. In all other patients with CUP (multiple 
nodes, nodes, node(s) greater than 6 cm, level III or IV nodes, and/or clinical or radiologic 
ENE), bilateral neck treatment is recommended as in these patients higher rates of 
contralateral involvement are noted and prognosis is worse.70
These above cited recommendations are in line with our presented results. However, 
the outcomes of interest in the above cited ASCO guidelines were survival, local and 
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regional disease control, and quality of life.70 In our presented results in chapters 5 
and 6, the occurrence of distant metastases was the most important limiting factor of 
survival. Again, this affected the more advanced staged necks, i.e. more than one lymph 
node or lymph node size more than 6cm (AJCC 7th N2b or higher). This underscores the 
importance of including distant disease control as primary endpoint in the evaluation 
of therapeutic strategies in CUP patients, as recently also was emphasized by Sprave 
et al.65
9.6. THE PROGNOSTIC VALUE OF LYMPH 
NODE METASTASES IN HPV-POSITIVE TSCCS 
AND HOW IT INFLUENCED THE 7TH AND THE 
8TH EDITION OF THE UICC CLASSIFICATION 
SYSTEM.
Chapter 7 describes that the predictive value of the 7th edition UICC tumor staging 
system for OPSCCs, and N-status in particular, has shifted over time as a consequence 
of the epidemic of HPV-associated HNSCCs. Since our study in 2009 (chapter 2), 
which was the first to report the direct correlation of HPV-status and the diminished 
prognostic value of N-status, different larger studies followed confirming our data.43 This 
finally resulted in the new 8th edition UICC tumor staging system, in which a separate 
classification system for HPV-positive tumors has been introduced.54 In chapter 7 we 
first summarized the changes of the 8th compared to the 7th edition of the UICC staging 
system: nodal stages underwent a transformation, clinical neck stages N1 until N2b 
were re-classified as cN1 including all ipsilateral neck metastases no greater than 6 
centimeters, bilateral neck nodes were classified as cN2, and nodes greater than 6 cm 
as cN3. Along with the clinical staging, a pathological staging system was introduced 
based on the number of positive nodes identified by histopathological examination 
after neck surgery. These changes in tumor staging were then evaluated by testing the 
prognostic value of the different 7th- as well as 8th UICC tumor stages in HPV-positive 
OSCCs. The examination also included the separate T-, N-, and M-stages. An unselected 
population of 368 patients with SCCs of the tonsil, which is the site associated with the 
highest prevalence of HPV, was included in the study.71 Next to T-, N-, and M-stages the 
influence of patient-associated clinical variables including tumor differentiation grade, 
age, smoking behavior, alcohol consumption and treatment were taken into account.
In total, 110 tumors were tested HPV-positive with p16Ink4a-IHC, HPV16-DNA PCR 
and/or FISH. Advanced stage HPV-positive tumors staged with the 7th edition UICC 
tumor staging system had a favorable prognosis. These tumors, however, had despite 
more advanced N-status (resulting in a higher overall stage) smaller primary tumors. 
When applying the 8th edition staging system we noted that 54% of all tumors were 
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classified as stage I compared to 5% of patients in the 7th edition. At the same time in 
the 7th edition 56% of the TSCCs were classified as stage IVa compared to only 3% of 
patients that were classified as stage IV in the 8th edition. We found that the 8th edition 
UICC tumor staging system, therefore, did better separate the different staged tumors 
in survival analysis. Our results were in line with other studies confirming that the 
introduction of the 8th HPV-associated tumor staging system is a step forward in staging 
HPV-associated OPSCCs.43 However, when testing T-, c/pN- and M-status separately we 
found only cN3- and M1-status to be “anatomical” variables that significantly influence 
prognosis negatively. As a consequence of a favorable prognosis in HPV-positive T4-
tumors, T-status in general was not associated with survival in our study. There was 
also no difference in survival dependent on pN-status. However, pN-status could be 
classified in only 38 HPV-positive TSCCs, because in those patients a neck dissection 
was performed.
Cramer et al. recently validated the 8th edition UICC staging system in a population 
of more than 15,000 patients (USA) and demonstrated an improved prediction of 
prognosis for HPV-positive OPSCC patients compard to the previous 7th edition UICC 
staging sytem.72 Also for T-, cN- and pN-status, the prognostic value could be validated 
in the HPV-positive population. In contrast to the validation study by Cramer et al., our 
study focused exclusively on SCCs of the tonsil, which is the subsite with the highest 
percentage of HPV-positive tumors. HPV-positivity was tested using HPV16-DNA PCR 
and/or FISH in addition to p16-IHC, which was the only test used in the study by Cramer 
et al. On the other hand, our study contained a much smaller patient population, 
although 110 unselected HPC-positive TSCCs were included. Despite these differences, 
the overall outcome of both studies were not similar. In our study population, the 8th 
edition of the UICC tumor staging system was also associated with a better prognostic 
value for tumor stage. However, in our study no significant prognostic value of N-stages 
cN0 to cN2 and pN0 to pN2 was found. Only cN3-status and M1-status were significantly 
associated with unfavorable prognosis. The cut-off point for a favorable prognostic 
value in our study of TSCCs was N3, however, only very few bilaterally involved (and 
thus cN2) neck stages were diagnosed. The study of MacKenzie et al. confirmed this 
observation and reported that only lymph nodes larger than 6cm (cN3) were associated 
with a worse survival.73
A clinically negative (cN0) neck status was not associated with a better prognosis 
compared to N1 in our HPV-positive TSCC patient population, and showed even 
a worse prognosis than the N1 neck. In the validation study by Cramer et al., also 
no significant differences in survival were found between cN stages cN0 versus cN1 
and cN2.72 Moreover, although the validation of the prognostic value of the clinical 
N-status (8th edition) was successfully performed, cN1-status was associated with a 
significantly better survival than N0 and also the bilateral involved neck (cN2-status) 
was not associated with a significantly worse survival than the clinically negative neck 
after adjustment for age, sex and race. Only cN3-status was significantly associated 
with a worse survival.72
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In previous research, it was noticed that patients with HPV-positive carcinomas more 
often had a lymph node as presenting symptom when compared to their HPV-negative 
counter parts. In HPV-positive carcinomas such a finding thus may guide the subsequent 
discovery of the primary tumor, and futhermore it led to the hypothesis that oncogenic 
HPV infection may play a substantial role in CUP-syndrome.3 As a consequence, patients 
presenting with these “alarming” nodes are expected to have a better prognosis upon 
treatment, which we did find in our study. Fritsch et al. and Ang et al. also described that 
patients with an HPV-positive single neck node between 3 and 6cm (N2a, 7th edition) 
had a better outcome than patients without lymph node metastases.6, 74 Fritsch et al. 
compared outcome based on N-status between HPV-dominant (tonsillar fossa and 
base of tongue) and non-HPV-dominant oropharyngeal subsites in more than 15,000 
OPSCCs.6 In the HPV-dominant population, cN2a (7th ed.) was associated with a better 
survival than cN0/1 and in the total population no differences in outcome were noted 
as long as lymph node metastases were unilateral (<cN2c). In our study only patients 
with TSCCs were included. In this strongly HPV dominant subgroup similar results were 
found and a clinically negative neck (cN0) in HPV-positive TSCCs was not associated with 
a better survival than necks with lymph nodes smaller than 6 centimeter in diameter 
(i.e. cN1- and cN2-status). Possibly, unknown factors next to HPV-driven carcinogenesis 
play a role in the outcome of the clinical negative neck in HPV-positive OPSCCs, taken 
also into account the fact that the presentation of OPSCCs without involved neck nodes 
is atypical for HPV-associated tumoral behavior.
A point of discussion in the literature is that the influence of N-status on prognosis in 
HPV-positive tumors is often analyzed for all oropharyngeal subsites, without even 
discriminating between HPV-dominant or non-dominant subsites. In chapters 2 and 
7, patients with TSCCs, the most HPV-dominant oropharyngeal subsite, were selected. 
Sood et al. described that a bilaterally involved neck status predominantly is seen in 
base of tongue tumors, indicating that lymph node dissemination patterns even differ 
within the HPV-dominant oropharyngeal sites.76 This may explain the low number 
of bilaterally involved necks in TSCCs and the lack of significance of the cN2-stage 
classifying for bilateral neck involvement in the 8th edition which we found in our 
study. The location of the tumor in the different subsites of the oropharynx therefore 
likely plays a prominent role in the development of advanced (N-) tumor stages in 
HPV-positive OPSCCs.
All in all, the cN status classification assessed for HPV-positive OPSCCs according to the 
8th edition UICC tumor staging system still turns out to be a suboptimal predictor of 
survival. In our study only cN3 and M1 were associated with a worse survival. Therefore, 
other, “non-anatomical” variables have been investigated to improve risk assessment 
of HPV-positive tumors.
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9.7. ADDITIONAL NON-ANATOMICAL FACTORS 
IMPROVING PROGNOSIS IN HPV-RELATED 
OROPHARYNGEAL TUMOR STAGING.
The goal of implementing the 8th UICC staging system for HPV-positive OPSCCs was 
to more accurately represent the superior survival outcomes seen in these tumors 
and thereby to improve the prognostic value of the system and possibilities to guide 
treatment decisions.77
As mentioned earlier, our results described in chapter 7 were in line with other studies 
confirming that the introduction of the 8th HPV-associated tumor staging system is a 
step forward in staging HPV-associated OPSCCs. However, in our study the survival of 
HPV-positive TSCCs was not predominantly dependent on TNM-status even when using 
the 8th edition. The most significant prognostic factors in HPV-positive TSCCs were 
smoking, age, N3-status, and the presence of distant metastases. Our study indicated 
that the prognostic value of the 8th edition UICC staging system can be improved 
by including smoking history and age with a cut-off point of 65 years as additional 
prognostic factors. Therefore, we have proposed a risk model for HPV-positive TSCCs 
based on smoking history, age, nodal size of >6 cm and presence of distant metastases 
resulting in 4 groups. The first group consisting of non- or former smokers (patients 
who quitted smoking more than 10 years prior to the diagnosis of TSCC independent of 
the number of previously smoked pack years) was associated with a 5-yr OS of 95.1% 
even in advanced tumor stages. In groups 2 and 3, all patients smoked daily. Group 2 
included smokers aged 65 or younger with an associated overall survival rate of 75.6%. 
In group 3 patients older than 65 who smoked had a 5-yr OS of 46.2%. Group 4 consisted 
of patients with N3- and M1-status (5-yr OS: 0%). Interestingly, two patients survived 
with a N3-staged neck, they were both non-smokers. Within the different groups, T- 
and/or N-status did not further differentiate between survival rate.
The issue of re-staging HPV-associated OPSCCs using N status alone or in combination 
with other clinical parameters has been addressed from various perspectives in 
the literature. Results of our research group on a prognostic model for OPSCCs was 
previously presented by Rios et al.78 These results were validated by Rietbergen et 
al. in a larger cohort, showing the large impact of performance status on outcome 
in the whole patient group.79 However, within the HPV-positive subgroup no further 
differentiation in risk profiles was provided.
In the recursive partitioning analysis of the radiation therapy oncology group by Ang et 
al. (2010), non- anatomic parameters such as age and tobacco smoking were included 
for the first time and an important prognostic value was found for tobacco smoking.75 A 
predictive model for the prognosis of stage III and IV OPSCCs treated with concomitant 
chemoradiotherapy was presented, in which smoking status was combined with N 
stages “N0-2a” and “N2b-3”. In the HPV-positive groups, smoking status discriminated 
between mild and moderate risk. These results were validated by others.80, 81 Huang 
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et al. (2015) discriminated 4 prognostic groups in HPV-associated OPSCCs without 
hematogenous metastases based on N status (N0-2c vs. N3), T status (T1-3 vs. T4), 
smoking behavior (fewer vs. more than 20 pack-years history) and age (younger vs. 
older than 70 years), with associated5-year overall survival rates of respectively 89%, 
64%, 57% and 40%.82 Regarding smoking, Marur et al. noticed that treatment failures 
in a de-escalating regime of combining cetuximab with radiotherapy were seen in 
smokers (>10 packyears).83 However, Haigentz et al. emphasized that including smoking 
in a predictive model goes along with great limitations as a consequence of the lack 
of validated, prospective data and the subjectivity of the data collection on tobacco 
use.84 Further study by Rietbergen et al. showed no differences in outcome regarding 
smokers versus non-smokers.79 In that study, smoking status was defined based on the 
number of pack years and no separate classification was performed for former-smoker 
status, which might have influenced the results for the smoking group.79 Moreover, 
Broughman et al. postulated to leave the 10 packyear rule, proposed by Ang et al. 
as stratifier in HPV-positive OPSCCs, because of the favorable prognosis of former-
smoking status independent of the number of pack years in their recent study. 75, 85 These 
findings correspond with our results which show favorable outcomes in former-smokers 
with HPV-positive OPSCCs as presented in chapter 7. This stresses the importance of 
adequate history taking regarding smoking status in the work-up in a patient population 
with HPV-positive OPSCCs.86
In conclusion, in our study the outcome of HPV-positive TSCCs was not predominantly 
dependent on TNM status even when using the 8th edition. The most significant 
prognostic factors in HPV-positive TSCCs were smoking, age, and also N3-status and 
the presence of distant metastases. In our predictive model, a prognostic role for age 
with a cut-off point of 65 years was observed. Non- or former smokers had a very 
favorable prognosis of more than 95% 5-year OS even in more advanced tumor stages 
and in former smokers who quitted smoking longer than 10 years ago the number of 
pack years had no influence on prognosis. We think that this model could provide a 
simple additional tool for predicting the prognosis of HPV-positive TSCCs in the clinical 
setting.
9.8. HPV-POSITIVE HNSCC BIOLOGY AND 
DIRECTIONS FOR THERAPY.
The previous chapters of this thesis pointed out that detection of biologically active HPV 
in HNSCCs has prognostic relevance and, therefore, a separate classification of HPV-
induced tumors has been introduced.3, 54 Further optimization of treatment protocols for 
this distinct group of HNSCCs is the next step. Data on treatment response of OPSCCs 
indicate that large low-risk subgroups of patients with HPV-positive tumors show up to 
30% better survival rates than patients with HPV-negative tumors, independent of the 
type of treatment, as a consequence of their different tumor biology (Chapters 2 and 
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7).3, 71, 75 Due to these advances in insights in the clinical and molecular behavior of HPV-
positive OPSCCs, the National Comprehensive Cancer Network (NccN) Guidelines have 
made a distinction between treatment pathways for P16Ink4a-positive and -negative 
OPSCCs. However, the incorporated treatment strategies for both groups in the current 
guidelines remain almost identical and are mainly based on surgery, radiotherapy and 
chemotherapy.87
To improve the efficacy of treatment while preventing increased side effects in patients 
with of HPV-positive OPSCCs, the question arose whether treatment de-intensification 
and/or new HPV-targeted therapeutic options are possible. This question was addressed 
in chapter 8, in a large review on (future) therapeutic options for HPV-positive tumors.88 
Literature describes two main strategies for specific treatment of HPV-positive tumors. 
The first strategy focuses on the unique clinical behavior of HPV-associated HNSCCs 
and selects the patients based on risk-profiles to modulate and possibly de-intensify 
treatment. Do HPV-positive tumors need treatment protocols as intensive as their 
HPV-negative counterparts? Does the high chemo- and radiosensitivity of HPV-positive 
HNSCCs offer possibilities for de-escalation of therapy leading to reduced therapy-
induced toxicities? In chapter 8, future directions for de-intensified treatment of HPV-
positive HNSCCs were discussed.88 Until now, mainly improved techniques associated 
with less treatment-related morbidity like IMRT/IMPT or TORS have been implemented 
in clinical practice.89-92 Since the publication of our review, several de-escalation therapy 
trials for HPV-positive OSCCs have been performed, which can be summarized in three 
categories. In the first category, there are four large phase II studies, in which induction 
chemotherapy followed by reduced-dose RT led to less toxicities in p16Ink4a-positive 
and/or HPV-positive patients treated with the reduction dose RT: different low-risk 
profiles (‘less than 20 pack years’: Quarterback-trial, ‘< T4, < N2c, and ≤ 10 pack-year 
smoking history’: ECOG E1308-study) and ‘T1-T3, N0-N2b, and <10 pack-years’: Optima 
II -trial) were associated with favorable outcomes in the reduction dose RT groups. 
These data support phase 3 clinical trials of radiation dose reduction after induction 
chemotherapy to be tested as a treatment strategy in HPV-positive OPSCCs and to 
quantify survival gain compared to standard of care.93-96
A second category is dose reduction of concurrent chemoradiotherapy. Chera et 
al. reported results of two performed phase II trials, in which patients with T0-T3, 
N0-N2c, M0, p16Ink4a-positive disease and a minimal smoking history were treated 
with 60 GY (16% less than standard dose) of intensity-modulated radiotherapy with 
concurrent weekly intravenous cisplatin (30 mg/m2; 40% less than standard dose). A 
good preservation of quality of life and an excellent 3-year tumor control and survival 
was found.97 These first promising results have been reported in the second half of the 
last decade, and a phase III trial have to be awaited for.
In a third category, outcome was evaluated when concurrent cetuximab-based 
chemotherapy instead of cisplatin-based chemotherapy was administered. Phase III-
trials by Gillison et al. and Mehanna et al. both noticed a higher locoregional control in 
the cetuximab-arm, however, overall survival was superior in the cisplatin-arm.98-99 Jones 
Jos_Binnenwerk_v3.indd   184 24/09/2020   17:04:25
185
General discussion and valorization
et al. recently updated the results of this large phase III trial and concluded that the 
standard regimen of concurrent chemoradiation therapy being cisplatin-radiotherapy 
should not be replaced in HPV-positive OPSCCs.100
On the basis of the above-mentioned conflicting results, there are no phase III trials to 
provide sufficient evidence that systemic therapy or radiotherapy may be de-intensified 
in HPV-positive HNSCC. Dose reduction of RT after a clinically good response to induction 
chemotherapy seems promising, particularly in well-defined low-risk subgroups of HPV-
positive OPSCCs.
A second strategy of altering the therapeutic approach for HPV-positive HNSCC is to 
target HPV-specific molecular characteristics and search for new therapeutic options, 
in other words to provide HPV-positive tumors with another treatment protocol than 
their HPV-negative counterparts? In chapter 8, we, therefore, focused next on present 
therapeutic HPV-targeting strategies.
Different prophylactic and therapeutic alternatives for the current treatments of HPV-
positive OPSCCs were discussed: 1) immunomodulating therapies including prophylactic 
and therapeutic vaccines. 2) antiviral therapies including interfering RNA and cidofovir; 
and 3) molecular therapy based on cellular targets including, protease inhitors ritonavir 
and lopinavir, artificial zinc fingers, NFκB and anti-EGFR therapy.88
Currently, these above mentioned targeted therapies for HPV-positive HNSCC seem 
promising, but still have not proven their efficacy in HPV-positive OPSCCs, i.e. data 
on vaccine efficacy in OPSCCs is lacking,101 or data is currently too preliminary.102, 103 
Interfering RNA has also not been tested in vivo in human HNSCCs up to now,104 and 
cidofovir was recently tested in human HPV-positive HNSCC cell lines where it induced S- 
and G2/M phase arrest, resulting in mitotic catastrophe but not in apoptosis.105 Protease 
inhibitors ritonavir and lopinavir have proven their efficacy in the treatment of HPV and 
although their therapeutic effect seems promising in cervical high-grade squamous 
intraepithelial lesions, clinical trials in HPV-positive OPSCCs are needed.106 Regarding 
EGFR-targeted therapy, finally, the inferiority of cetuximab to cisplatinum in concurrent 
radiotherapeutic regimes in overall survival in the general HPV-positive populations was 
described above.98, 99 A second EGFR-targeted therapeutic agent, panitumumab, did 
also not show better outcome in HPV-positive OPSCCs in the SPECTRUM and PARTNER 
trials.107, 108 The lack of overexpression of EGFR in a large group of HPV-positive OPSCCs 
may contribute to the failure of improving outcome based on EGFR-targeted therapies. 
Notwithstanding, narrowcasting EGFR-targeted therapy to the right selection of HNSCC 
patients still seems a serious option to explore.
A recent perspective regarding alternative therapies for HPV-positive HNSCC since 
the publication of our review is immunotherapy. Kim et al. recently classified OPSCCs 
immunologically into immune-rich (IR), mesenchymal (MS) and xenobiotic (XB) subtypes 
based on RNA-sequencing data.109 All IR type tumors were HPV-positive, most XB types 
were HPV negative, and MS types showed both HPV-positive and -negative tumors. 
The IR type was associated with a favorable response signature during anti-PD-1/PD-L1 
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therapy, which seems a promising target in this HPV-positive OPSCC subgroup.110 The 
programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as 
the PD pathway) induces immunosuppression in the tumor microenvironment: tumor 
cells and other cells in tumor microenvironment can express high levels of PD-L1, which 
results in suppressed immunity upon interaction with PD-1. PD-L1–expressing cells use 
multiple mechanisms to suppress tumor immunity, e.g. PD-L1 on tumor cells can act as 
a receptor, and the signal delivered from PD-1 on T cells can protect tumor cells from 
cytotoxic lysis.110 Normal human tissues seldom express PD-L1 protein on their cell 
surface, with the exception of tonsillar tissue a.o.110 Based on durable objective response 
rates and a favorable safety profile (according to the results of the CheckMate 141 
and KEYNOTE-048 trials), PD-L1-checkpoint inhibitors Nivolumab and Pembrolizumab 
(i.e. antibodies targeting the PD-1 receptor of lymphocytes) have been approved by 
the US Food and drug administration (FDA) for the treatment in HNSCCs.111,112 So far, 
however, no phase 3 trials were conducted regarding outcome after immunotherapy 
in HPV-positive OPSCCs. he implementation of immune checkpoint inhibitors revealed 
a new research field in cancer therapeutics which is evolving quickly. Besides anti-PD-1 
and anti-PD-L1 therapy, other therapeutics which interfere with immune checkpoint 
are currently subject of ongoing studies in HNSCCs. Table 1 gives an overview of the 
ongoing studies related to anti-PD-1, anti-PD-L1, anti-CTLA4, anti-NKG2A and anti-PI3K 
therapeutics in HNSCCs. 
Overall, the development of new antiviral and immunomodulatory treatments may be 
instrumental in the future therapy management of HPV-positive HNSCCs to improve 
survival rates and decrease disease-and-treatment-related morbidity. There is rapidly 
increasing evidence for molecular and immunologic subgroups within the HPV-positive 
OPSCCs and also within HNSCCs in general, including the HPV-positive tumors. These 
subgroups most likely will show a different tumoral behavior and response to therapy. 
For example, Zhang et al. described different subgroups of HPV-positive HNSCCs that 
can be identified molecularly, i.e. HPV-KRT (upregulation of keratinization and oxidation-
reduction process) and HPV-IMU (upregulation of mesenchymal and immune-response 
genes).113 They emphasizes that further research is needed for a better understanding of 
these HPV-positive subgroups. The HPV-KRT group for example proved to be associated 
with the occurrence of PIK3CA mutations in the tumor. Recently, Beaty et al. performed 
two phase II trials in which the clinical significance of PIK3CA mutations in 77 HPV-
associated OPSCC patients was studied. In these studies de-intensified CRT (60 Gy 
intensity-modulated radiotherapy with concurrent weekly cisplatin) was given.114 PIK3CA 
mutation was the only variable which was significantly associated with a worse disease-
free survival (multivariate analysis: HR 5.71). Furthermore, recent research by Locati et 
al. reclassified these two molecularly defined subgroups (HPV-KRT en HPV-IMU) into 
three clusters.115 Cluster 1 is an immune-related subgroup characterized by high IFNγ 
signaling, associated with a good prognosis and probably the subgroup with a good 
response to immunotherapy. The HPV-KRT subgroup was further reclassified into two 
subgroups: Cluster 2 is an epithelial-mesenchymal transition-related subgroup (EMT), 
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characterized by fibroblast infiltration, increase in hypoxia and EMT-upregulation, and 
Cluster 3 is a proliferation-related subgroup, characterized by upregulation of E2F 
(G1 checkpoint transcription factor) and G2M checkpoint genes. HPV-positive tumors 
in Cluster 3 are associated with an intermediate risk profile and tumors in Cluster 2 
with a high rate of integration of HPV DNA into the host genome and an unfavorable 
prognosis. HPV-positive tumors in this latter Cluster 2 subgroup are potential candidates 
for treatment intensification according to Locati et al.115
Further research must help to gain insight and develop tools for identification of risk-
profiles based on clinical (smoking, age, cN3-status a.o.) and molecular characteristics 
(PIK3CA-mutation a.o.), which will play a key role in the stratification of patients for 
therapeutic decision making.
9.9. CONCLUSION: CHOOSING THE RIGHT 
THERAPY FOR THE RIGHT PATIENTS
HPV-positive OPSCCs have a different tumor biology and clinical behavior compared 
with their HPV-negative counterparts. The reported favorable prognosis despite 
frequent spread of HPV-associated tumors to the cervical lymph nodes have strongly 
influenced the discussion of adequate tumor staging in HPV-positive OPSCCs. This 
led to the implementation of a separate staging system for HPV-positive OPSCCs in 
the 8th UICC tumor staging edition. The associated favorable prognosis make HPV-
related tumors more eligible for de-escalation of therapy to reduce treatment-related 
toxicities. However, HPV-positive tumors also prove to be a heterogeneous group of 
tumors and additional parameters are needed in stratifying risk groups, e.g. non-and 
former smoking status and age. Moreover, the rapidly increasing evidence of molecular 
and immunologic subgroups within the HPV-positive OPSCCs and within HNSCCs in 
general indicate that also other factors are influencing tumoral behavior and response 
to therapy. Therefore, when developing new HPV-targeted therapeutic strategies, these 
different molecular and biological characteristics must be taken into account.
The expected role of HPV infection in cervical lymph nodes of unknown primary origin 
was refuted in this thesis. Nevertheless, de-escalation of therapy in CUP still remains a 
serious option, independent of HPV, because it proved to be safe in a comprehensive, 
treated patient population described in this thesis.
Future trials on next generation treatment strategies for HPV-associated cancers 
should focus on reducing adjuvant radiotherapy and chemotherapy, whether or not in 
combination with therapeutic options specifically targeting HPV, HPV-related molecular 
biomarkers, and HPV-related subgroups defined by immunological and biological 
characteristics. This will enable the selection of superior treatment strategies for high-
risk tumors and possible de-escalation therapies for low-risk groups to reduce toxic 
side-effects and minimalize compromised functional outcome.
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Chapter 10
In this thesis the clinical features of HPV-related head and neck cancers and their 
implications for tumor staging and therapeutic strategies were studied. A couple of 
important, clinically relevant findings were made. Compared to HPV-negative tumors, 
HPV-positive tumors have different clinical and biological characteristics. The prognostic 
value of the severity of neck node involvement is significantly reduced in HPV-positive 
tumors, which we published as the first group worldwide. [Chapter 2]. A series of other 
and larger studies followed, which confirmed our observation and finally contributed 
to an adapted TNM classification for HPV-positive oropharyngeal squamous cell 
carcinomas (8th edition UICC tumor staging system OPSCCs), which is partly based 
on our data. Next, we showed that p16Ink4a-immunostaining is a strong surrogate 
marker for high risk-HPV16 in OPSCCs and tonsillar dysplasias [Chapter 3]. Definitions 
of HPV-positivity have impact on TNM-classification and patients’ prognosis: adequate 
testing with at least PCR for detecting HPV DNA next to P16Ink4a-immunostaining is 
emphasized.
During our research the question arose whether the presence of HPV in neck metastases 
of cancers of unknown primary (CUP) could be used to identify the primary tumor 
location and to guide treatment. However, only a very low rate of HPV-positive 
metastases was found. [Chapter 4]. On the other hand we were able to show that de-
intensified therapeutic regimens without postoperative radiation of the pharyngeal 
axis and the contralateral neck do not worsen prognosis, first in a smaller and more 
heterogeneous [Chapter 5] and subsequently in a larger and more homogeneous 
population [Chapter 6]. Results recently contributed to the publication of the first 
guideline on diagnosis and management of squamous cell carcinoma of unknown 
primary in the head and neck by the American Society of Clinical Oncology (ASCO).
In the recently introduced 8th edition UICC tumor staging system for HPV-positive 
tumors, still only anatomical parameters have been used to stage OPSCC, although in 
literature there were indications that non-anatomical parameters also are of significance 
to predict prognosis. We therefore tested the prognostic value of the 8th edition UICC 
tumor staging system for HPV-positive OPSCCs in a large series of exclusively tonsillar 
squamous cell carcinomas (TSCCs) and tested the prognostic value of other, non-
anatomical factors [Chapter 7]. We have shown that the correlation between N-status 
and prognosis is still limited and that non-anatomical factors have a highly significant 
influence on prognosis (particularly non- and former smoking status and age). Based on 
this finding we proposed a further improved staging system for OPSCC.
The possibilities to improve existing and to develop new therapeutic options based on 
the different clinical and biological characteristics of HPV-positive compared to HPV-
negative OPSCCs have been addressed in a review on the most promising approaches 
[Chapter 8]. Present therapeutic HPV-targeting strategies and future directions for de-
intensified treatment of HPV-positive HNSCC were updated and are further debated in 
the general discussion [Chapter 9, point 9.8.
In dit proefschrift werden de klinische kenmerken van HPV-gerelateerde 
hoofdhalstumoren en hun implicaties voor tumorstadiëring en therapeutische 
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strategieën bestudeerd. Er werden een aantal belangrijke en klinisch relevante 
bevindingen gedaan. Vergeleken met HPV-negatieve tumoren hebben HPV-positieve 
tumoren andere klinische en biologische kenmerken. De prognostische waarde van de 
ernst van de betrokkenheid van lymfklieren is bij HPV-positieve tumoren significant 
verminderd, hetgeen wij als eerste groep wereldwijd publiceerden. [Hoofdstuk 2]. 
Een reeks andere en grotere studies volgden die onze observatie bevestigden, en 
uiteindelijk hebben geleid tot een aangepaste TNM classificatie voor HPV-positieve 
orofarynxcarcinomen (OPSCC’s) (8e editie UICC tumor staging system), mede gebaseerd 
op onze data. Vervolgens toonden we dat p16Ink4a-immunostaining een sterke 
surrogaatmarker is voor hoog-risico-HPV16 in OPSCC’s en tonsillaire dysplasieën 
[Hoofdstuk 3]. Definities van HPV-positiviteit hebben echter invloed op de TNM-
classificatie en de prognose van patiënten: adequate tests met ten minste PCR voor 
het opsporen van HPV-DNA naast P16Ink4a-immunostaining wordt benadrukt.
Tijdens ons onderzoek kwam de vraag naar voren of de aanwezigheid van HPV in 
nekmetastasen van onbekende primaire tumoren gebruikt kan worden om de primaire 
tumorlocatie te identificeren en de behandeling te begeleiden. Er werd echter slechts 
een zeer laag percentage HPV-positieve metastasen gevonden. [Hoofdstuk 4]. Aan de 
andere kant konden we aantonen dat de prognose niet verslechterd wordt door minder 
intensieve therapeutische regimes zonder postoperatieve bestraling van de pharyngeale 
as en de contralaterale hals, eerst in een kleinere en meer heterogene populatie 
[Hoofdstuk 5] en later in een grotere en meer homogene populatie [Hoofdstuk 6]. De 
resultaten hebben recent bijgedragen aan de publicatie van de eerste richtlijn over de 
diagnose en behandeling van plaveiselcelcarcinoom van onbekende primaire tumoren 
in het hoofd en de nek door de American Society of Clinical Oncology (ASCO).
In de recent geïntroduceerde 8e editie UICC tumor stadiëring voor HPV-positieve 
tumoren worden vooralsnog enkel anatomische parameters gebruikt om OPSCC’s te 
classificeren, hoewel er in de literatuur aanwijzingen zijn dat ook niet-anatomische 
parameters van significante invloed zijn op de prognose. Daarom hebben we de 
prognostische waarde van de 8e editie TNM classificatie van OPSCC’s getest in een grote 
reeks van uitsluitend tonsilcarcinomen en hebben we de prognostische waarde van 
andere, niet-anatomische factoren [Hoofdstuk 6] getest. We hebben aangetoond dat de 
correlatie tussen N-status en prognose nog steeds beperkt is en dat niet-anatomische 
factoren een zeer significante invloed hebben op de prognose (m.n. niet-roken en 
gestopt met roken, en leeftijd). Op basis hiervan hebben we een verbeterde stadiëring 
voor OPSCC’s voorgesteld.
De mogelijkheden om bestaande en nieuwe therapeutische opties te verbeteren op 
basis van de verschillende klinische en biologische kenmerken van HPV-positieve in 
vergelijking met HPV-negatieve OPSCC’s zijn onderzocht in een review van de hiervoor 
meest veelbelovende benaderingen [Hoofdstuk 7]. De huidige therapeutische 
strategieën gericht op HPV en toekomstige richtingen voor minder intensieve 
behandeling van HPV-positieve hoofd-halstumoren werden geüpdate en verder 
besproken in de algemene discussie [Hoofdstuk 9, punt 9.8.].
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Als eerste mijn promotoren, prof. dr. B. Kremer en prof. dr. E.J.M. Speel.
Bernd, als opleider KNO heb je me de mogelijkheid geboden mijn droom te kunnen 
verwezenlijken om KNO-arts en vervolgens hoofd-halschirurg te worden, waarvoor 
dank. Ik bewonder de wijze waarop je leiding geeft en de gunstige invloed van jouw 
people management op het opleidingsklimaat in het MUMC+. Ik heb veel van je geleerd 
en raak telkens weer geïnspireerd tijdens onze ontmoetingen omtrent de voortgang 
van dit proefschrift. Ik hoop dat we elkaar na het afronden van dit promotietraject nog 
vaak mogen ontmoeten om de samenwerking tussen onze vakgroepen in de regio Zuid-
Limburg verder uit te diepen, al was het maar voor de voortreffelijke kazen en wijnen 
die je telkens bij deze ontmoetingen presenteert.
Ernst-Jan, dank voor al jouw hulp bij dit proefschrift. Vanuit jouw moleculaire 
celbiologische achtergrond, bracht je telkenmale interessante invalshoeken naar voren 
omtrent de gepresenteerde klinische resultaten. Dit voegde doorheen het proefschrift 
een erg boeiende dimensie toe die ik als zeer verrijkend heb ervaren. Daarnaast heb ik 
je ook tijdens de buitenlandse congressen meer en meer als mens mogen leren kennen 
en waarderen.
De collega’s die bijdroegen tot de totstandkoming van de diverse artikels in dit 
proefschrift. Met name Frank Hoebers, Jos de Jong, Jeroen Mooren, Nadine Olthof, 
Julia Vent en Sanne Wagemakers.
Nadine en Jeroen, dank voor de fijne samenwerking bij de publicaties die we samen 
schreven. Mijn jaloezie ging meer dan eens uit naar jullie voortreffelijke HPV-
gerelateerde moleculaire kennis . Ik hoop dat ik net zoals jullie met veel verve mijn 
proefschrift kan verdedigen.
Julia, thanks for the enthusiastic cooperation. I really enjoyed our pizzas-meetings in 
Cologne.
Sanne, dank voor je samenwerking en met name je nauwgezette dataverzameling die 
een van de laatste hoofdstukken mee hielp afronden. Ik wens je een erg mooie carrière 
toe.
Frank en Jos, als leden van de vakgroep radiotherapie aan de Maastro heb ik veel van 
jullie geleerd. De dynamiek die in jullie kliniek heerst werkt inspirerend en straalt veel 
ambitie uit.
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De stafleden, de fellows en de AIOS MUMC+ tijdens mijn assistenten- en fellow-
jaren aldaar. Dank voor de samenwerking, en gezelligheid tijdens die periode. De 
assistententrips zijn onuitwisbaar uit het geheugen.
Dank aan de B-opleiders die me hebben begeleid tijdens de perifere stages gedurende 
de opleiding KNO. Frank, Nies en Maarten, nog steeds koester ik de ontzettend gezellige 
tijd bij jullie in het Catharien. Paul, Martijn en Harm, dank voor de fijne tijd als allereerste 
Helmondse opleideling.
Prof. Manni, met veel droefheid vernamen we uw heengaan dit voorjaar. Ik ben u 
dankbaar voor uw niet aflatende interesse in de voortgang en de begeleiding van 
eenieder die zich interesseerde in het KNO- en hoofd-halschirurgische vak.
Prof. Tan, beste Bing, als opleider dank ik u voor de fijne samenwerking samen met alle 
collega’s van het hoofd-halsteam in het NKI-AVL, stafleden, assistenten en onderzoekers. 
Ik beschouw mezelf als bevoorrecht om als fellow hoofd-hals deel te hebben mogen 
uitmaken van jullie prachtige multidisciplinaire organisatie.
De vakgroepleden KNO Zuyderland MC. Beste collega’s, met veel liefde richt ik me 
tot jullie om mijn dank te uiten voor de fijne weg die we de afgelopen jaren hebben 
afgelegd. De fusie van onze huizen heeft ons onbezorgd welbevinden op de proef 
gesteld en ons tegelijk gesterkt als vakgroep. De gezelligheid is er, de expertise ook, en 
de ambitie om beide te laten excelleren en balanceren. Ik ben trots om deel uit maken 
van ons team. Op de vele toasts die mogen volgen!
De oud-leden vakgroep Atrium MC. Beste Henk, Gert-Jan en Tammo, dank voor de 
fundamenten van de maatschap KNO die jullie ons achterlieten. Ik ben trots dat 
we collegialiteit, gezamenlijkheid, en gelijke inzet hoog in ons vaandel houden. We 
blijven gelukkig in nauw contact, (nazorg aan oud-leden wordt immers contractueel 
geborgd).
De medewerkers op de poli KNO en OK in het Zuyderland medisch centrum. Allen dank 
voor jullie gezellige aanwezigheid op de werkvloer. Jullie inzet en toewijding getuigen 
van een intrinsieke motivatie die mij nauw aan het hart ligt. Het doet me elke dag plezier 
jullie betrokkenheid te mogen ervaren. Ik gun mezelf een loopbaan in een dergelijke 
sfeer.
Paranimfen Job Postelmans en Lennaert Hoep.
Beste Job, als KNO-opleidingsmaatje bouwden we een band op die ook vandaag nog 
steeds overeind blijft. Weinig woorden zijn nodig om te begrijpen hoe de vlag erbij 
hangt. Leuk dat je wilt paranimfen, hopelijk mag je een stelling voorlezen.
Beste Lennaert, de afgelopen jaren heb ik je leren kennen als een integere en fijne 
collega. Ik heb erg genoten van de tijd in jullie praktijk en kijk met plezier terug op hoe 
de lijntjes in Roermond zo lekker kort en efficiënt bleken. De samenwerking op jullie poli 
en koffieleuten met de dames zijn mooie herinneringen. Fijn dat je wilt paranimfen.
Mijn familie en vrienden. Sanne dank voor je mooie cover en je vriendschap. Dank aan 
alle vrienden en (schoon)familie voor de humor van elke dag en het samenzijn op de 
momenten die ons zijn gegund.
A
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Zussen Greta, Ann en Danielle, dank voor jullie geduld en liefde. Ik zie jullie en jullie 
families erg graag.
Lieve mama en papa, opvoeding en omgeving zijn zo belangrijke bouwstenen voor 
ons als mens. Dank voor de zorgeloze kindertijd, de liefde waarmee jullie ons leerden 
naar het leven te kijken, te relativeren en de belangrijke momenten naar waarde te 
schatten. Dank ook voor de kansen die we allen volop kregen, en voor de wilskracht en 
volhardendheid om ze te benutten.
Aan mijn vrouw Ilse. Gelukkig zeggen we elkaar voldoende vaak hoe graag we elkaar 
zien. Leven met jou geeft alle momenten the extra touch. Dank voor Camille en Julien, 
onze twee schatten mogen zich gelukkig prijzen met jou als hun moeder. Die liefde is 
oneindig!
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CURRICULUM VITAE
Jos Marie Jan Arthur Alfons Straetmans werd op 17 augustus 1981 geboren 
in Luik (Rocourt), België. Hij doorliep zijn middelbare onderwijs op het Onze-
Lieve-Vrouwecollege in Tongeren waar hij in 1999 zijn humaniora afrondde in de 
afstudeerrichting Latijn-Wetenschappen. Aansluitend begon hij zijn studie geneeskunde 
aan de Universiteit van Maastricht die hij afrondde in 2005. In 2006 startte hij de 
opleiding tot KNO-arts aan het MUMC+ (opleiders: prof. dr. Bernd Kremer en prof. dr. 
Robert Stokroos) waarbij twee perifere stages werden doorlopen in resp. het Elkerliek 
Ziekenhuis Helmond (opleider: dr. Paul Schuil) en Catharina Ziekenhuis Eindhoven 
(opleider: dr. Frank Adriaansen). Aansluitend volgde hij een opleiding tot KNO-arts/
Hoofd-halschirurg tijdens een fellowship Hoofd-halsoncologie dat hij doorliep in het 
MUMC+ (opleider: prof. dr. Bernd Kremer) en het NKI-AVL te Amsterdam (opleider: 
prof. dr. Bing Tan). Tijdens deze gehele opleidingsperiode werd de basis gelegd voor 
dit proefschrift. Hij bleef hierna iets meer dan een jaar verbonden aan het MUMC+ en 
startte parallel als chef-de-clinique in zowel het Laurentius Ziekenhuis in Roermond 
als het Atrium Medisch Centrum in Heerlen. Op 1 december 2014 werd hij voltijds 
maatschapslid van de vakgroep KNO in het Atrium MC te Heerlen, die opging in de 
vakgroep KNO Zuyderland Medisch Centrum, als gevolg van de fusie van het Atrium 
MC met het Orbis Medische Centrum Sittard. Vanaf 2017 was hij tevens bestuurslid bij 
het Medisch Specialistisch Bedrijf Zuyderland MC tot aan de oprichting van de huidige 
Bestuursraad medio 2019. Sinds 1 juni 2019 vervult hij de rol van voorzitter van de 
vakgroep KNO. Grensoverschrijdend Zuid-Limburg is zijn thuis waar hij woont met zijn 
vrouw Ilse en twee kinderen Camille en Julien. Samen genieten ze er van de mooie 
omgeving, lekker eten, en reizen naar het zuiden.
A
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